Increased intake of fermentable carbohydrates induces IBS-like symptoms; a complementary understanding of mechanisms involved. by Kamphuis, Jasper
En vue de l'obtention du
DOCTORAT DE L'UNIVERSITÉ DE TOULOUSE
Délivré par :
Institut National Polytechnique de Toulouse (Toulouse INP)
Discipline ou spécialité :
Pathologie, Toxicologie, Génétique et Nutrition
Présentée et soutenue par :
M. JASPER KAMPHUIS
le vendredi 4 octobre 2019
Titre :
Unité de recherche :
Ecole doctorale :
Increased intake of fermentable carbohydrates induces IBS-like symptoms;
a complementary understanding of mechanisms involved
Sciences Ecologiques, Vétérinaires, Agronomiques et Bioingénieries (SEVAB)
Toxicologie Alimentaire (ToxAlim)
Directeur(s) de Thèse :
MME HÉLÈNE EUTAMENE
MME VASSILIA THEODOROU
Rapporteurs :
M. BRUNO BONAZ, CHU GRENOBLE
M. JAVIER SANTOS VICENTE, VALL D'HEBRON UNIVERSITY HOSPITAL
Membre(s) du jury :
Mme CATHERINE MULLER, UNIVERSITE TOULOUSE 3, Président
Mme HÉLÈNE EUTAMENE, EI PURPAN, Membre
Mme INGRID RENES, NUTRICIA RESEARCH UTRECHT, Membre
Mme VASSILIA THEODOROU, EI PURPAN, Membre
  
   
   
 Increased intake of fermentable 
carbohydrates induces IBS-like symptoms;  
a complementary understanding of 
mechanisms involved 
Visceral sensitivity, intestinal barrier function,  
bacterial metabolites, and organisation of mucus secretions  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Jasper Kamphuis, 2019 
  
  Peering into a microscope in the dark invites the mind to make new friends,   
some of which are displayed on the Chapter pages of this dissertation; the “Faces in Faeces”. 
 
 
 
 
 
 
 
 
 
 
 
 
“....By this the Earth it self, which lyes so near us, under our feet, shews quite a new thing to us, and in 
every little particle of its matter, we now behold almost as great a variety of Creatures, as we were able 
before to reckon up in the Whole Universe it self....”  
  ~Robert Hooke in Micrographia, 1665 
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Summary 
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder (FGID) characterized by 
abdominal pain, bloating, and erratic bowel habits. It is an affliction with a high prevalence of 
around 11% worldwide. It carries a significant economic cost in lost productivity and work 
absence, and more importantly, it has a strong negative impact on quality of life. Because it is a 
functional disorder of which the causes are not well understood, treatment is difficult. In recent 
years, a low-FODMAP diet (low in Fermentable Oligo-, Di-, Mono-saccharides And Polyols) has 
been successfully used to reduce symptoms of IBS. The efficacity of this approach is not 
completely understood, but a reduction in enteric distension by reduced gas production and 
small intestinal water bulk by osmotic effects are most often cited. The bacterial metabolic toxin 
hypothesis, proposed by Campbell et al. poses that anaerobic fermentation of unabsorbed 
carbohydrates by the colonic gut microbiota, producing such metabolites as alcohols, ketones, 
and aldehydes, are responsible for food intolerances such as lactose intolerance. We 
hypothesized that this same mechanism could be extended to FODMAPs to explain the efficacity 
of the low-FODMAP diet. 
In this thesis, we looked for complementary mechanisms on how FODMAPs could influence IBS 
symptoms, besides distension related complaints. Our studies in a healthy mouse model show 
a complex role for FODMAPs in IBS physiopathology; FODMAP treatments cause a visceral and 
abdominal hypersensitivity, and a mucus barrier dysregulation, characterized using an 
innovative approach.  
We hypothesized that this is due to generation of glycating agents by the intestinal microbiota, 
and the prevention of these effects by co-treatment with pyridoxamine indicates that this 
hypothesis is correct. Mucosal mast cell counts were increased in FODMAP treated animals, but 
not in animals co-treated with pyridoxamine. Mast cells are implicated in visceral 
hypersensitivity, as well as in mucus barrier dysregulation, and increased mucosal mast cell 
numbers or activity are often linked to IBS.  
This work thus offers a link between the efficacity of the low-FODMAP diet and the involvement 
of intestinal mast cells in IBS. 
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Résumé 
Le syndrome de l’intestin irritable (SII) est un trouble gastro-intestinal fonctionnel caractérisé 
par des douleurs abdominales, des ballonnements et des troubles du transit intestinal. Cette 
pathologie digestive a une prévalence mondiale importante d'environ 11%. Elle entraîne un coût 
économique important : perte de productivité et absentéisme au travail. De plus, elle entraine 
une forte dégradation de la qualité de la vie des patients. Les causes de ce trouble fonctionnel 
ne sont pas bien comprises rendant le traitement thérapeutique difficile. Au cours des dernières 
années, un régime alimentaire à faible teneur en FODMAPs (Fermentable Oligo-, Di-, Mono-
saccharides And Polyols) s’est révélé efficace dans la réduction des symptômes du SII. Sur le plan 
mécanistique ces effets positifs restent à élucider. Toutefois, on cite le plus souvent une 
réduction de la distension entérique due à une réduction de la production de gaz et du volume 
d’eau intestinale par des effets osmotiques. Campbell et al. pose l’hypothèse qu’une 
fermentation anaérobie de carbohydrates non-absorbés par le microbiote intestinal provoque 
la formation endoluminale de métabolites tels que les alcools, les cétones et les aldéhydes, 
responsables d'intolérances alimentaires comme l'intolérance au lactose. Nous avons émis 
l’hypothèse que ce mécanisme pourrait être étendu aux FODMAPs pour expliquer l’efficacité du 
régime alimentaire pauvre en FODMAPs chez les patients SII. 
Nos études montrent un rôle complexe des FODMAPs sur des modèles murins qui reflètent la 
physiopathologie du SII. Les traitements par FODMAPs (lactose et fructo-oligosaccharides) 
provoquent une hypersensibilité viscérale et abdominale et une dysfonction de la barrière de 
mucus au niveau de la muqueuse intestinale.  
Nous avons démontré que ces effets étaient dûs à la production d’agents de glycation par le 
microbiote intestinal. En effet, ces effets étaient prévenus par un co-traitement à la 
pyridoxamine. Le nombre de mastocytes muqueux était également augmenté chez les animaux 
traités par FODMAPs et significativement réduit par un co-traitement à la pyridoxamine. Les 
mastocytes sont connus pour être impliqués dans l’hypersensibilité viscérale et dans la 
dysrégulation de la barrière de mucus de l’intestin. Par ailleurs, une augmentation du nombre 
et/ou de l'activité des mastocytes est retrouvée sur des biopsie de patients SII.  
Ce travail de thèse original permet donc de faire un lien entre l'efficacité du régime alimentaire 
à faible teneur en FODMAPs, la symptomatologie et l'implication des mastocytes intestinaux 
chez le patient SII. 
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1 General Introduction 
This thesis project was part of the Initial Training Network (ITN) NeuroGUT, financed by the 
People Programme of the European Union’s Seventh Framework Programme. This training 
network aimed to offer training in neurogastroenterology and complementary skills to young 
researchers, to help form the next generation of scientists dedicated to the rapidly developing 
field of neurogastroenterology. The projects financed in this way all pertain to functional 
gastrointestinal disorders (FGIDs) and investigate such topics as the involvement of gut-brain 
interaction, nutritional challenges of the immune system, low-grade inflammation, and post-
infectious changes to the enteric nervous system as possible pathophysiological mechanisms. 
The network contains both clinical and basic science partners, and fellows with both medical 
and research science backgrounds were recruited. During the project, fellows met several times 
per year for training activities and annual meetings, as well as for scientific conferences. One 
such training activities was a Summer School organised around the Bologna IBS Days 2016, and 
the results of training activities during this summer school were published as a Position Paper in 
the Neurogastroenterology and Motility journal (Albusoda, Barki et al., 2017), which is included 
as the first section after this general introduction. 
The goal of this thesis project was to investigate and describe mechanisms by which FODMAPs 
(Fermentable Oligo-, Di-, Mono-saccharides and Polyols) can induce symptoms of Irritable Bowel 
Syndrome (IBS), based on the facts that a low-FODMAP diet can successfully reduce symptoms 
in IBS patients (Gibson and Shepherd, 2005; Halmos, Power et al., 2014; Böhn, Störsrud et al., 
2015; Marum, Moreira et al., 2016a; Prince, Myers et al., 2016; McIntosh, Reed et al., 2017), 
and that fermentation of certain non-absorbable carbohydrates can lead to the formation of 
methylglyoxal, with negative local and systemic effects (Campbell, Waud et al., 2005; Campbell, 
Matthews et al., 2010). We hypothesized that FODMAP fermentation could have sensitizing and 
immuno-modulatory effects in the colon by production of toxic microbial metabolites, which 
supplements the prevailing idea that the efficacity of the low-FODMAP diet is related to the 
increased intestinal distension via osmotic effects and gas production (Barrett, Gearry et al., 
2010; Ong, Mitchell et al., 2010) induced by FODMAP intake, in an already hypersensitive 
system. To get more insight into this matter and test our hypothesis, we used an animal model 
to measure relevant markers in colonic tissues and digesta, such as mastocyte counts, mucus 
barrier function, and aldehyde contents of faeces, as well as more systemic parameters, such as 
visceral and abdominal sensitivity.
10 | P a g e  
 
1.1  A fresh look at IBS – opportunities for systems medicine approaches 
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Abstract 
NeuroGUT is a EU-funded initial training network (ITN) of 14 research projects in 
neurogastroenterology that have employed an equal number of early-stage research-
ers. Neurogut trainees have-among other activities-attended an international con-
ference on irritable bowel syndrome (185) in Balogna in 2016 and were asked to 
critically review and evaluate the current knowledge on 185 for their respective re-
search activities, and to state what they were missing. Most appreciated were the 
tapies brain imaging of gut activity, the role of the gut microbiota, the pharmacology 
of gut functions, the 185-18D interrelation, the new Rome IV criteria, the role of gas, 
and the placebo response in functional disorders. Missed were more detailed coverage 
of high-resolution manometry, functional brain imaging, advanced "systems medicine" 
approaches and bioinformatics technology, better sub-classification of 185 patients, 
and the development of disease biomarkers, extended at the molecular (genetic/ epi-
genetic, proteonomic) level. They summarize that despite excellent specialized re-
search, there is a gap open that should be filled with systems medicine. For t his, it 
would be necessary that medical research learns even more from the data sciences 
and other basic disciplines, for example, information technology and system biology, 
and also welcomes a change in paradigm that enhances open sharing of data, informa-
tion, and resources. 
KEYWORDS 
functional bowel disorders, irritable bowel syndrome 
1 THE NEUROGUT TRAINING NETWORK 2014 and will last for 4 years, with a total budgetary EU contribution 
of 3.687 Mio€. 
NeuroGUT is an initial training network (ITN) of the European Union's 
7th Framework Programme (7FP) (2007-2013), according to the rules 
released by the EU.1 lts proposai was submitted for review in the years 
2010, 2011, 2012, and 2013, before it was approved in May 2013, and 
received funding by the end of 2013. NeuroGUT started February 1st, 
Ali authors contributed equally to this paper. 
ln agreement with the ru les for ITNs, NeuroGUT proposed a t rain-
ing network of 14 projects in the area of neurogastroenterology and 
motility, stating that "neurogastroenterology is a new and emerging 
medical/ scientific subspecialty that currently has no formai training 
opportunities in medicine and related disciplines despite its exis-
tence as scientific community for more than 20 years. lt includes basic 
science aspects (neurophysiology, neurobiology, neuropsychology, 
psychophysiology, pharmacology, biotechnology) as well as clinical 
Neurogastroenterol Mon/. 2017;29:e12989. 
https://doi.org/ 10.1111/nmo.12989 
wileyonlinelibrary.com/ journal/nmo © 2016 John W iley & Sons Ltd 1 1 of 4 
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aspects (gastroenterology, neurology, internai medicine, surgery, psy-
chology, psychosomatic medicine) of the neural control of intestinal 
functions (motility, secretion, absorption, immunity, sensitivity, food 
intake) in health and disease."2 
Initial training networks are thought as training networks, notas 
much as research projects: this implies that the focus is-beside sci-
entific excellence-on training of a future generation of scientists and 
clinicians, to qualify them for academic, clinical, or industrial work in 
the related areas. ln consequence, the funding received is to allow 
completion of 3-year PhD training for early stage researchers (ESRs) 
at each participating partner laboratory, with supplementary money 
for the participating centres. Among others, the requirement to work 
as ESR in one of the projects is mobility of the researcher: he/she 
cannot have resided in the country of his/ her host institution for 
more than 1 year in the 3 years prier to his/her recruitment; in most 
cases he/she has to change the country of residency. ITNs within 
FP7 also included experienced (post-doctoral) researchers (ERs) es-
pecially to work with industrial partners (small and medium-size en-
terprises, SME) for 2 years. NeuroGUT involves 11 ESRs and 3 ERs 
(see Table 1). 
Ali ESRs had to enroll in local PhD programs in addition to their 
NeuroGUT training activities; these included seminars in paper and 
grant writing, didactic courses in oral presentation skills, a mini-MBA 
course to foster business activities, summer, and winter schools on spe-
cific topics of general interest, self-organized researcher camps, and sec-
ondments (short-term stays in other laboratories, etc.). One such activity 
was the participation in the international IBS Bologna Days 2016.3 
The principle investigators and supervisors of the ESRs/ERs of the 
NeuroGUT network consist of internationally leading experts in the 
respective research fields, coming from academia and from the private 
Project title Pl 
Projects for early state researchers (ESR), 36 months 
Enck 
ALBUSODA ET AL. 
KEY POINTS 
• NeuroGUT trainees attended an international conference on 
irritable bowel syndrome (IBS) in Bologna in 2016. 
• They critically evaluated the current knowledge on IB5 pre-
sented for t heir respective research activities. 
• They summarize that there is a gap open that should be fil led 
with systems medicine. 
sector, that have designed 14 state-of the-art research subprojects to 
explore the neuronal and immunological control of gut functions in 
health and in major functional gastrointestinal disorders such as the 
irritable bowel syndrome (IBS). 
These 14 projects were distributed to three work packages (basic 
science, translational science, clinical science), each supplemented 
with one industry-based project. Ali projects were pre-arranged in a 
kind of cycle (called the "digestive cycle") starting and ending with the 
process of food ingestion, as organizing principle (see Figure 1). 
The research project for each ESR covered a period of 3 years, 
while projects for ERs were planned for 2 years. For details of the indi-
vidual projects, we refer to the NeuroGUTwebsite.2 
2 THE TASK 
Both ESRs and ERs of NeuroGUT are exposed to a number of learn-
ing events beyond the individual PhD programs they are involved in 
TABLE 1 Short titles of the 14 
ESR/ER 
subprojects (SP) of the ITN NeuroGUT with 
principle investigator (Pl) and ESR/ ER 
IL (initiais); see www.neurogut.eu for further 
details 
SP1: Central representation of food intake in health & disease 
SP2: Epithelial barrier function and micro-inflammation Theodorou JBJK 
SP3: Mucosa-ENS-signaling in chronic bowel diseases 
SP4: Dysfunction of esophagus & esophagogastric junction 
SPS: Luminal bacteria, immune system and enteric nerves 
SP6: Neuro-immune mechanisms in visceral pain perception 
SP7: Inflammation and Pain 
SPS: Pathophysiological alterations/ symptoms in FBD 
SP9: Gastrointestinal motility/ sensitivity as a key to FBD 
SP10: Autonomie nervous system in visceral hypersensitivity 
SP11: Processing of visceral sensation & the gui microbiome 
Projects for experienced researcher (ER), 24 months 
SP12: Intestinal motility by endoluminal image analysis 
SP13: SHT and other receptors in visceral hypersensitivity 
SP14: Bacterial flora in health and functional bowel disorder 
'Position empty alter 11 months. 
Schemann 
Smout 
Stanghellini 
Boeckxstaens 
Grundy 
Simren 
Azpiroz 
Aziz 
Enck 
Rabinovitz/ Horn 
(Given) 
Schemann/Grundy 
Zimmermann 
(Symbio) 
ML 
TH 
TBK 
EP 
FU 
AP 
TP 
AA 
HW 
NN' 
NB 
NM 
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ALBUSODA ET AL. 
0 Work package 1 
Work package 2 
FIGURE 1 Arrangement of the 
subprojects (SPs) of the NeuroGUT 
network. Colors and shapes represent 
work packages (see text below) and are 
related to the collaborative aspects of the 
NeuroGUT networking 
ENS = Enteric nervous system 
ANS = Autonomie nervous system 
SP = Subproject 
6 Work package 3 
• 
Workpackage 4 
at their home institutions, and among them are training seminars and 
summer schools. W ith respect to the latter, rather than inviting them to 
special events (usually 3-day courses with a specific tapie and faculty), 
NeuroGUT attempted to test new formats of learning by integrating 
them into scientific events of a larger scale, for example, international 
conferences such as the European Neurogastroenterology and Motility 
conference in Istanbul 2015 and the international IBS Balogna Days in 
2016. The respective tasks assigned to them during the conferences 
were adjusted to their respective level of training achieved so far. 
During the Bologna meeting, their task was twofold: to report back 
(i) which of t he presentation du ring the conference was the most valu-
able for their own and specific PhD project, and (ii) which tapie or as-
pect they missed most for their work, and for functional gastrointestinal 
disorders in general and IBS specifically. Therefore, t his report allows a 
fresh-men's and fresh-women's view on the current research on IBS. 
3 THE TOPICS MOST APPRECIATED 
As can be predicted, t he appreciation of individual talks at t he IBS meet-
ing was co-determined by the research focus of the single ESR/ ER re-
searcher, but not surprisingly as well, the ranking also reflects the areas 
less well covered by NeuroGUT: the talks by Lucas Oudenhoven (on brain 
imaging of gut activity) and Steven Collins (on the raie of the gut micro-
biota) found high appreciation, as did the pharmacology of gut functions 
(by Jan Tack), the IBS-IBD interrelation (byThierry Piché), the new Rome 
IV criteria (by Douglas Drossman), the raie of gas (by Fernando Azpiroz) 
and the placebo response (by Paul Enck) for functional disorders. 
4 THE TOPICS MISSED 
More important t han the tapies covered during the conference may 
be the ones that t he NeuroGUT trainees missed in the presentations 
of the conference; they can be subdivided into 3 categories: Research 
Techniques, Symptom Assessments, and Mechanisms of Action: 
4.1 1 Research techniques 
lt was felt that high-resolution manometry deserved a wider appli-
cation than is currently implemented for esophageal and anorectal 
diagnostics, for example, for recording activity of t he colon, a w idely 
ignored area for many years. lt was also stated that functional brain 
imaging is grossly underestimated due to the complexity of the tech-
nology on the one hand and a lack of understanding of its options on 
the other; many more laboratories should cooperate with imaging fa-
cilities to enhance this applications. With the number of putative bio-
markers of IBS constantly increasing, and with inclusion of "big data" 
from "omics"-sciences (genomics, microbiomics, metabolomics, pro-
teomics) the need for advanced "systems medicine" approaches and 
bioinformation technology appears evident , whi le current methodol-
ogy still looks "old fashion" and lacks the options these approaches 
allow nowadays. The same applies to further integration of other 
disciplines of biomedical research (systems biology, microbiology, 
genetics, psychology, neuroscience) into neurogastroenterology. 
4.2 1 Symptom assessment 
Among the symptoms not receiving enough attention in the IBS debate 
was heartburn, and among other deficits mentioned was the insuffi-
cient sub-classification of IBS patients, beyond the ongoing Rome (IV) 
differentiation. Furthermore, it was felt that symptom differentiation 
needs supplementation by the development of disease biomarkers. 
4.3 1 Methodological deficits 
The biomarker discussion needs to be extended at the molecu-
lar (genetic/epigenetic, proteonomic) level and linked to visceral 
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1.2 IBS, FODMAPs 
The main subject of this thesis concerns the mechanism of effect by which a low-FODMAP diet 
reduces symptoms in irritable bowel syndrome (IBS). In this chapter, the current state of 
knowledge concerning IBS and some other functional gastrointestinal disorders (FGIDs) will be 
discussed.  
1.2.1 Functional gastrointestinal disorders (FGIDs) 
Functional gastrointestinal disorders (FGIDs) are a group of distinct disorders of different 
sections of the gastrointestinal tract with the commonality that they have no clear 
pathophysiological cause (hence ‘functional’). FGIDs are common among the population, with 
Irritable Bowel Syndrome (IBS) and Functional Dyspepsia the most frequent. On a whole, FGIDs 
are the most commonly diagnosed disorders by gastroenterologists. Because they are difficult 
to define and, for the moment, have no clear pathological cause, their treatment is complicated, 
consisting of a variety of pharmacological, psychological, dietary, and complementary medical 
treatments (Whitfield and Shulman, 2009). In an ongoing effort to classify and define the FGIDs 
for diagnosis, the international “Rome process” has yielded the 4th edition of the Rome criteria 
for FGIDs in 2016 (Drossman, 2016). 
1.2.1.1 Rome Process and criteria 
The Rome Foundation first issued criteria for the diagnosis of Irritable Bowel Syndrome in 1989 
(Thompson et al. 1989), following with the Rome Classification System for FGIDs in 
1990 (Drossman, 2007). Since then, 4 classifications have been published; Rome I (1994), Rome 
II (1999-2000), Rome III (2006), and Rome IV (2016) (Drossman, 2016). It has grown from being 
mostly a tool for researchers of FGIDs to better classify experimental subjects, to a robust 
diagnostic tool for clinical practitioners. The current Rome IV criteria have been updated to 
specifically take ‘pain’ into account, changing from ‘discomfort’ which was often difficult for 
patients to respond to, and doesn’t translate well between cultures (Drossman, 2016). A full 
overview of Functional Gastrointestinal Disorders specified by Rome IV can be found in Table 1. 
There are some limitations to using the Rome criteria in clinical practice. For example, they may 
exclude some treatable patients who do not strictly fall within the definitions set for each 
disorder, and patients with multiple FGIDs might not be recognized as such (Oświęcimska, 
Szymlak et al., 2017). Additionally, changing diagnosis criteria from one iteration to the next 
might cause some patients to be ‘cured’ of their disease on rediagnosis, without any change in 
their health situation.  
16 | P a g e  
 
Although the Rome criteria are increasingly useful and accepted for clinical practice, its 
background as a tool for patient selection for trial purposes means its first goal was mostly to 
select for those patients who were the most clearly includable and thus likely to respond to 
treatment, preventing false positives. 
 
Table 1 – Overview of FGIDs specified by Rome IV (Drossman, 2016) 
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1.2.1.2 Irritable Bowel Syndrome 
Irritable Bowel Syndrome (IBS) is one of the FGIDs defined by Rome IV; it is a mild to serious 
disease with a high prevalence in many societies, ranging from 7% (South-East Asia) to 21% 
(South America), with a pooled prevalence of 11% (Lovell and Ford, 2012b), see Table 2. 
 
IBS is characterized by abdominal pain, bloating, erratic bowel habits, and variable changes in 
the consistency of stools (Enck, Aziz et al., 2016; Spiller, 2016). It is a heterogeneous disorder, 
with 4 defined sub-types; Diarrhoea predominant (IBS-D), Constipation Predominant IBS (IBS-C), 
Mixed bowel habits (IBS-M), or Unclassified (IBS-U) (Drossman, 2016). Even though it is a 
functional disorder, IBS has a high impact on the quality of life (QOL), akin to that suffered by 
patients of (organic) inflammatory bowel disorders such as Crohn’s disease or ulcerative colitis 
(UC) (Pace, Molteni et al., 2003). An important risk factor to IBS is female sex (Lovell and Ford, 
2012a) as well as occurrence in relatives (Saito, Petersen et al., 2010), which can be linked to 
genetics, shared environment, or social learning behaviour (Levy, Jones et al., 2001). Differences 
in reported prevalence among the sexes is likely due to differences in hormonal regulation, 
though a difference could also be linked to differential usage of healthcare services (Enck, Aziz 
et al., 2016). Alternatively, a subset of IBS patients develops their symptoms acutely, following 
an infectious gastroenteritis. In this case, the syndrome is termed post-infectious IBS (PI-
IBS) (Ghoshal, Park et al., 2010). 84% of IBS patients self-report that symptoms are elicited by 
certain foods (Bohn, Storsrud et al., 2013), which influences their eating behaviour, with 
potentially negative social and nutritional effects. Additionally, there are some psychiatric 
comorbidities noted in IBS patients, such as depression or anxiety, though the majority of IBS 
patients do not warrant a diagnosis of a mood or anxiety disorder (Janssens, Zijlema et al., 2015). 
  
Table 2 – Pooled prevalence of IBS according to geographic location (Lovell and Ford, 2012b) 
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1.2.1.3 Types of IBS Classification and Diagnostics 
The Rome IV criteria are used to diagnose IBS and distinguish IBS from transient gut symptoms, 
and gut disorders with an organic origin. To qualify as IBS, symptoms must have occurred for the 
first time 6 months before presentation for diagnosis (Longstreth, Thompson et al., 2006), and 
have occurred 1 days per week during the last 3 months. Additionally, symptoms get better or 
worse after defecation, and stools show changes in frequency and form (Lacy, Mearin et al., 
2016). The subtype is characterised as IBS-C if 25% of stools is hard or lumpy and <25% loose 
or watery; IBS-D if 25% of stools is loose or watery, and <25% hard or lumpy; IBS-M 25% of 
stools is hard or lumpy or 25% of stools is loose or watery; and IBS-U if there is insufficient 
abnormality to classify one of the other types (see Figure 1).  
A tool often used to characterise stool form is the Bristol Stool Form Scale (Lewis and Heaton, 
1997a), displayed in Table 3. According to the authors, the shape and form of stools is directly 
related to the transit time of stools through the gastro-intestinal tract, and is a better 
representation than frequency of defecation (Lewis and Heaton, 1997a). However, a later study 
using more modern methods to measure transit time found no correlation between whole gut 
transit and stool form in healthy adults, though moderate correlations with stool form were 
observed for constipated patients (Saad, Rao et al., 2009). 
Table 3 - Bristol Stool Form Scale, adapted from (Lewis and Heaton, 1997a) 
Type 1 Separate hard lumps, like nuts 
Type 2 Sausage-shaped but lumpy 
Type 3 Like a sausage or snake but with cracks on surface 
Type 4 Like a sausage or snake, smooth and soft 
Type 5 Soft blobs with clear-cut edges 
Type 6 Fluffy pieces with ragged edges, a mushy stool 
Type 7 Watery, no solid pieces 
 
To measure the severity of IBS, the IBS-Severity Scoring System (IBS-SSS) questionnaire is used. 
By asking about the incidence, severity of pain, severity of bloating, satisfaction with bowel 
function, and interference in personal life related to the IBS symptoms, a score for the patient’s 
IBS severity is calculated. On a scale from 0-500, mild (75-175), moderate (175-300) and severe 
(≥300) categories are defined. Scores below 75 can be considered as non-IBS, or in 
remission (Francis, Morris et al., 1997).  
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A type of IBS characterized not by its symptoms, but by its onset is post-infectious IBS (PI-IBS). 
PI-IBS has an incidence of approximately 10% within a year after acute infectious 
gastroenteritis (Klem, Wadhwa et al., 2017), but is less likely after ‘traveller’s diarrhoea’ at 
5,4% (Schwille‐Kiuntke, Mazurak et al., 2015). PI-IBS is often diarrhoea predominant (Ghoshal 
and Ranjan, 2011). It is defined as acute onset IBS after a gastroenteritis in patients not 
previously defined as having IBS according to the Rome Criteria. PI-IBS, because of its clear 
organic origin, is renewing interest in the role of impaired intestinal permeability function in 
IBS (Matricon, Meleine et al., 2012; Piche, 2014). 
Apart from the different symptoms, there is a differential impact on disease specific Quality of 
Life (QOL) scores between the sub-groups of IBS. IBS-M and IBS-D score lower on IBS-QOL 
questionnaire assessment than IBS-C, indicating a greater subjective impact on their life (Singh, 
Staller et al., 2015), which is consistent with the expected urgency of the main symptoms. 
 
  
Figure 1 - Subtypes of IBS 
 Adapted from (Longstreth, Thompson et al., 2006) 
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1.2.1.4 Chronic Functional Abdominal Pain 
Chronic Functional Abdominal Pain (CFAP) is another FGID characterized by abdominal pain. The 
difference with IBS is that CFAP is not related to changes in bowel habit or stool form (Drossman, 
2016). The absence of changes in bowel habit in CFAP can be taken as indication that the pain 
component in CFAP, but likely also in subgroups of IBS patients, is not related to motility 
disorders or other defects likely to influence stool transit. An altered visceral sensitivity and 
changes to the function of the brain-gut axis are therefore more likely causes. 
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1.2.2 Aetiology IBS and physiopathology 
As mentioned before, IBS has an unclear aetiology and pathophysiology. However, a growing 
number of publications point to several factors implied in causing and/or perpetuating it. A 
combination of visceral hypersensitivity, genetics, psychological stress, dysfunctional intestinal 
permeability, and involvement of the microbiota are all possibly implicated in IBS.  
1.2.2.1 Visceral sensitivity  
A key component of IBS is abdominal pain. A logical and probable cause for this abdominal pain 
is an increased visceral sensitivity to different stimuli of the gastrointestinal tract. The first to 
describe the increased sensitivity to distension of IBS patients was James Ritchie, in 
1973 (Ritchie, 1973), and he considered this to be a likely factor in the aetiology of IBS. Bouin et 
al. (Bouin, Plourde et al., 2002) again showed that IBS patients, but not controls or patients with 
functional constipation (without pain) show a lower pain threshold, using a barostat (Table 4), 
indicating a hypersensitivity of the rectum.  
Azpiroz, Bouin et al. (Azpiroz, Bouin et al., 2007) report three criteria of altered rectal perception 
in IBS patients; (1) a decreased pain threshold (33 instead of 40 mmHg), (2) a sensitisation to 
repeated distensions, where a second set of distensions shows a threshold of 28, vs 41 mmHg 
for controls, and (3) referral of pain to aberrant sites instead of the sacral area in 83% of IBS 
patients, versus 10% in controls. The authors point to the concept of dysregulation of the neural 
sensory system to explain these observations. Furthermore, it is highly likely that this 
dysregulation is peripheral in nature (Azpiroz, Bouin et al., 2007), indicated, among other 
reasons, by the infiltration of inflammatory cells into the gut mucosa or enteric plexuses often 
observed in IBS patients (Barbara, Stanghellini et al., 2004). It is likely that there are different 
mechanisms of visceral hypersensitivity at play between regular IBS patients, and PI-IBS patients 
which developed symptoms after irritation of the gut by infectious agents. Visceral 
hypersensitivity seems to be correlated with the severity of other gastrointestinal (GI) 
symptoms (Simrén, Törnblom et al., 2017), implying that visceral hypersensitivity contributes to 
GI symptom generation, or that third contributors are responsible for both GI symptoms and 
Table 4 – Rectal balloon distension by barostat 
Adapted from Bouin et al. (Bouin, Plourde et al., 2002) 
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visceral hypersensitivity. Illustrating the possible common cause of visceral sensitivity and GI 
symptoms, a reduction of visceral sensitivity by blocking the histamine receptor HRH1 is 
accompanied by a reduction in GI symptoms (Wouters, Balemans et al., 2016). 
Hypersensitivity issues can be 
seen to occur as either allodynia, 
in case there is pain in response to 
a non-painful stimulus, or 
hyperalgesia, an increased 
sensitivity to pain. In 2008, the 
International Association for the 
Study of Pain (IASP) redefined the 
terms allodynia and hyperalgesia. 
Since then, the terms are 
differentiated based on the 
possible involvement of 
nociceptors. In this new definition, 
allodynia refers to pain in 
response to interaction with low-
threshold sensory nerve fibres, 
whereas hyperalgesia involves 
high-threshold fibres; nociceptors 
(Figure 2) (Sandkühler, 2009). 
  
Figure 2 – Hyperalgesia and allodynia 
 (Sandkühler, 2009) 
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There is a clear link between mental stress and an increase of visceral sensitivity, and this effect 
is mainly mediated by the release of corticotropin-releasing factor (CRF) by the hypothalamus. 
This activates release of adrenocorticotropic hormone (ACTH) from the pituitary gland into the 
bloodstream, which then leads to cortisol release from the adrenal glands. Cortisol has many 
effects in the body, for example, it is involved in increasing blood-glucose concentration, and 
suppression of the immune system. We will however focus on the effects of Hypothalamic-
Pituitary-Adrenal (HPA)-axis activation on visceral sensitivity.  
In rats, visceral hyperalgesia can be induced by repeated water-avoidance stress treatments, a 
model of psychological stress. This effect can be prevented by injection of CRF antagonists, 
showing that CRF-receptors play a main role in the generation of hyperalgesia by psychological 
stress (Larauche, Bradesi et al., 2008). Similarly, it has been shown that mast cells play a role in 
the generation of visceral hypersensitivity due to stressful conditions, through central pathways 
involving CRF (Gue, Del Rio-Lacheze et al., 1997). The nervous system can directly convey signals 
resulting from psychological stress to mast cells by CRF and/or Substance P (SP) release, which 
can trigger them to release mediators via piecemeal degranulation, in response to crowding 
stress (Vicario, Guilarte et al., 2010).  
Figure 3 – Pathophysiology of visceral pain. GR – Glucocorticoid receptor; CRH – Corticotropin releasing hormone (CRF) 
 (Greenwood-Van Meerveld, Moloney et al., 2016) 
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1.2.2.2 Genetics/ epidemiology  
Regardless of the largely unclear aetiology and pathophysiology of IBS, epidemiology can shed 
light on correlated and possibly causative factors. Research into this topic has focused on 
relation to family connections, comorbidity with psychological afflictions, and the local 
occurrence of infectious diseases. 
Firstly, looking at social connections, IBS aggregates heavily to families. It has a high odds ratio 
(OR) between siblings (3.12), children (2.12), and parents (1.91). Interestingly, there was no 
correlation between spouses (OR 0.89), indicating that genetics and not shared environment 
might be responsible for the observed effect (Saito, Petersen et al., 2010). This effect could then 
be explained by genes directly responsible for IBS, or genes increasing the likelihood of a related 
trait, such as lactose intolerance, depression or anxiety, somatization, or an immune system that 
increases risk of infection (Saito, Petersen et al., 2010). In a recent study done on twins, familial 
and intra-uterine factors were shown to affect the co-occurrence of IBS and psychological 
factors such as depression and anxiety. They were able to show that the comorbidity of IBS with 
mental disorders (depression and anxiety) were only present for those twins in a lower weight 
group of smaller than 2,5kg (Bengtson, Aamodt et al., 2015). This has led to the hypothesis that 
the HPA-axis links these two afflictions in intrauterine growth restriction and might explain the 
often-observed comorbidity, because an intrauterine physical stress could pre-program the 
HPA-axis to be more responsive (Bengtson, Aamodt et al., 2015). 
Looking further into the genetic aspects of this family aggregation it is important to realize that 
the susceptibility of the majority of IBS patients is caused by a complex interaction of many 
genes and the environment of the patient (Henström and D’Amato, 2016). However, in some 
cases, single genes may be responsible for symptom generation. A loss-of-function mutation of 
the SCN5A gene, encoding for the NaV1.5 ion channel present on interstitial cells of Cajal, seems 
to be heavily related to IBS-C (Beyder, Mazzone et al., 2014). Because of the more well-known 
function of the NaV1.5 ion channel, these patients were initially identified because of cardiac 
arrhythmia. Another gene of interest is TNFSF15, which codes for TNF-like ligand 1A, which is a 
clear susceptibility related gene for IBS (Zucchelli, Camilleri et al., 2011). This gene is also 
involved in the development of colitis in mice by DSS treatment, by supporting TH1 and TH17 
effector functions (Takedatsu, Michelsen et al., 2008), furthermore, it is an important 
susceptibility locus in for example Crohn’s Disease (CD) (Barrett, Hansoul et al., 2008) and 
arthritis of the spine (Zinovieva, Bourgain et al., 2009). That this gene is related to IBS can be 
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seen as an indication that IBS is related to an altered immune response in patients with positively 
correlated alleles.  
1.2.2.3 Stress and anxiety 
Because IBS and certain psychological 
profiles seem to be related, it is 
interesting to investigate the effects 
of mental stress and anxiety on IBS 
symptom generation and perception. 
Early life trauma, such as childhood 
abuse, has a significantly higher 
prevalence in IBS patients than in 
healthy controls, particularly in 
women. A history of emotional abuse 
specifically has a high predicting 
power; feeling ignored, and sexual 
abuse increase the odds of 
developing IBS with 2.08 and 3.05 
times, respectively (Bradford, Shih et 
al., 2012). IBS patients meeting 
criteria for any psychiatric disorder 
range from 40% to 94% in some 
studies, though this is most likely an 
overestimation due to tertiary care 
patient selection. It is clear however 
that IBS patients have a higher frequency of depressive, panic, or generalized anxiety disorders 
than other patients in the same clinics (Surdea-Blaga, Băban et al., 2012). 
The mechanisms for this observed association are likely to involve both true psychological 
factors, as well as the gut-brain and HPA axes (see Figure 4). In rats, psychological stress can 
increase visceral hypersensitivity by corticotropin releasing factor (CRF) release, which involves 
mast cell activation (Gue, Del Rio-Lacheze et al., 1997). Similarly, stress can increase the 
paracellular permeability through corticotropin releasing factor (CRF), stimulating the release of 
nerve growth factor (NGF) by mast cells (Barreau, Cartier et al., 2007) and the increase of mucus 
Figure 4 - HPA axis 
AMY (amygdala), HC (hippocampus, HYP (hypothalamus), NTS (nucleus of 
the tractus solitarius, PFDtc (prefrontal cortex). ACTH (adrenocorticotropic 
hormone), AVP (arginine vasopressin) CRH (corticotropin releasing hormone) 
GABA (gamma aminobutyric acid) 
 (Gunnar and Vazquez, 2006) 
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production in response to stress is mast cell dependent as well (Castagliuolo, Lamont et al., 
1996). Alternatively, somatization is considered an important factor in IBS, correlating with 
visceral hypersensitivity (Grinsvall, Törnblom et al., 2017). Because of this, cognitive behavioural 
therapy can improve GI symptoms through pathways improving anxiety levels (Jones, Koloski et 
al., 2011). Logically, improving stress levels in this way would improve both HPA-axis and 
psychological mediators.  
While an understanding of the proximate causes of the link between stress and visceral 
sensitivity is crucial in research, appreciating a more ultimate cause of this link is important too. 
Stress, either physical or psychological, induces adaptive responses by activation of both the 
HPA axis, as already discussed, and the sympathetic adrenomedullary system (SAM). Activation 
of SAM is very rapid, directly responsible for adaptations related to the flight-or-fight response 
and characterized by the release of adrenaline and noradrenaline by chromaffin cells innervated 
by the sympathetic preganglionic neurons, leading to acute adaptations such as increased 
cardiac output and blood glucose levels. Interestingly the noradrenaline:adrenaline release ratio 
seems to be dependent on neural integration in response to the nature and magnitude of 
stimulus (Vollmer, 1996). In contrast, activation of the HPA axis and subsequent increased 
cortisol levels have more chronic effects, and work mainly through regulating gene 
transcription (Sapolsky, Romero et al., 2000). Proper HPA axis function permits effective flight-
or-flight by optimising the response to adrenaline (the SAM response). Glucocorticoids released 
in HPA axis activation interact with 2 types of receptors in the brain, glucocorticoid receptors 
(GR) and mineralocorticoid receptors (MR), activation of which often have opposite effects. The 
balance of activation is determined by the concentration of glucocorticoids; at basal 
concentrations, only the MRs are activated, supporting maintenance processes such as ensuring 
responsiveness of neurons to neurotransmitters and regulating the circadian rhythm (Sapolsky, 
Romero et al., 2000), these processes permit effective responses to stress by optimising 
responses to adrenaline/noradrenaline (Gunnar and Vazquez, 2006). At peak concentrations 
GRs are engaged as well, which leads to stress responses, but with deleterious effects on brain 
function, such as inhibiting glucose utilisation by neurons, and impairing neural plasticity, 
learning and memory (Gunnar and Quevedo, 2007). These negative effects are likely meant to 
reverse the acute response to stressors, and support a return to homeostasis (Sapolsky, Romero 
et al., 2000). The balancing act between the activity of the HPA axis and SAM function to 
maintain homeostasis is called ‘allostasis’ (McEwen and Seeman, 1999), where the intended 
equilibrium is not at a fixed level, but dependent on context.  
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In case of prolonged or repeated stress, this allostatic system begins to become deleterious, due 
to negative health effects of otherwise adaptive responses (Gunnar and Quevedo, 2007; 
Greenwood-Van Meerveld, Moloney et al., 2016), with the gastrointestinal tract particularly 
vulnerable to negative effects (Mayer, 2000). 
1.2.2.4 Gut permeability in IBS 
An increase in gut permeability has been seen in IBS patients, particularly in PI-IBS, and can be 
associated to inflammatory processes and increased visceral sensitivity. In this section, we will 
investigate the role of increased permeability in IBS. For more information on intestinal 
permeability in general, please refer to section 1.5.2. 
It has been shown that the increased visceral sensitivity in response to acute (restraint) stress in 
rats is mediated by an increase in intestinal permeability, and prevention of this increase in 
permeability prevents the effect on sensitivity (Ait-Belgnaoui, Bradesi et al., 2005). In short, 
activation of stress pathways leads to mast cell activation, which produces mediators that lead 
to an increase in paracellular permeability, by opening tight junctions. The resulting increase in 
mucosal uptake of bacterial fragments and toxins activate the mucosal immune system, and 
together with the mast cell mediators, this causes visceral hyperalgesia (see Figure 5) (Ait-
Belgnaoui, Bradesi et al., 2005). In the same vein, it has been shown that public thesis defence 
stress increases small bowel permeability, an effect which can be blocked by mast-cell stabilizer 
cromoglicate (Vanuytsel, van Wanrooy et al., 2014), again showing that corticotropin releasing 
factor (CRF) release acts on intestinal permeability via mast cell activation. Volunteers were 
injected with CRF, which increased small intestinal permeability, but treatment with both CRF 
and cromoglicate did not do so. 
In IBS patients, paracellular permeability of colonic biopsies has been found to be increased in 
all subtypes of IBS, and this increase can be transferred in vitro to Caco-2 cell monolayers via 
soluble mediators derived from patient biopsies (Piche, Barbara et al., 2009). This shows that, 
like stressed animals, IBS patients have an increased paracellular permeability, and this increase 
is due to soluble mediators in the mucosa. The involvement of mast cells is implied both by their 
described capability of increasing intestinal permeability (Santos, Yang et al., 2001), as well as 
their role in increasing sensitivity (Barbara, Stanghellini et al., 2004; Barbara, Wang et al., 2007),  
 
28 | P a g e  
 
and the observation that IBS patients have increased mucosal mast cell counts (Matricon, 
Meleine et al., 2012), which holds up in a recent meta-analysis (Bashashati, Moossavi et al., 
2017). Another recent study claims that the colonic barrier function is uncompromised in female 
IBS-C patients (Peters, Edogawa et al., 2017), in contradiction to earlier findings claiming the 
opposite (Piche, Barbara et al., 2009). Additionally, they found no differences in expression of 
the important tight junction proteins Occludin, ZO-1, ZO-2, or ZO-3 (Peters, Edogawa et al., 
2017).  
Figure 5 – Possible mechanism by which stress can lead to increased visceral sensitivity through increased intestinal 
permeability. (Ait-Belgnaoui, Bradesi et al., 2005) 
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A possible explanation for these conflicting reports might be the use of different fluorescent 
markers in the ex vivo biopsy study; fluorescein–5.6 sulfonic acid (478 Da) for Piche, versus 4kDa 
FITC–dextran for Peters, and that the earlier study conducted by Piche, Barbara et al. used a 
cohort of IBS patients of all subtypes, diagnosed using Rome 2 criteria including slightly less IBS-
C patients, whereas the study by Peters, Edogawa et al. only looked at IBS-C patients diagnosed 
using Rome 3 criteria. This underlines the importance of distinguishing subgroups of IBS not only 
on their symptoms, but possibly also on the underlying causes for their affliction, although the 
study by Piche, Barbara et al. found no differences between subgroups.  
There are other possible mechanisms that could be responsible for the observed increase in 
permeability in IBS; a variety of proteases, whether derived from the host or the microbiota, 
have been described as involved in increasing the paracellular permeability of the host (Van 
Spaendonk, Ceuleers et al., 2017). Especially mast-cell derived trypsin and tryptase can be 
responsible for an increase in permeability due to PAR-2 activation, at the same time causing an 
increase in visceral sensitivity (Annahazi, Ferrier et al., 2013). Likewise, in the context of PI-IBS, 
an increased intestinal permeability plays an important role. Following Campylobacter infection, 
approximately 25% of patients develop ‘post-dysenteric irritable bowel syndrome’ (later called 
post-infectious IBS, or PI-IBS), characterized by increased intestinal permeability (Spiller, Jenkins 
et al., 2000). Furthermore, a study investigating possible genetic risk factors in the development 
of PI-IBS shows that certain alleles of IL-6, TLR9, and CDH1 rendered the patient more 
susceptible (Villani, Lemire et al., 2010). CDH1 (cadherin-1/E-cadherin) is a trans-membrane 
glycoprotein involved in cell-cell adhesion, and tight-junction formation by facilitating Adherens 
junctions (Hartsock and Nelson, 2008). Disruption of epithelial tight-junctions by enteric 
pathogens such as Campylobacter or E.coli causes an increase in intestinal permeability during 
infection (Berkes, Viswanathan et al., 2003; Wu, Rhee et al., 2007); so it is interesting that certain 
variants of the E-cadherin gene could be linked to development of PI-IBS. Either an impaired 
ability to adequately restore tight-junctions after infection, or a pre-existing higher permeability 
caused by this genetic variation could increase the likelihood of PI-IBS. 
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1.2.2.5 Immune System 
As mentioned before, the immune system is often seen as a key player in the physiopathology 
of IBS, and not only in the context of post-infectious IBS. Here, some possible mechanisms of 
involvement of the immune system in IBS will be discussed. 
Firstly, the clearest link between IBS and the immune system is represented by post-infectious 
IBS. After an infectious gastroenteritis, the risk of developing IBS is increased six times, which 
lasts for up to three years after the infection is resolved (Thabane, Kottachchi et al., 2007). 
Apparently, the activation of the immune system during the infection has long lasting effects on 
gut function, even after elimination of the infectious agent. In a similar fashion, IBD patients in 
remission often have IBS-like complaints (Barbara, Cremon et al., 2014), which indicates that 
even after the inflammation is abated, the recent immune activation has leftover effects 
resembling IBS. The reason for this link between inflammation and IBS symptoms might be 
related to the increased permeability of the tissue induced by it, as discussed in the previous 
section. 
A marker of the innate immune system, β-defensin 2, produced by neutrophils, monocytes and 
lymphocytes is increased in IBS patients, like in Ulcerative Colitis patients (Langhorst, Junge et 
al., 2009). Anti-microbial β-defensin 2 production is induced by pro-inflammatory cytokines in 
response to microbial invasion, after activation of toll-like receptors (TLRs) (Selsted and 
Ouellette, 2005), possibly indicating a partially shared origin of these maladies, or merely 
indicating an increase in permeability permitting more bacterial components to trigger TLRs in 
both cases. IBS symptoms in quiescent IBD seem to be related to undetectable inflammation 
involving increased numbers of intraepithelial lymphocytes and TNF-α, which were absent in IBS 
patients and quiescent IBD patients without IBS symptoms (Vivinus-Nebot, Frin-Mathy et al., 
2014).  
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Similarly, IBD patients with IBS symptoms show increased faecal calprotectin levels compared 
to IBD patients without IBS symptoms, again indicating occult inflammation (Keohane, 
O'Mahony et al., 2010). Increased calprotectin levels are indicative of neutrophil activation and 
thus inflammation and are generally not significantly increased in IBS. This would indicate that 
the IBS symptoms in IBD patients have a different origin than those of IBS patients (neutrophil 
mediated inflammation v mast cell mediated inflammation), though mechanisms such as 
subsequent increased permeability are similar in both cases. Alternatively, IBS has been 
described as a syndrome characterized by a low-grade inflammation, with a number of immune 
markers modestly but significantly increased compared to healthy controls, though still with a 
significant overlap with controls (Barbara, Cremon et al., 2011). In this view, IBS and IBD are 
positioned on different parts of a single spectrum of inflammation.  
Figure 6 - Possible shared mechanisms generating IBS symptoms in IBS and IBD in remission 
 (Spiller and Major, 2016) 
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IBD patients in remission that do not show occult inflammation, i.e., without increased faecal 
calprotectin levels but showing IBS symptoms, make up 31% of total IBD patients in 
remission (Berrill, Green et al., 2013), which is a higher proportion than observed in the general 
population. Figure 6 shows the possible mechanisms that could explain these patients, with 
mechanisms that largely correspond to PI-IBS, which is not surprising, considering the shared 
history of inflammation in PI-IBS and IBD patients. A subtle but interesting difference exists 
between the sanguine cytokine levels of healthy subjects and IBS patients. While no 
distinguishing profiles could be characterized, subgroups of IBS patients showed an increased 
immune activity, and cytokine profiles were more variable in the IBS group (Bennet, Polster et 
al., 2016). This further indicates the involvement of the immune system, at least in subsets of 
IBS patients. 
Inflammatory processes can lead to increased sensitivity by disconnecting nerves with their 
targets, which then causes reconnection and remodelling of these nerves (Byers, Suzuki et al., 
2003; Spiller and Major, 2016). For example, following recovery from TNBS induced colitis, 
substance P levels remained significantly increased in mucosal nerves in the medium term, and 
mucosal nerve galanin and muscular nerve substance P remained elevated on the long term 
together with a generally increased nerve innervation throughout the affected tissues, indicative 
of an increased potential for nociception (Simpson, Sundler et al., 2008). Relatedly, visceral 
sensitivity in IBS-D patients has been linked to mast-cell derived nerve growth factor (NGF) (Xu, 
Zhang et al., 2017), which could play a role in similar ways; promoting nerve growth and 
differentiation. However, the increased mucosal mast cell counts in IBS-D patients found in the 
same work might also be related to the increased visceral sensitivity independent of concurring 
increased levels of NGF. A recent meta-analysis indicates that mucosal mast cell numbers in the 
descending and rectosigmoid colon are indeed significantly increased in IBS patients, but no 
significant increase is observed in the ascending colon, additionally, CD3+ T cells show a 
significant increase in the rectosigmoid region, in IBS patients (Bashashati, Moossavi et al., 
2017).  
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Mast cell mediators such as histamine and proteases are known to activate enteric 
nerves (Schemann, Michel et al., 2005), and the close relation between mast cells and nerve 
endings has been linked to visceral pain (Barbara, Stanghellini et al., 2004; Barbara, Wang et al., 
2007). The interaction between mast cells and nerves in the intestinal mucosa is a two-way 
process, with mast cells activating and being activated by nerves (Van Nassauw, Adriaensen et 
al., 2007; Wouters, Vicario et al., 2016), which is illustrated in Figure 7. This bi-directionality is 
key to understanding the link between the nervous system and gastrointestinal function. Not 
only chemical signalling, but also psychological stress can activate mast cells (Gue, Del Rio-
Lacheze et al., 1997; Overman, Rivier et al., 2012). Recent unpublished yet interesting work 
indicates that mast cell activation in the gastrointestinal tract might also induce anxiety-like 
behaviour (Cordner, Liu et al., 2017; Liu, Cordner et al., 2017) in rats, and such psychological 
factors are a common occurrence in IBS, as seen in previous chapters. Since other mast cell 
products besides histamine, such as NGF and tryptase, can also be responsible for IBS symptoms, 
it makes sense that pure histamine receptor antagonists might be less useful in IBS than 
compounds with a general mast cell stabilizing effect. Such compounds, such as 
ketotifen (Klooker, Braak et al., 2010) and cromolyn sodium (Stefanini, Prati et al., 1992), do 
indeed show promise in the treatment of IBS symptoms, and can also prevent the increase in 
intestinal permeability following psychological stress (Vanuytsel, van Wanrooy et al., 2014). 
Figure 7 - Bidirectional interaction between mast cells and enteric nociceptors 
 (Wouters, Vicario et al., 2016) 
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1.2.2.6 Microbiota particularities/ dysbiosis 
Starting with the recognition of the association of gastroenteritis, as discussed before, and the 
use of antibiotics as a risk factor for developing IBS (Villarreal, Aberger et al., 2012), the 
microbiota is increasingly recognized as a possible factor in IBS. The microbiota profiles of IBS 
patients tend to differ from those of healthy patients (Rajilic-Stojanovic, Biagi et al., 2011), and 
they can be used to predict the responsiveness of IBS patients to dietary intervention with a low-
FODMAP diet (Bennet, Böhn et al., 2017; Valeur, Smastuen et al., 2018). However, because IBS 
is characterized by changes in bowel habits, which are very likely to influence the microbiota 
composition, specific differences are difficult to interpret. Additionally, it is not yet clear whether 
a specific microbiota pattern exists for IBS, but in general, a reduction of bacterial diversity and 
an increased instability have been consistently found (Collins, 2014). 
It is very likely that the two-way signalling between microbiota and epithelium which can 
regulate secretion of mucus and other molecules involved in host-microbe interactions is 
involved in IBS, because IBS patients show a dysregulation of the mucus layer and β-defensin-2 
peptides (Swidsinski, Loening-Baucke et al., 2008; Langhorst, Junge et al., 2009; Simren, Barbara 
et al., 2013). Illustrating a role for microbiota in IBS, patients show a modulated expression of 
certain Toll-like receptors (TLRs), which perceive pathogen-associated molecular patterns 
(PAMPs) such as lipopolysaccharides (LPS) for the innate immune system, indicating 
involvement of microbiota-immune interactions in IBS. Both IBD and IBS patients show 
alterations in the composition of the gut microbiota (Spiller and Lam, 2011; Casen, Vebo et al., 
2015), also known as ‘dysbiosis’, though it is not immediately clear whether this dysbiosis is 
cause, effect, or both.  
Transit time and stool consistency directly influence microbiota composition (Vandeputte, 
Falony et al., 2015), and both these factors are altered in IBS and IBD, making it difficult to relate 
microbiota differences as a cause. Additionally, microbiota composition is affected by dietary 
patterns (Rajilic-Stojanovic, Jonkers et al., 2015), and patients often change their dietary habits 
in an effort to mitigate symptoms. Perhaps unsurprisingly, the measure of dysbiosis found in IBS 
patients is correlated to the gravity of their symptoms (Tap, Derrien et al., 2017), and 
interestingly, these differences in microbiota composition were not correlated to diet.  
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It is not straightforward to clearly link certain phyla or species of bacteria to IBS, but certain 
trends have been consistently observed; such as a depletion of Bifidobacteria in both faecal and 
mucosal microbiota (Malinen, Rinttila et al., 2005; Kerckhoffs, Samsom et al., 2009). Duplicate 
HITChip microarray analyses of faecal samples of IBS patients and healthy controls in Finland 
showed that IBS patients had 1.5-fold decreased Bifidobacteria counts, and a 2-fold increased 
ratio of Firmicutes/Bacteroidetes (Rajilic-Stojanovic, Biagi et al., 2011). Additionally, a Japanese 
study showed that a pooled group of IBS-subtypes had significantly higher counts of Veillonella 
and Lactobacillus than healthy controls (Tana, Umesaki et al., 2010).  
That it is possible for the microbiota to have a causative effect in generating IBS symptoms has 
been shown in animal experiments. Inoculating germ-free rats with a microbiota from IBS 
patients renders them hypersensitive to colorectal distension, compared to conventional rats, 
but being inoculated with healthy human microbiota does not have this effect (Crouzet, Gaultier 
et al., 2013), and similarly, a decreased transit time, impaired intestinal permeability, and 
anxiety-like behaviour can be transferred to germ-free mice by inoculating them with IBS-D 
patient microbiota (De Palma, Lynch et al., 2017), results which indicate a possible causative 
effect of a disorder-associated microbiota profile. 
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1.2.2.7 Small intestinal bacterial overgrowth 
Small intestinal bacterial overgrowth (SIBO) is a syndrome often linked to IBS. It consists of an 
increased number of bacteria in the small bowel, defined as numbers over 1*103cfu/ml proximal 
jejunal contents (Khoshini, Dai et al., 2008), while the small bowel should normally contain small 
bacterial populations (Bouhnik, Alain et al., 1999; Bures, Cyrany et al., 2010). The expansion of 
bacteria from the large into the small intestine is held responsible for such symptoms as 
bloating, abdominal discomfort, and changes in stool form (Pimentel and Lezcano, 2008), which 
is reminiscent of IBS, but with an organic cause. However, a higher proportion of diagnosed IBS 
patients than healthy controls are reported to present with SIBO (Lupascu, Gabrielli et al., 2005), 
which makes it questionable whether they actually have true IBS, or it might indeed indicate a 
causative role for SIBO in IBS, depending on interpretation.  
This possible causal relationship between SIBO and (all cases of) IBS has been hotly contested, 
among other reasons, because there are issues with the methods used to characterize SIBO; the 
lactulose hydrogen breath test (LHBT) to determine abnormally early carbohydrate 
fermentation is flawed, and it has recently been shown that in most (88%) of the IBS patients 
for who the test is positive, the bolus was already in the caecum, as measured by oro-caecal 
scintigraphy (Yu, Cheeseman et al., 2010). Additionally, bacterial numbers in the jejunum used 
to determine severity of SIBO do not seem to correlate to IBS symptom severity (Grover, 
Kanazawa et al., 2008). In short, it is unlikely that SIBO has a clear causal role to play in 
IBS (Spiegel, 2011).  
It is often beneficial for patients to exclude lactose from the diet and to reduce other simple 
sugars (Bures, Cyrany et al., 2010), which resembles the low-FODMAP diet in form and function, 
i.e., lower the amount of available fermentable carbohydrates to the gut microbiota. SIBO is 
often mis- or underdiagnosed due to the wide range of clinical manifestations, and 
understanding its mechanisms better will hopefully lead to future improvements to patient 
care (Sachdev and Pimentel, 2013).  
We will talk more about the functions of the microbiota in a later chapter (1.3) devoted to the 
matter.  
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1.2.2.8 Biomarkers IBS 
To better characterize patients, and to facilitate diagnosis, a lot of effort has been targeted to 
identify biochemical markers (biomarkers) for IBS and its subgroups, with varying success. 
Though IBS is increasingly seen as having organic characteristics, its history as a functional 
disorder has not yielded much in the way of biomarkers. However, there are some promising 
developments to help determine appropriate treatment of patients; microbiota profiles can 
apparently serve to predict responsiveness to dietary intervention (Bennet, Böhn et al., 2017), 
and genetic markers can be used to predict responsiveness to certain drugs (Enck, Aziz et al., 
2016). Additionally, technical advancements such as the pressure-, temperature-, and 
pH‑sensitive SmartPill (Given Imaging Ltd, Yoqneam, Israel) can be used to get detailed insights 
into gastrointestinal motility of patients (Rao, Kuo et al., 2009), which can be used for patient 
characterisation and help to identify targets for antispasmodics (Enck, Aziz et al., 2016). Another 
possible approach is the use of cytokine profiles (Bennet, Polster et al., 2016), though as of yet, 
there are no biomarkers that can be used to reliably diagnose IBS. 
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1.2.3 Clinical practice 
Treatment of IBS is complicated, with many treatments not sufficiently effective. Because the 
underlying causes for IBS are not well understood, it has proven difficult to design evidence-
based therapies with a clear mechanism of effect. Additionally, scientific underpinning for 
treatment of functional disorders in general suffers from a high placebo effect to treatment. 
Diagnosis of IBS depends mostly on excluding any other cause for the symptoms. Diagnostic 
algorithms for diagnosis of IBS must therefore make sure that there are no more serious origins 
of complaints (Enck, Aziz et al., 2016). 
What follows now is an oversight of current clinical practice in IBS patients. 
1.2.3.1 IBS – Medication 
Several pharmaceutical treatments of IBS have been developed over the years, mostly aimed at 
tackling one or the other symptom, in accordance with the functional nature of the syndrome. 
To treat the constipation in a subset of IBS patients, laxatives can be effective, and the laxative 
and analgesic linaclotide has proven useful in treating constipation in IBS (Chey, Lembo et al., 
2012), while at the same time reducing pain by activating epithelial guanylate cyclase-C receptor 
(GC-C), which increases extracellular cGMP, thereby reducing nociceptor sensitivity (Castro, 
Harrington et al., 2013). To reduce painful smooth muscle spasms, common in IBS, 
antispasmodic drugs are used. However, these drugs can cause constipation, and should not be 
tried in already constipated patients (Enck, Aziz et al., 2016). One such antispasmodics is 
peppermint oil, which blocks calcium channels, thereby inhibiting contractions (Hawthorn, 
Ferrante et al., 1988). It is specifically effective when administered in capsules which release 
throughout the small intestine (Cash, Epstein et al., 2016). It follows from what we know about 
the involvement of mast cells in IBS, that mastocyte stabilizers can be expected to have 
beneficial effects in IBS. An animal IBS model inducing visceral sensitivity in rats by partial 
restraint stress (PRS), shows that mast cell stabilizer doxantrazole suppresses stress-induced 
visceral hypersensitivity (Gue, Del Rio-Lacheze et al., 1997). Similarly, an animal IBS model using 
chemical induction of visceral hypersensitivity by acetic acid-induced colitis shows that the same 
mast cell stabilizer can significantly attenuate the hypersensitivity (La, Kim et al., 2004). In 
humans, trials with anti-inflammatory drugs have proven more ambiguous, with mast-cell 
stabiliser ketotifen showing promise in reducing visceral hypersensitivity and improving 
QOL (Klooker, Braak et al., 2010), but mesalazine, another mast cell stabilizer, no better than 
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placebo, after a pilot study initially yielded hopeful results (Corinaldesi, Stanghellini et al., 2009; 
Barbara, Cremon et al., 2016). 
1.2.3.2 IBS – Probiotics 
Because of the often-cited link to the intestinal microbiota, there is a significant interest in 
treating IBS with probiotics. Oral probiotics are defined as ‘live micro-organisms, which upon 
ingestion in certain numbers, exert health benefits beyond inherent basic nutrition’ (Guarner 
and Schaafsma, 1998), and later by the WHO, very similarly, as ‘Live microorganisms which when 
administered in adequate amounts confer a health benefit on the host’ (Joint FAO/WHO 
Working Group, 2002) although it has to be considered that non-live microbial preparations and 
subcellular components are often sufficient to induce beneficial effects (Collins, 2014).  
In a maternal deprivation early life stress rat model of IBS, and similarly in the more acute partial 
restraint stress (PRS) model, it has been clearly shown that certain probiotics are superior to 
others in preventing the increase in gut permeability and sensitivity induced by these stressors. 
Lactobacillus paracasei NCC2461, but not Bifidobacterium lactis NCC362 or Lactobacillus 
johnsonii NCC533, was effective in ameliorating gut health impacted by stress, showing both 
that probiotics can be effective in these cases, and that this efficacity is strain-
specific (Eutamene, Lamine et al., 2007). Similarly, a recent in vitro study has shown that 
potential probiotic strains of lactic acid bacteria (LAB) can modulate goblet cell gene expression 
in a treatment time- and strain-specific manner (Ren, Dokter‐Fokkens et al., 2018). Extrapolation 
of these results to in vivo situations would indicate that these LAB can exert an effect on the gut 
barrier function by modulating mucus-related genes. Interpretation is complicated due to the 
strong fluctuations, both positive and negative, of gene expression profiles on short-scale 
treatment time differences reported in this paper. This makes it entirely unclear how to translate 
such findings to an in vivo setting, in which exact exposure time cannot be controlled, but 
progresses naturally.  
A meta-analysis of randomised controlled trials (RCTs) of probiotic treatment of IBS patients 
showed a general positive effect, in contrast to prebiotics and synbiotics, which were not shown 
to be effective (Ford, Quigley et al., 2014). However, these kinds of meta-analyses often cite a 
lack of high-quality data, whilst claiming a positive effect for probiotics, according to a meta-
analysis from a year later, identifying reasons for difficulties to reach a strong overall conclusion 
on the efficacity of probiotics in treating IBS (Mazurak, Broelz et al., 2015). They found that the 
grouping of different probiotic species and strains as ‘probiotics’ is a major hurdle to a strong 
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conclusion (Mazurak, Broelz et al., 2015), which supports the idea of strong variability between 
strains and species.  
Additionally, to better treat IBS patients with probiotics, it would be helpful to first analyse their 
microbiota and thereby characterise their possible dysbiosis. In a patient for which the bacterial 
function to be supplemented is not lacking, doing so should not be expected to bring about 
significant improvement, and no normalisation of microbiota function should be expected by 
this approach. 
It is not clear that the efficacy of probiotics indicates an important role for the microbiota in IBS, 
because oral administration of probiotics can be viewed as simply delivering substances of 
therapeutic value (of microbial origin), with little effect on the host microbiota. Upon reaching 
the colon, where the majority of the intestinal microbiota resides, the concentration of 
probiotics alive after passing through the preceding gastrointestinal tract is orders of magnitude 
less abundant than the endogenous bacteria, and after stopping treatment with probiotics, the 
comparatively small effect on microbiota composition is soon lost (Collins, 2014). 
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1.2.3.3 IBS – Diet 
Around 60% (Brandt, Chey et al., 2009) to 82% (Bohn, Storsrud et al., 2013) of IBS patients say 
that their symptoms worsen with the intake of certain foods, which, together with the 
inadequacy of pharmaceutical treatments, has led to the development of dietary interventions. 
A common dietary intervention aims to increase the dietary fibre intake, often through 
supplementation, to improve bowel movements (Enck, Aziz et al., 2016). However, these 
interventions have often not shown a convincing increased effect over placebo diet treatments, 
and a meta-analysis of 14 randomised controlled trials (RCTs) yielded a weak recommendation 
of these kinds of treatments in IBS patients (Ford, Moayyedi et al., 2014). Additionally, it is noted 
that fibres can lead to increased fermentation in the intestines, leading to production of gases, 
a variety of other metabolites, as well as increasing the microbial population (Flamm, Glinsmann 
et al., 2001; Eswaran, Muir et al., 2013). These effects of increased dietary fibre intake can be 
problematic in IBS patients, the corresponding increase in distension can be painful in patients 
with increased visceral sensitivity. One systematic review found that they can be beneficial in 
some patients, but ineffective or even worsen symptoms in other patients, with especially 
insoluble fibres proven problematic (Bijkerk, Muris et al., 2004) shown also by a randomised 
placebo controlled trial, where (poorly fermentable) soluble psyllium proved useful, while 
insoluble bran proved problematic enough for patients to drop-out of the trial at an increased 
rate (Bijkerk, De Wit et al., 2009). On the other hand, fermentable soluble fibres have also been 
linked to gastrointestinal troubles, such as bloating, flatulence, and painful cramps. Fructo-
oligosaccharides (FOS) and galacto-oligosaccharides (GOS) for example, are rapidly fermented 
in the terminal ileum and early colon under production of a lot of gas which can induce 
gastrointestinal symptoms in IBS patients (Eswaran, Muir et al., 2013). It is too broad to state 
the efficacy of fibres in general, because their properties are not uniform; fermentable or non-
fermentable, soluble or insoluble. 
Currently, dietary advice most often dispensed are the ‘traditional IBS diet’, and the ‘low-
FODMAP diet’. A traditional IBS dietary approach generally calls for increased attention to when 
and how to eat rather than focusing on specific dietary choices (Böhn, Störsrud et al., 2015). 
Nicely summarised in this paper: “the participants were instructed to regularly eat 3 meals and 
3 snacks a day, never too much or too little each time, never to be hungry or too full; to eat in 
peace and quiet and to chew thoroughly; reduce intake of fatty or spicy foods, coffee, alcohol, 
onions, cabbage, and beans; avoid soft drinks and carbonated beverages, chewing gums, and 
sweeteners that end with -ol, and to eat fibres but distribute the intake evenly during the 
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day.” (Böhn, Störsrud et al., 2015). The low-FODMAP diet calls for avoidance of ‘fermentable 
oligo-, di-, mono-saccharides and polyols’, which are represented by dietary carbohydrates such 
as fructose, galactans, and mannitol; for an extensive list of prevalent foodstuffs containing 
sizeable amounts of FODMAPs, see Table 5. 
It is noteworthy that both diets call for avoidance of soft drinks, which are generally rich in 
fructose, vegetables rich in fermentable fructans and galactans, and polyol-type sweeteners. 
The low-FODMAP diet is sometimes claimed to work better than traditional IBS dietary 
advice (Staudacher, Whelan et al., 2011), while a more recent study claims they are equally 
effective (Böhn, Störsrud et al., 2015). Of course, it is difficult to control for pre-existing dietary 
differences between trials performed in different cultures, or the differences in advice provided 
by different dieticians, to make a real assessment on the efficacity of a low-FODMAP diet versus 
a traditional IBS diet.  
  
Table 5 - Examples of foods rich in specific FODMAPs (adapted from (Gibson and Shepherd, 2010)) 
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1.2.4 FODMAP diet 
As already introduced before, in recent years a low-FODMAP diet has been successfully used to 
reduce symptoms of IBS, with a proposed mechanistic basis of effect (Gibson and Shepherd, 
2010; Halmos, Power et al., 2014). Because it is the main target of investigation in this thesis, 
we will take a more in-depth look into this diet and the expected effects, positive and/or 
negative. 
1.2.4.1 Theoretical background; list of FODMAPS/ diet specifics 
To begin with, many symptoms of IBS, principally abdominal pain, but also bloating, are noted 
in response to luminal distension. Gibson and Shepherd proposed that minimizing the 
consumption of those dietary compounds that lead to distension of the intestine would lead to 
improvement of symptoms of FGIDs. A group of dietary components the same authors had 
previously coined ‘FODMAPs’, for Fermentable Oligo-, Di-, Mono-saccharides And 
Polyols (Gibson and Shepherd, 2005) have those properties that can lead to distension; they are 
poorly absorbed in the small intestine, osmotically active, and are rapidly fermented by the gut 
microbiota upon reaching the colon (Gibson and Shepherd, 2010), see Figure 8. It is generally 
claimed that FODMAPs themselves are not responsible for symptoms in IBS patients, but induce 
adverse effects due to inherent responses in these patients (Molina-Infante, Serra et al., 2016).  
 
Figure 8 - Mechanisms by which FODMAPs can induce gastrointestinal symptoms. In the small intestine, unabsorbed 
FODMAPs can increase small intestinal water, thereby causing distension. In the large intestine, fermentation of FODMAPs 
leads to production of gases and ultimately luminal distension, and SCFAs. (Staudacher and Whelan, 2017) 
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However, these dietary components can induce gastrointestinal problems in healthy persons 
too. A monosaccharide FODMAP, fructose, can lead to a variety of gastrointestinal symptoms, 
Table 6 - Trials investigating the efficacy of a low-FODMAP diet 
Ref Study design Participants N Duration 
Symptom 
scoring 
Findings 
Controlled trials 
 (Staudacher, 
Lomer et al., 
2016) 
Placebo-
controlled 
dietary advice 
RCT (single 
blind) 
Rome III IBS-
D, IBS-M,  
IBS-U 
LFD n=51 
Sham diet 
n=53 
4 weeks 
AR, 
IBS-SSS, 
IBS-QOL 
Primary outcome: No difference in AR (LFD 
57% vs control 38%; p=0.051)  
Secondary outcomes: Lower IBS-SSS score 
(LFD 173 vs control 224; p=0.001) and 
greater numbers achieving MCID for IBS-QOL 
(LFD 51% vs control 26%; p<0.023) 
 (Staudacher, 
Lomer et al., 
2012) 
Dietary advice 
RCT (unblind) 
Rome III IBS 
with 
bloating or 
diarrhoea 
LFD n=19 
Habitual diet 
n=22 
4 weeks 
AR, 
GSRS, 
Bristol Stool 
Form 
Primary outcome: Lower luminal abundance 
of Bifidobacteria 
Secondary outcomes: Greater numbers 
reporting AR (LFD 68% vs control 23%; 
p=0.005) Lower bloating, borborygmi, overall 
symptoms LFD versus control (p<0.05) 
Greater number of normal stools (LFD 24% vs 
control 7%; p=0.02) 
 (Schultz, 
Harvie et al., 
2013) 
Dietary advice 
RCT (unblind) 
Rome III IBS 
LFD n=23 
Waiting list 
n=27 
3 months 
IBS-SSS, 
IBS-QOL 
Outcomes: Greater reduction in IBS-SSS (LFD 
276 to 129 pt. vs control 247 to 204 pt.; 
p<0.01), frequency of pain episodes (p<0.01)  
Greater increase in IBS-QOL score for LFD 
versus control (p<0.0001) 
 (Pedersen, 
Andersen et 
al., 2014) 
Dietary advice 
RCT (unblind) 
Rome III IBS 
LFD n=42 
Probiotic n=41 
Habitual diet 
n=40 
6 weeks 
IBS-SSS, 
IBS-QOL 
Primary outcome: Greater reduction in IBS-
SSS (LFD −75 pt. vs control −32 pt.; p<0.01)  
Secondary outcome: No change in IBS-QOL 
for all groups 
 (Halmos, 
Power et al., 
2014) 
Placebo-
controlled 
feeding RCT, 
crossover 
(single blind) 
Rome III IBS 
LFD n=27, 
Typical diet 
n=27 
21 days 
100 mm 
symptom 
VAS, 
Stool 
frequency, 
Stool water 
content 
Primary outcome: Lower overall GI 
symptoms (LFD 23 mm vs control 45 mm; 
p<0.001). Secondary outcome: Lower stool 
frequency in IBS-Din LFD versus control 
Comparative trials 
 (McIntosh, 
Reed et al., 
2017) 
Dietary advice 
RCT (single 
blind) 
Rome III IBS 
LFD n=20, HFD 
n=20 
3 weeks 
Responder: 
≥50 pt. 
reduction 
IBS-SSS 
Primary outcome: area under the curve for 
lactulose breath test  
Secondary outcomes: Greater number of 
responders (LFD 72% vs HFD 21%; p<0.009) 
Lower IBS-SSS in LFD versus HFD (p=0.01) 
 (Hustoft, 
Hausken et al., 
2017) 
Dietary advice 
RCT, crossover 
(double blind) 
Rome III, 
IBS-D, IBS-M 
LFD+placebo 
n=20 
LFD+fructans 
n=20 
6 weeks 
IBS-SSS,  
100 mm 
symptom 
VAS 
Outcomes: Lower IBS-SSS (LFD 80% vs 
control 30%; p=0.014) and severity of 
nausea/vomiting, belching, flatulence in LFD 
versus control (p<0.05) 
 (Eswaran, 
Chey et al., 
2016) 
Dietary advice 
RCT 
 (unblind) 
Rome III IBS-
D 
LFD=45 
Modified NICE 
guideline n=39 
4 weeks 
Responder: 
AR ≥50% of 
weeks 3,4; 
Composite 
pain and 
stool score 
Primary outcome: No difference in numbers 
of responders (LFD 52% vs control 41%; 
p=0.31) Secondary outcomes: No difference 
in those achieving composite score endpoint 
(LFD 27% vs control 13%; p=0.13) Greater 
reduction in pain (LFD 51% vs control 23%; 
p=0.008) 
 (Peters, Yao 
et al., 2016) 
Dietary advice 
RCT (unblind) 
Rome III IBS 
LFD  
n=24 
Hypnotherapy 
n=25 
LFD + 
hypnotherapy 
n=25 
6 weeks 
Responder: 
≥20 mm 
VAS 
improveme
nt in 
symptoms, 
IBS-QOL 
Primary outcome: No difference in numbers 
of responders (LFD 71% vs hypnotherapy 
72% vs combination 72%; p=0.67).  
Secondary outcomes: Lower symptom 
severity in LFD and hypnotherapy versus 
baseline (p<0.05) and higher IBS-QOL scores 
in all groups compared with baseline 
(p<0.001) but no differences between groups 
for symptoms or IBS-QOL 
 (Böhn, 
Störsrud et al., 
2015) 
Dietary advice 
RCT (single 
blind) 
Rome III IBS 
LFD  
n=38  
NICE guideline 
n=37 
4 weeks 
Responder: 
≥50 pt. 
reduction 
IBS-SSS, 
Stool 
frequency 
and 
consistency  
Primary outcome: No difference in number 
of responders (LFD 50% vs control 46%; 
p=0.72) 
AR, adequate relief; FFQ, Food Frequency Questionnaire; GSRS, Gastrointestinal Symptom Rating Scale; HFD, high FODMAP diet; IBS-QOL, IBS 
Quality of Life Questionnaire; IBS-SSS, IBS Severity Scoring System; LFD, low FODMAP diet; MCID, minimal clinically important difference; NICE, 
National institute for Health and Care Excellence; RCT, randomised controlled trial; VAS, visual analogue scale.  
Adapted from Staudacher and Whelan, 2017 (Staudacher and Whelan, 2017) 
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such as diarrhoea, cramps and flatulence (Ravich, Bayless et al., 1983; Major, Pritchard et al., 
2017), but fructose malabsorption is ameliorated when fructose is taken together with glucose, 
due to the facilitating effect to small intestinal absorption of these two compounds together 
which prevents symptom generation (Truswell, Seach et al., 1988). These days, fructose is 
consumed at increasing doses as a result of the growing usage of high-fructose corn syrup in 
many products, likely increasing the concentration reaching the colon for microbial processing. 
In lactase non-persistent persons, the disaccharide FODMAP lactose reduces the oro-caecal 
transit time, independently from the increased luminal distension of the small intestine induced 
by the osmotically active lactose (He, Venema et al., 2008). Instead, it is claimed that colonic 
fermentation of lactose in maldigesters could be partly responsible for symptoms of lactose 
intolerance (He, Priebe et al., 2006). In relatively high doses, inulin, a fructo-oligosaccharide, can 
lead to gastro-intestinal symptoms such as flatulence (Pedersen, Sandström et al., 1997; Major, 
Pritchard et al., 2017). Sorbitol, a polyol FODMAP, too is known to induce gastrointestinal 
symptoms at higher doses (>10 g) (Hyams, 1983). However, simultaneous malabsorption of 
modest doses of multiple of these compounds is relatively rare (Ladas, Grammenos et al., 2000), 
as measured by the occurrence of gastrointestinal symptoms, showing that generally, 
reasonable doses are tolerated in healthy subjects. As mentioned before, the low-FODMAP diet 
intends to reduce the intake of these compounds (see Table 5), to lessen intestinal distension, 
and thus, lessen the provocation of symptoms in IBS patients. The diet has shown promising 
results since it has been introduced, see Table 6.  
Generally, these studies show that the low-FODMAP is effective in reducing IBS symptoms, 
though it is not superior to NICE guidelines (traditional IBS diet) (Böhn, Störsrud et al., 2015), or 
hypnotherapy (Peters, Yao et al., 2016). Although another study shows an increased effect on 
abdominal pain, bloating, stool consistency, stool frequency, and urgency in IBS-D patients, 
compared to modified NICE guidelines, but not on general adequate relief (AR) (Eswaran, Chey 
et al., 2016). A meta-analysis from 2015 covering 6 RCT and 16 non-randomized interventions 
supports the efficacy of low-FODMAP diet compared to non-treatment, with pooled odds ratios 
for significant improvement of IBS-SSS questionnaire scores of 0.44 for RCTs and 0.03 for the 
non-randomized trials (Marsh, Eslick et al., 2016). Generally, we can conclude that the low-
FODMAP diet delivers a significant improvement to the situation of IBS patients. 
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1.2.4.2 Possible adverse effects low-FODMAP diet 
In most cases, the low-FODMAP approach calls for drastic changes to the day-to-day diet. Here, 
we will look at the possible adverse effects of following a low-FODMAP diet.  
First, since FODMAPs are fermentable, they have a prebiotic function, meaning that they provide 
the intestinal microbiota with nutrients, and therefore support the bacterial populations in the 
gut. Drastically reducing these compounds logically influences the composition and density of 
the intestinal microbiota. Because of this, the main concern with the low-FODMAP approach are 
unintended long-term consequences to the intestinal microbiota (Halmos, Christophersen et al., 
2015), as well as possible nutritional deficiencies due to the restrictive diet (Staudacher and 
Whelan, 2017), although in a comparative study, only calcium intake was slightly impacted, due 
to the reduced intake of lactose-containing dairy products (Staudacher, Lomer et al., 2012). 
However, since a low-FODMAP diet is supported by a professional dietician, we can expect 
nutritional sufficiency to be better safeguarded than in patients who try to adapt their diet by 
themselves to prevent adverse events; which is common among IBS patients (Monsbakken, 
Vandvik et al., 2006).  
Concerning microbiota composition, several studies have been undertaken, showing a low-
FODMAP diet can be responsible for a reduction in Bifidobacteria (Staudacher, Lomer et al., 
2012; Halmos, Christophersen et al., 2015; McIntosh, Reed et al., 2017; Staudacher, Lomer et 
al., 2017), F.prausnitzii, Clostridium cluster IV, and total bacterial numbers (Halmos, 
Christophersen et al., 2015). However, it is still unclear whether there are health effects to these 
changes and what these would be, though Bifidobacteria are generally considered to be 
beneficial, and have been shown to already be reduced in untreated IBS patients (Malinen, 
Rinttila et al., 2005; Kerckhoffs, Samsom et al., 2009; Rajilic-Stojanovic, Biagi et al., 2011). The 
patients in these studies were not on specified diets, so it is possible that they have lower 
Bifidobacteria counts due to evasion of prebiotic FODMAPs on their own initiative.  
Apart from effects on the composition of the microbiota, a reduction in supposedly beneficial 
bacterial metabolites, such as short-chain fatty acids (SCFA) is an additional possible concern.  
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Technical difficulties and conflicting results have left this consideration to be clarified for the 
time being. Faecal SCFA concentrations have been shown to be actually higher in IBS patients 
than in control patients, with total SCFA, propionic acid, and acetic acid significantly increased, 
which was correlated with IBS symptoms (Tana, Umesaki et al., 2010), although the direction of 
the possible causation is not clear. In animal experiments however, butyrate enemas can induce 
a visceral hypersensitivity in rats mediated by CGRP receptor, offering a non-inflammatory 
hypersensitivity model of IBS, according to the authors (Bourdu, Dapoigny et al., 2005). 
Conversely, SCFA produced by bacteria play an important role in host energy 
provision (Bergman, 1990), enterocyte energy provision in particular (Basson, Turowski et al., 
1996), and colonic Treg cell homeostasis (Smith, Howitt et al., 2013) among other important 
functions. Consistent with the decreased intake of prebiotic material, faecal SCFA 
concentrations are reduced in IBS-M and IBS-D patients on a low-FODMAP diet (Hustoft, 
Hausken et al., 2017).  
However, it has to be noted that faecal SCFA analysis is not a reliable method, because it reflects 
colonic absorption better than production (Cook and Sellin, 1998; Sakata, 2018), and is heavily 
influenced by transit time (Ringel-Kulka, Choi et al., 2015), which we know can be highly variable, 
in particular between IBS patients with either diarrhoea or constipation, and healthy patients. 
In short, without measuring SCFA concentrations where they are produced, mostly in the 
ascending colon, it will not be possible to clearly identify the link between SCFA concentrations, 
IBS symptoms, and possible effects of the low-FODMAP diet (Staudacher and Whelan, 2017), so 
most of these results can be interpreted as a mix of artefacts of sampling method and less than 
useful correlations. 
 
  
 P a g e  | 49 
 
1.3 Intestinal microbiota 
The intestinal microbiota plays a vital role in vertebrate health. In this chapter we will look into 
the many functions the gut microbiota has, but also how it can be co-responsible for some health 
issues.  
1.3.1 Function 
Our gastrointestinal tract is populated by microbes whose numbers, complex population 
composition, and ecology boggle the mind. They do not limit themselves to being impressive 
though; they are important in digestion, immunity, and resistance to pathogens as well. 
The gut microbiota is needed for the correct development of innate and adaptive immunity, the 
integrity of the intestinal epithelium, provision of the host with both energy sources and 
vitamins, prevention of colonization of our gastrointestinal tract by pathogenic microbes as 
well (Dave, Higgins et al., 2012). Research into the microbiome has become more and more 
translational in recent years, now driving investments coming from big pharma and other 
private institutions to benefit from the many expected applications of knowledge to treat health 
conditions with probiotics, as well as of identification of useful microbiota diagnostic 
biomarkers (Gilbert, Blaser et al., 2018).  
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1.3.1.1 Symbiosis; never alone 
The human gut microbiota has evolved together with us, and due to this long-shared history, 
there is a high level of symbiosis. Vertebrates benefit greatly from their microbiota, although, as 
shown in the possibility of rearing germ-free animals, it is not essential in the strict sense. 
Normally, we are inoculated by gut microbes during natural birth (Mandar and Mikelsaar, 1996), 
a process which does not take place during Caesarean section, with possible ramifications to 
later health (Di Mauro, Neu et al., 2013; Jakobsson, Abrahamsson et al., 2014). A healthy 
microbiota contains many different phylogenetic types; molecular analysis of stool samples of 
124 subjects shows that there are over 1000 bacterial species associated to the human 
microbiota, with at least 160 species per individual (Qin, Li et al., 2010). This large microbial 
diversity contains many unique genes, which, by modest estimation, contains at least 9 million 
unique genes (Yang, Xie et al., 2009) though this relates to the totality of known gut microbiota 
species, which are not all present in every individual. Still, seeing as the human genome contains 
a maximum of approximately 39 thousand genes (including hypothetical and unannotated 
genes) (Venter, Adams et al., 2001), the bacterial genes associated to our gut microbiota are at 
least 200 times more abundant than eukaryotic host genes. We have to keep in mind that most 
of these genes regulate normal functioning of bacterial lifecycles and metabolism and that many 
are homologous and/or analogous between different species and strains, indicating a 
substantial redundancy. It is often claimed that there are 10 times more bacterial cells in the 
intestines than there are animal cells in our bodies (Savage, 1977), a claim that is eagerly 
repeated in many article introductions. However, this number is based on two very rough 
estimates for host and microbial cell numbers. In 2016, using more informed calculations, it has 
been estimated that the ratio is closer to 1:1,3, wherein bacteria still outnumber host 
cells (Sender, Fuchs et al., 2016). They have not recalculated the number of host cells, which 
might still change this ratio.  
What drives the relation between host and microbe is a common interest in metabolism as a 
requisite for life. The host provides the microbiota with nutrients by its animal mobility and 
motivations, as well as a highly beneficial anaerobic, warm, and humid environment represented 
by the gastrointestinal tract. Our gut and its microbial ecology are so suitable for the guest 
organisms that we can cultivate the majority of gut microbiota exclusively inside of ourselves. 
However, considerable advancements have recently been made on the cultivability of gut 
bacteria, based on the extensive sporulation taking place. This sporulation and the subsequent 
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reactivation under suitable conditions is key to the colonisation of and transit through 
inhospitable environments (Browne, Forster et al., 2016).  
A good host always makes sure that their guests are well-fed, even at a possible cost to 
themselves. A very nice example of this is reported in a study from 2014, where it is shown that 
animals suffering from an infection and going through a temporary anorexia to deal with this 
infection will increase fucosylation of the intestinal epithelium to support the commensal 
bacteria, which would otherwise have no energy provision (Pickard, Maurice et al., 2014). This 
underlines that the host is a pro-active actor in their relationship with the gut microbiota.  
Genetics and co-evolution play a role in host-microbe interactions, already visible in the 
exclusivity of bacterial capabilities to colonize mammals, indicating the necessity of a certain 
suitable set of traits. Within our species, genetical differences between people can influence 
which microbes feel at home, though this effect is limited; there is a small but significant increase 
in similarity in microbiota composition between homozygotic twins compared to dizygotic 
twins (Goodrich, Waters et al., 2014). 
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1.3.1.2 Metabolism; collecting the rent 
Of course, a host does not always accept guests without expecting something in return. The 
microbiota pays us back by indispensable metabolic processes, digesting components which are 
indigestible to us, producing simpler molecules that we can use. Additionally, the gut microbiota 
is an important source of vitamins, such as riboflavin (vitamin B2), biotin (vitamin B7), folic acid 
(vitamin B9), cobalamin (vitamin B12), and vitamin K (Hill, 1997). In herbivore animals, cellulose 
and other cell wall components are processed by microbes to provide otherwise unavailable 
energy, particularly important in ruminants (Flint, 1997), but also in omnivores such as humans, 
the microbiota plays an important role in breaking down dietary carbohydrates (Cockburn and 
Koropatkin, 2016). Interestingly, the mucus produced by the host supports a metabolic network 
based on mucolytic activities of bacteria such as Akkermansia muciniphila that produces 
butyrate and vitamin B12 as well (Belzer, Chia et al., 2017). Butyrate produced by the microbiota 
is an important source of energy especially for colonocytes, who forego glucose from the blood 
in favour of butyrate produced by the microbiota (Roediger, 1980), other short-chain fatty acids 
produced are also absorbed and transported to be metabolised by rest of the body (den Besten, 
van Eunen et al., 2013). It is estimated that in humans, 6 to 10 per cent of energy requirements 
are provided by microbiota-derived SCFAs, based on the intake of a standard British 
diet (McNeil, 1984; Bergman, 1990), the authors point out however, that fermentable 
carbohydrate consumption differs greatly around the world, and therefore these energy 
contributions must vary substantially as well (Bergman, 1990).  
The metabolites produced during microbial processing of intestinal contents are not only utilised 
by the host, but a complex ecology exists between different microbes as well. Many species are 
dependent on other species with complementary activities, and in this way, a complex metabolic 
network forms with mutualistic, amensalistic, or parasitic relationships between different 
species, where mutualism in the gut is particularly increased under anoxic conditions (Heinken 
and Thiele, 2015). Depending on the variety of resources they can utilize, species can be 
classified as either generalists or specialists. While we would normally expect generalists to be 
widely distributed and specialists to occur mostly in smaller niches (Cockburn and Koropatkin, 
2016), in the gut, this does not necessarily hold true (Carbonero, Oakley et al., 2014), with 
specialists often being more widely distributed than generalist species. 
  
 P a g e  | 53 
 
1.3.1.3 House rules; reciprocal control 
In the relation between the host and the intestinal microbiome, both actors influence each other 
and exert a modicum of control. Under healthy conditions, the host enforces sterility where it is 
necessary, and supports the microbiota where desired. The microbiota in its turn, communicates 
with the host to support immune tolerance and optimal conditions to its prosperity.  
The microbiota, through their gene expression and products, but also metabolites such as SCFAs, 
influences the host immune cells and cytokine production (Geuking, Koller et al., 2014), while it 
itself is subject to change by host-produced antimicrobial peptides and IgA secretions, which 
have regulatory functions, which can be, but are not always, microbicidal (Neish, 2009). The 
innate and adaptive immunity both play a significant role in monitoring and regulating the 
microbiota. For the innate immune system, some of these are produced independently from 
circumstances, such as α- and β-defensins (Pütsep, Axelsson et al., 2000), and Crohn’s disease 
patients exhibit a defect in α-defensin production by Paneth cells, underlining its important 
function (Wehkamp, Salzman et al., 2005),the abundance of other secretions, such as C-type-
lectin Reg3γ, is regulated by the activity of pattern recognition receptors (PRRs) (Gong, Xu et al., 
2010), important regulators of innate immunity. Reg3γ is poorly expressed in germ-free mice, 
and introduction of a mixed mouse microbiota increases this expression 20-fold, related to the 
ability of the bacteria to reach the epithelium (Cash, Whitham et al., 2006), indicating the 
involvement of epithelial sensing, most likely through PRRs. Many of these PRRs belong to the 
toll-like receptor family (TLRs), but Nod1 and Nod2, as well as several other types of receptors 
are important PRRs too. Many PRRs are activated by microbe-associated molecular patterns 
(MAMPs), which are represented among others by lipopeptides, lipoproteins, flagellins, and 
lipopolysaccharides; i.e., molecules that indicate the presence of microbes (Medzhitov and 
Janeway, 2002). Upon recognition of such a molecule, the PRR is activated and, depending on 
which PRR it is, activates regulatory pathways such as the mitogen-activated protein kinase 
(MAPK), nuclear factor B (NF-B)/Rel pathways, or the inflammasome (Neish, 2009). PRRs can 
be present on the cell membrane, on endosomes, or in the cytoplasm (Neish, 2009). In most 
tissues, PRRs activate inflammatory pathways, but because of the high microbial presence in the 
gut, PRRs there are also used to retain tolerance. For example, while activation of basolaterally 
positioned TLR9 leads to NF-B activation by degradation of IBα, apical activation leads to 
stabilisation of IBα and p105, preventing activation of the NF-B pathway (Lee, Mo et al., 
2006). TLR9-/- mice have a lower NF-B activation threshold, and consequently are more 
susceptible to experimental colitis induced by DSS (Lee, Mo et al., 2006), further indicating the 
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vital role of apical PRRs in maintaining immune tolerance in the gut. Similarly, flagellin-sensitive 
TLR5 is located only basolaterally to be activated when bacteria are present on the ‘wrong’ side 
of the epithelium, inducing inflammatory processes upon activation by bacteria penetrating the 
epithelium (Gewirtz, Navas et al., 2001). 
On the side of the adaptive immune system, there is an impressive production of IgA-type 
antibodies, which are secreted into the lumen. Production of bacterial antigen specific IgAs is 
induced upon colonisation of the gut, and the variety of specificities of these antibodies is 
related to the composition of the microbiota (Hapfelmeier, Lawson et al., 2010). In mice, a 
deleterious mutation in AID, leading to defective somatic hypermutation and thus loss of 
affinity-maturated antibodies, the composition of the microbiota is altered, indicating the 
capacity of specific antibody production to shape microbiota composition (Wei, Shinkura et al., 
2011). In animals lacking both immunoglobulin isotype switching and somatic hypermutation, 
leading to the lack of specific antibody production and the absence of IgA isotypes, overgrowth 
of anaerobes in the small intestine takes place (Fagarasan, Muramatsu et al., 2002), indicating a 
role for this IgA production in maintaining a favourable symbiotic relation with the gut 
microbiota. To regulate the response to the intestinal microbiota, the immune system uses a 
variety of cell types, informed by the intestinal epithelial cells, such as dendritic cells (DCs), intra-
epithelial lymphocytes (IELs), and macrophages. Based on epithelial cell signals in the form of 
retinoic acid, thymic stromal lymphopoietin (TLSP), and TGFβ, tolerogenic dendritic cells (DCs) 
and macrophages are generated. Migrating CD103+ DCs present microbial antigens to the 
adaptive immune system in a context of tolerance, while intestine-resident macrophages stay 
in close contact with epithelial cells to rapidly clear any microbes that pass the intestinal 
epithelial barrier (Peterson and Artis, 2014) (see Figure 9). 
Microbial metabolites, for their part, regulate host immune responses as well. For example, 
microbiota-produced SCFAs play a crucial role in regulation and proper resolution of the 
inflammatory response through their interaction with G-protein-coupled receptor 43 (GPR43), 
evidenced by an exacerbated DSS-induced colitis in GPR43-deficient mice, and in germ-free 
mice (Maslowski, Vieira et al., 2009). Similarly, the increase in SCFAs (e.g., butyrate) connected 
to increased dietary fibre intake can help reduce inflammation in ulcerative colitis (UC) (Hallert, 
Bjorck et al., 2003), based on the notion that application of butyrate can reduce inflammation 
in UC patients (Scheppach, Sommer et al., 1992). 
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Supporting this anti-inflammatory effect of SCFAs, microbiota-derived butyrate induces the 
peripheral generation of regulatory T cells (Tregs) (Arpaia, Campbell et al., 2013), pointing to a 
credible mechanism for the observed beneficial effects. However, the microbiota has a strong 
capacity to be pro-inflammatory as well, and, due to the passage of endotoxins such as LPS into 
the general circulation, this is not exclusive to the gut. Colonization of germ-free mice with the 
common gut bacterium E.coli increases macrophage infiltration and inflammatory cytokine 
production (Caesar, Reigstad et al., 2012), and oral treatment of mice with LPS increases adipose 
tissue inflammation and induces insulin resistance (Cani, Amar et al., 2007), mirroring the 
increased systemic LPS levels and adipose tissue inflammation observed in type 2 diabetes 
patients (Creely, McTernan et al., 2007). A high-fat diet causes metabolic disease among others 
by increasing circulating LPS due to its absorption in chylomicrons (Cani, Amar et al., 2007), the 
formation of which is increased in the presence of more fatty acids (Ghoshal, Witta et al., 2009). 
  
Figure 9 - Immune regulation in relation to intestinal microbes;  
 (Peterson and Artis, 2014) 
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1.3.2 Toxic metabolite hypothesis 
As written in previous chapters, the gut microbiota produces many useful metabolites. However, 
it also has the capacity to make products with negative effects on gut function and general 
health. For example, bacteria-produced proteases can induce inflammation and break down the 
mucus barrier (Steck, Mueller et al., 2012), and production of methane by bacteria such as 
Methanobrevibacter smithii increases gut transit time, which can lead to constipation (Bennet, 
Öhman et al., 2015).  
Some particularly toxic products can be generated during anaerobic fermentation of 
unabsorbed carbohydrates; methylglyoxal and other reactive aldehydes and ketones (Campbell, 
Matthews et al., 2010). Campbell et al. hold these metabolites responsible for a wide range of 
local and systemic effects observed in lactose malabsorption, such as headache, fatigue, heart 
palpitations, and depression. The mechanisms by which methylglyoxal can induce health 
complications are elucidated more deeply, which will be further discussed in the coming section 
1.4. Methylglyoxal, or pyruvaldehyde, affects both prokaryote cells, e.g., impacting growth rates 
and thus changing the microbiota, and eukaryotic cells, e.g., changing cell proliferation, gene 
expression patterns and cell signalling processes (Campbell, Matthews et al., 2010). 
Fermentation products of non-absorbed carbohydrates such as lactose can induce symptoms 
reminiscent of IBS, both in terms of gut symptoms, and more systemic symptoms, but other 
metabolites, such as those produced by putrefaction of proteins and amino acids are often toxic 
as well (Campbell, Waud et al., 2005). Another way by which bacterial fermentation can impact 
gut health is by changes in pH. In IBS patients, colonic intraluminal pH is decreased compared to 
healthy controls, as measured using a pH-measuring ingested SmartPill system, which indicates 
an increased fermentation (Ringel-Kulka, Choi et al., 2015). 
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1.4 Bacterial Metabolites; aldehydes/ methylglyoxal 
We have already seen the many functions of the microbiota, and its possible association to IBS. 
In this chapter we will take a more in-depth look into the role bacterial fermentation of 
carbohydrates and the resulting reactive metabolites can play in gastrointestinal health, 
particularly in the context of reactive glycating metabolites. 
As we have seen before (in 1.3.2), the production of methylglyoxal by the intestinal microbiota 
is hypothesised to play a role in a wide variety of health issues. Here we will look at the 
properties of methylglyoxal and other reactive dicarbonyl metabolites. 
1.4.1 Chemical properties of methylglyoxal 
Methylglyoxal (Figure 10), also known as pyruvaldehyde, chemical 
formula CH3C (O)CHO, is a derivative of pyruvic acid, and a possible 
side-product of glycolysis. Its molecular mass is 72,06266 Da. 
Methylglyoxal is the most reactive dicarbonyl compound produced 
during glycolysis, it glycates lysine and cysteine residues (Price, Hassi 
et al., 2010) but prefers arginine and thus causes the formation of 
hydroimidazolone residues in proteins (Rabbani and Thornalley, 
2012). Methylglyoxal can be formed by the spontaneous degradation 
of triosephosphates, glyceraldehyde-3-phosphate (GA3P), and dihydroxyacetone phosphate 
(DHAP) (Phillips and Thornalley, 1993), as well as by oxidation of acetone during ketone body 
catabolism (Reichard, Skutches et al., 1986).   
Methylglyoxal 
Figure 10 - Formula of 
methylglyoxal 
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1.4.2 Biological properties of methylglyoxal 
During bacterial anaerobic 
fermentation of 
carbohydrates, 
methylglyoxal is produced 
by the activity of 
methylglyoxal synthase 
(MGS), which is practically 
universally present among 
bacterial species (Figure 
11). In the expansive but 
incomplete NCBI database 
of characterized proteins, 
the search key 
“Methylglyoxal synthase” 
returns >83000 results 
from a wide variety of 
prokaryote species and 
phyla, not necessarily 
directly reflective of 
particularly active species, 
but perhaps more of 
particularly active researchers interested in those species. It had already been shown that 
different culturable species isolated from human faeces express MGS and are able to produce 
methylglyoxal in culture (Baskaran, Rajan et al., 1989). During bacterial glycolysis, 
dihydroxyacetone phosphate can be transformed to methylglyoxal, when it actives MGS. On the 
other hand, one of the products of this transformation, phosphate, inhibits MGS (Hopper and 
Cooper, 1971).  
Like the production of ethanol is a limiting factor to the vitality of yeast in the production of wine 
and beer, the production of methylglyoxal poses problems to its producers, and higher 
concentrations (starting from 1mM for E.coli) will negatively impact bacterial growth 
rates (Campbell, Matthews et al., 2010). Because not all species are equally sensitive, this can 
change the composition of the microbiota. For example, Prevotella ruminicola will produce high 
Figure 11 - Results of NCBI Protein search for 
“Methylglyoxal synthase” 
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concentrations (3-4 mM) of methylglyoxal when offered an excess of glucose, which will kill the 
culture, but different strains of this species were not equal producers (Russell, 1993). 
Additionally, the activity of the glyoxalase detoxification system in bacteria is predictive of their 
ability to cope with methylglyoxal, and glyoxalase knockout mutants become very sensitive to 
even modest concentrations (Ferguson, Totemeyer et al., 1998). It seems that for bacteria, the 
production of methylglyoxal serves to balance phosphate metabolism, and a MGS knockout 
mutant E.coli reaches growth inhibition more rapidly due to accumulation of toxic 
phosphorylated metabolites (Totemeyer, Booth et al., 1998).  
Similarly, growing E.coli in phosphate-limited medium elevates methylglyoxal levels, which can 
be increased by overexpressing MGS (Booth, Ferguson et al., 2003), again indicating an intended 
increase in phosphate turnover. An important observation is that abundant methylglyoxal 
production is expected in case of a sudden influx of carbon sources, causing a loss of control 
over carbon entry in the bacterial cells (Totemeyer, Booth et al., 1998) which is indeed the 
situation caused by the ingestion of significant amounts of unabsorbable carbohydrates, 
prevented by a low-FODMAP diet.  
In diabetic humans, the methylglyoxal levels in the blood are increased, which is unlikely to be 
directly related to activity of the microbiota. The generally accepted hypothesis explaining the 
increased MG levels in diabetic patients points to hyperglycaemia, leading to an increased 
production of methylglyoxal in blood cells (Kalapos, 2013). Even brief periods of hyperglycaemia 
can significantly increase MG levels (Beisswenger, Howell et al., 2001), leading to accumulation 
of dicarbonyl metabolites and the modification of DNA and proteins (Rabbani, Xue et al., 2016a), 
which will be elaborated upon in the next section. 
Apart from methylglyoxal, glyoxal and 3-deoxyglucosone (3-DG) are important reactive 
dicarbonyl compounds as well, with similar effects and detoxification processes (Hellwig, 
Gensberger-Reigl et al., 2018).  
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1.4.3 Deleterious effects of dicarbonyl stress 
Methylglyoxal is one of several highly reactive dicarbonyl metabolites naturally present in 
physiological systems. Chemical reactions of these reactive carbonyls with proteins, DNA, and 
phospholipids lead to the formation of Advanced Glycation End products (AGEs) (Thornalley, 
Yurek-George et al., 2000), which are stable, and can accumulate in tissues in certain health 
conditions, such as diabetes, obesity, cardiovascular disease, and renal failure, or during the 
natural process of ageing (Rabbani, Xue et al., 2016a). In diabetes, insulin resistance is worsened 
by hyperglycaemia, because the resulting increase in MG and AGEs dampen the response of 
insulin receptors (Riboulet-Chavey, Pierron et al., 2006), leading to a vicious circle of worsening 
hyperglycaemia and less responsive insulin signalling. In vitro, methylglyoxal at non-cytotoxic 
levels inhibited beta-cell insulin response and secretion, indicating the capacity of methylglyoxal 
to induce beta cell failure (Fiory, Lombardi et al., 2011). Typically, MG concentrations in human 
plasma are 50-150 nM, the concentration in cells is higher, at 1-4 µM. Concentrations above this 
level risk impairing health, causing protein and cell dysfunction (Rabbani, Xue et al., 2016a).  
The generation of Advanced Glycation End Products (AGEs) (see Figure 12), which lead to 
Receptor for Advanced Glycation End products (RAGE) activation (Thornalley, Langborg et al., 
1999), cause ROS generation and a pro-inflammatory state through NF-B pathway 
signalling (Wautier, Guillausseau et al., 2016). Advanced Glycation End products thus produced 
in conditions of heightened dicarbonyl stress can activate NF-B in RAGE expressing cells, 
leading to prolonged, instead of transient, activation by increased NF-Bp65 production, which 
Figure 12 – Methylglyoxal metabolism (adapted from (Kalapos, 2013)) 
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could be a cause of long-term low-grade inflammation in diabetes (Bierhaus, Schiekofer et al., 
2001). Furthermore, RAGE functions as a counterreceptor for leukocyte integrins, meaning it 
supports leukocyte recruitment in inflammatory processes. This mechanism can be relevant in 
disorders with increased RAGE expression (Chavakis, Bierhaus et al., 2003).  
Since an increase in AGE increases the expression 
of RAGE (He, Zheng et al., 2000; Simm, 
Casselmann et al., 2004; Bierhaus and Nawroth, 
2009), and the activation of RAGE leads to ROS 
production, which favours generation of 
AGE (Baynes, 1991; Ott, Jacobs et al., 2014), a 
positive feedback loop can occur (Figure 13), 
which can be interrupted by detoxification 
processes, which will be discussed in the next 
section, 1.4.4.  
  
Figure 13 - Positive feedback loop between 
increased AGE, RAGE activation, and ROS. AGEs 
activate RAGE, which leads to inflammatory 
processes and the production of ROS, which creates 
a favourable environment for the generation of 
more AGEs. 
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1.4.4 Detoxification – glyoxalase system 
Reflective of its basic nature, methylglyoxal as a metabolite is common to prokaryotes and 
eukaryotes. For the same reason, mechanisms to cope with this toxic molecule have emerged 
very early in the history of life, and mechanisms are conserved across Kingdoms. Such a 
mechanism is the glyoxalase system, which converts methylglyoxal to D-lactate, and consists of 
glyoxalase I (Glo1), (lactoylglutathione lyase) and glyoxalase II (Glo2) (hydroxyacylglutathione 
hydrolase). The conversion is dependent on glutathione (GSH) as a catalyser (Figure 14). This 
same reaction takes place in Animals, Plants, Fungi, and even Prokaryotes (Thornalley, 1993). 
The enzymes are active in the cytosol, with Glo2 also active in organelles such as the 
mitochondria, in plants and animals (Thornalley, 1993), and additionally in 
chloroplasts (Schmitz, Dittmar et al., 2017). Glo1 is in the top 13% in the human proteasome, 
reflective of its key role in life (Rabbani, Xue et al., 2016b). 
In some bacteria, particularly in gram-negative ones, Glyoxalase 1 enzymes are more effectively 
activated by Ni2+ and Co2+ ions, but inhibited by Zn2+, while in animals, this metalloenzyme is 
maximally active with Zn2+ (Suttisansanee and Honek, 2011). This varying metal-dependency 
(Zn2+-activated v non-Zn2+-activated) could open up possibilities to selectively inhibit microbial 
species by limiting the availability of certain metal ions in conditions of dicarbonyl stress.  
A third glyoxalase (Glyoxalase 3; Glo3) can be present in plants (Ghosh, Kushwaha et al., 2016), 
fungi (Zhao, Su et al., 2014), and bacteria (Misra, Banerjee et al., 1995). Glyoxalase 3 is 
glutathione-independent and thought to catalyse the conversion from methylglyoxal directly to 
D-lactate (Misra, Banerjee et al., 1995). However, more recent work indicates that what was 
known as glyoxalase 3 in E.coli actually deglycates proteins by attacking the early glycation 
intermediates hemithioacetals and aminocarbinols, generating repaired proteins, and lactate 
and glycolate (Mihoub, Abdallah et al., 2015). In 
that way, glyoxalase 3 uses early glycation 
intermediates as reaction intermediates and can 
help to prevent the formation of AGEs. 
It has been suggested in literature that the high 
expression of glyoxalases in the epithelium of the 
intestine is related to the production of 
methylglyoxal by enteric bacteria (Ferguson, 
Totemeyer et al., 1998), for which they cite 
Figure 14 - Glyoxalase system (Rabbani and 
Thornalley, 2012) 
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Baskaran et al. (Baskaran, Rajan et al., 1989) who demonstrated the presence of Glyoxalase 1 in 
simian intestine (Baskaran and Balasubramanian, 1987). Their claim that this expression may 
protect against methylglyoxal produced by enterobacteria is based on an article that shows 
glyoxalase expression in erythrocytes and liver cells (Aronsson and Mannervik, 1977).  
While the hypothesis has merit, this train of inferences skips several logical steps, as none of the 
sources show a particularly high glyoxalase expression in the intestine which would support it, 
and findings have been mischaracterised from one publication to the next. Comparative 
expression levels of glyoxalase throughout animal tissues are hard to come by, but one study on 
bovines show the highest level of glyoxalase 1 expressed in the liver, though regrettably they 
did not analyse intestinal tissues (Hayes, Milner et al., 1989). However, based on the general 
understanding that glyoxalase is ubiquitously expressed, and the microbiota is capable of 
producing methylglyoxal, intestinal detoxification of this chemical would indeed be necessary to 
prevent health complications.  
In the brain, where glucose is the major energy substrate, and detoxification of by-products of 
glycolysis is important, it can equally be expected that the glyoxalases are highly expressed. 
Indeed, the glyoxalase system seems to be important in protecting the brain, with expression in 
the brain increasing until 55 years of age as levels of dicarbonyl stress rise with age, after which 
expression levels drop and neurodegenerative processes associated with ageing show a 
significant increase (Kuhla, Boeck et al., 2006), and AGEs accumulate (Luth, Ogunlade et al., 
2005). There is a significantly higher expression of Glo1 in astrocytes compared to neurons (9.8 
times higher) (Belanger, Yang et al., 2011), which corresponds to their higher rate of glycolysis, 
after which they supply derived energy substrates to the neurons, which have a higher energy 
expenditure (Allaman, Belanger et al., 2015). This mechanism might be effective in shielding 
neurons, which are less replaceable, from glycation damage. 
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To help protect against the negative effects of dicarbonyl stress in a clinical or medical setting, 
some interesting strategies have been envisioned. For example, quite a lot of attention has been 
spent on dicarbonyl scavengers, drugs that are meant to chemically capture and neutralise 
reactive dicarbonyls, such as aminoguanidine and phenacylthiazolium bromide. While showing 
promise, issues with toxicity and molecular stability prevented further employment of these 
compounds (Rabbani, Xue et al., 2016a). Pyridoxamine can be used to prevent the formation of 
AGEs in vitro in lens proteins and in vivo in diabetic rat plasma proteins (Nagaraj, Sarkar et al., 
2002). Other MG scavengers are the imidazole based carnosine, and the 2-aminomethylphenols 
pyridoxamine (PM), 5′-O-pentyl-pyridoxamine (PPM), and 2-methoxy-benzylamine (2-
HOBA) (Davies and Zhang, 2017) (see Table 7). 
  
 
• Pilot studies show improved glucose tolerance and insulin sensitivity 
in overweight and obese subjects (de Courten, Jakubova et al., 2016)  
• Improved symptoms of neurodegeneration; Parkinson’s (Boldyrev, 
Fedorova et al., 2008), and Alzheimer’s (Cornelli, 2010) 
• Mildly improves diabetic nephropathy in humans (Williams, Bolton et 
al., 2007), marked improvements in renal function (Tanimoto, Gohda 
et al., 2007) and plasma glucose handling (Maessen, Brouwers et al., 
2016) in animal models  
• Efficient in other diabetes models like atherosclerosis (Watson, Soro-
Paavonen et al., 2011) and cardiac function (Cao, Chen et al., 2015) 
 
 
• Efficient in mouse model of hypertension (Kirabo, Fontana et al., 
2014) 
 
• Efficient in animal models of Alzheimer’s (Davies, Bodine et al., 2011), 
epilepsy (Pearson, Warren et al., 2017), aging (Nguyen, Caito et al., 
2016), and hypertension (Kirabo, Fontana et al., 2014) 
Table 7 - Different methylglyoxal scavengers with pre-clinical or clinical application (adapted from (Davies and Zhang, 2017)) 
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Another suitable strategy to alleviate dicarbonyl stress in patients is by increasing Glo1 
expression, and a synergetic effect of 2 clinically applicable substances (trans-resveratrol (tRES) 
and hesperetin (HESP)) have been shown to induce this effect. A treatment with these 2 
compounds could increase expression of Glo1 by 27%, thus reducing total body methylglyoxal-
protein glycation by 14%, in highly overweight subjects (Xue, Weickert et al., 2016). In metabolic 
syndrome and diabetes, such a treatment could help prevent complications, but it is possibly 
less optimal for situations which present more topical dicarbonyl stress. 
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Figure 15 - Intestinal Epithelial Cells (IECs) of the small and large intestine. 
IESC, Intestinal Epithelial Stem Cell; AMP, antimicrobial proteins; sIgA, secretory immunoglobulin A; TFF3, trefoil factor 3; 
DC, dendritic cell 
Epithelial cells are generated from the IESC at the bottom of the crypts and differentiated cells then migrate upwards 
through the crypt, except for Paneth cells, which stay at the bottom. The release of AMPs, sIgA, TFF3, as well as mucins, 
which form a mucus layer, all contribute to the separation of the luminal milieu from the mucosal immune system.  
Adapted from (Peterson and Artis, 2014) 
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1.5 Intestinal barrier function 
We have seen that diet together with the intestinal microbiota can generate problems, which 
can impact the crucial barrier that separates the self from the environment. In this chapter, we 
will look at the functioning of the intestinal barrier, and some pathophysiologically relevant 
complications of its disturbance.  
1.5.1 Epithelial barrier 
When we think of our intestines, we usually picture it as part of our inside. However, the 
gastrointestinal lumen is part of the external environment, with our bodies forming a continuous 
tube. To keep external and internal separated, the mucosal lining of our gastrointestinal tract 
has an important barrier function. The first cellular components in contact with the exterior are 
the epithelial cells, which form the luminal part of the mucosal lining of the gastrointestinal tract. 
Underneath the epithelium are located the lamina propria, and the muscularis mucosa. The 
epithelial cells are tightly connected by so-called tight and adherens junctions which regulate 
passage in between cells. The cells themselves are impermeable to most hydrophilic 
components by virtue of their cell plasma membranes, unless there is a specific transporter 
protein (-complex) present. Epithelial cells in the small intestine consist of absorptive 
enterocytes, goblet cells, enteroendocrine cells, and Paneth cells. In the large intestine, there 
are enterocytes, enteroendocrine cells, and goblet cells (see Figure 15). These components 
together form a dynamic barrier that protects the organism from harmful inflammatory stimuli, 
while at the same time allowing digestion and absorption of nutrients.  
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1.5.1.1 Small intestine barrier function and morphology 
The small intestine’s tasks are digestion of chyme and absorption of nutrients, and the barrier 
function in this part of the intestinal tract mirrors these functions. The microbiota is kept in 
check by the production of antibodies and antimicrobial peptides such as α-defensins, 
RegIIIγ (Cash, Whitham et al., 2006), and lysozyme (Dommett, Zilbauer et al., 2005).  
The epithelium in the small intestine covers so-called villi, projections into the lumen that greatly 
increase the surface area of the small intestinal lining, to help with digestion, through increasing 
contact area of digestive enzymes on cellular surfaces, and absorption, through increased 
contact area of nutrients with absorptive enterocytes. The enterocytes themselves are covered 
apically by microvilli, projections on the cell surface that, again, increase the effective surface 
area of the small intestine. Capillary blood vessels and lymph channels called lacteals project 
through the villi and export absorbed nutrients. Covering nodes of lymphatic tissue in the small 
intestine called Peyer’s patches, follicle-associated epithelium is a layer of epithelial cells that 
include microfold cells (M cells) that facilitate antigen uptake from the lumen, inducing an 
immune response or tolerance in the immune cells in the underlying Peyer’s patch (Gebert, 
Rothkötter et al., 1996). The mucus produced here is loose and patchy and easily 
removed (Atuma, Strugala et al., 2001; Ermund, Schutte et al., 2013), it thus mostly serves as a 
Figure 16 - Epithelial barrier of the small intestine 
Adapted from (Peterson and Artis, 2014) 
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matrix for antimicrobial peptides and antibodies. Structural integrity and barrier functions 
demand that the epithelial cells are tightly connected, which is the responsibility of tight 
junctions, adherens junctions, and desmosomes, protein complexes which extrude from the cell 
membrane and interconnect and pull together cells, which will be discussed more in the 
paragraph dedicated to paracellular permeability. 
1.5.1.2 Large intestine barrier function and morphology 
Compared to the small intestine, the large intestine has a larger 
volume and a smaller surface area, related to its functions, which 
are fermentation of chyme by the microbiota, resorption of 
water and condensation of chyme into faeces, absorption of 
useful fermentation products, and storage of faeces before 
defecation. Likewise, the barrier function in this part of the 
intestine mirrors these function in several distinct ways. In the 
colon, Paneth cells are absent, and to retain separation of luminal 
microbes and the host tissues, mucus plays a more important role 
than in the small intestine, at the same time lubricating the 
passage of the increasingly dry and abrasive stool. Colonocytes, 
enterocytes of the colon, have a greater capacity to actively 
absorb water against the ion gradient compared to enterocytes 
of the small intestine, and have a lower expression of digestive 
brush border enzymes (Real, Xu et al., 1992). The colon has a 
large capacity to absorb water of around 5.7 litre/ day, tested by 
direct infusion of water into the cecum of healthy 
volunteers (Debongnie and Phillips, 1978). Of course, since most 
water is already absorbed in the small intestine (see Figure 18), 
the colon normally absorbs just over one litre/day (Thiagarajah and Verkman, 2018), but against 
a much stronger osmotic gradient due to the lower water content of colonic contents compared 
to ileal contents. Fermentation products of the microbiota, which are a lot more abundant in 
this part of the intestine, are absorbed here, together with water. In the colon, mucus is a more 
important component of the barrier compared to the small intestine, goblet cell secretions in 
this part of the intestine form a dense mucus layer devoid of bacteria, separating the epithelium 
from the microbes present in the stool (Johansson, Phillipson et al., 2008).  
  
Figure 17 - Epithelial barrier of the 
large intestine 
Adapted from (Peterson and Artis, 
2014) 
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This mucus is generally reported to be 
around 95% water (Strugala, Allen et 
al., 2003), though the original source 
for this number is hard to pin down. 
Stools are around 70% 
water (Aichbichler, Wenzl et al., 
1998; Bliss, 1999), with up to 55% 
bacterial mass (Stephen and 
Cummings, 1980) from which water is 
not freely available to be extracted, 
so if colonic mucus is also 95% water, the question arises how it is possible to extract water from 
the drier stools through this mucus layer. On first glance, we would expect the mucus layer to 
lose humidity together with the contents, changing its rheological properties. 
The large intestine is characterized by the most concentrated microbial presence of any part of 
the human body, and the barrier function in this part of the gastrointestinal tract is adapted to 
cope with this particular challenge. In the absence of a mucus barrier, such as caused by a 
knockout mutation for muc2 (Muc2-/- mice), a spontaneous and lethal colitis occurs, but fewer 
problems occur in the earlier compartments of the intestines (Van der Sluis, De Koning et al., 
2006), although muc2 is the main component of excreted mucus in these parts too. In the colon, 
antimicrobial peptides specific for Paneth cells in the small intestine, are much more rare, due 
to the absence of Paneth cells. However, in chronic inflammation, the colon can generate Paneth 
cells (Paterson and Watson, 1961), and these metaplastic Paneth cells produce human α-
defensin 5 (HD-5), lysozyme, and secretory phospholipase 2 (sPLA2) (Cunliffe and Mahida, 
2004). Apart from the excreted mucus barrier, another barrier awaits for any elements passing 
through; the glycocalyx. The glycocalyx is a carbohydrate-rich network of glycolipids and 
glycoproteins, anchored to the cell membrane (Okumura and Takeda, 2017). Transmembrane 
mucins such as MUC1, MUC4, and MUC13 together form the cell surface mucin layer (Linden, 
Sutton et al., 2008). Transmembrane mucins can shed in reaction to pathogens, acting as decoys, 
binding bacteria, to prevent adhesion to the cell surface (Ashida, Ogawa et al., 2011). For this 
reason, Muc1-/- mice are more susceptible to H.pylori (Linden, Sheng et al., 2009). 
In the next sections (1.5.2 and 1.5.3) we will look further into the regulation of cellular 
permeability and physical mucus barrier function. 
Figure 18 - Water excretion/absorption throughout the GI-
tract (Thiagarajah and Verkman, 2018) 
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1.5.2 Permeability 
The intestinal barrier is meant to be a selective filter for nutritional and immunological purposes. 
Simultaneously, it must facilitate passage of useful resources; nutrients, and information; e.g., 
antigen sampling, while impeding free passage of bacteria, toxins, and antigens, over a 
considerable surface. The surface area of human intestine is about 32m2, according to the latest 
calculations (Helander and Fandriks, 2014), which is approximately 10 times smaller than the 
number often cited in literature (Macdonald and Monteleone, 2005; Niess and Reinecker, 2006). 
1.5.2.1 Paracellular 
The paracellular pathway of passage through the 
epithelium involves elements moving through the space 
in between cells. As mentioned before, IECs form a tight 
network through the adhesive function of the tight and 
adherens junction complexes as well as desmosomes 
(see Figure 19). Claudin, Occludin, and ZO1 proteins 
form an adhesive network that limits the passage of 
solutes through the space in between cells, regulated by 
actin and myosin, which can tighten or loosen the 
bonds (Turner, 2009). Additionally, tight junctions 
safeguard cell polarity, by preventing diffusion of 
apically located receptors in the basolateral 
direction (König, Wells et al., 2016). Adherens junctions, 
formed between cadherins, serve to initiate the 
construction of a fully functional paracellular barrier, and are necessary for the formation of 
tight junctions (Hartsock and Nelson, 2008). Desmosomes, lastly, are responsible for the strong 
resistance to mechanical stress that most tissues have. They are specialised in keeping cell-cell 
bonds intact by anchoring to intracellular filamentous cytoskeleton elements (Garrod and 
Chidgey, 2008). The paracellular route of passage then is mostly available to small hydrophilic 
solutes (He, Murby et al., 1998).  
In short, the paracellular pathway functions as a semi-selective sieve, allowing for passive 
diffusion of small hydrophilic molecules across the epithelial lining, following concentration 
gradients.  
Figure 19 - Cell-cell junctions between IECs 
Adapted from (Turner, 2009) 
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1.5.2.2 Transcellular 
“Transcellular pathway” refers to the passage of molecules through cells. It involves passive 
transport by hydrophobic molecules partitioning in and out of lipid bilayers, active transport by 
specific transporter proteins and channels, or endocytosis by the cell membrane (Keita and 
Söderholm, 2010). The transcellular pathway is mostly inaccessible to hydrophilic elements, due 
to the lipid bilayer of the cell plasma membranes. Instead, membrane-bound receptors and 
pores on the one hand, and endocytosis on the other hand can provide access to components, 
to take this route through the epithelium. Transcellular transport is partially dependent on the 
integrity of the paracellular barrier, because the established concentration gradient would cause 
passive diffusion to re-establish equilibrium otherwise (Turner, 2009).  
Transcellular transport is performed by a set of highly regulated and complex processes, and 
apart from the uptake of nutrients, serves to transport antigens to be processed by the immune 
system. 
 
 P a g e  | 73 
  
1.5.3 Mucus barrier  
An often-misunderstood component of the intestinal barrier is the mucus barrier, which consists 
of excreted and membrane-bound mucins which form a semi-permeable chemical, physical, and 
biological barrier, in interplay with other barrier components. Mucins, glycoproteins containing 
galactose, fucose, N-acetylglucosamine, N-acetylgalactosamine, and sialic acids, are the 
essential component of the mucus barrier. The property essential to their character is the 
structure of the sugars attached to a central protein core; hundreds of sugars branching out, 
resembling a bottle brush (Allen, 1983). The mucus barrier consists of the glycocalyx, apically 
located transmembrane mucins and secreted elements covering the epithelial cells, and 
excreted mucins which form a net-like gel of disulphide-linked macromolecules (Johansson, 
Sjövall et al., 2013).  
This mucus lubricates the passage of stools, supports the intestinal microbiota by providing a 
matrix as well as energy/carbon source, and it serves as a barrier protecting against luminal 
threats, such as pathogens and potentially harmful particles. In the gastrointestinal tract, it has 
different properties based on the region of the intestine, as depicted in Figure 20.  
Figure 20 - Mucus layer thickness in different regions of the gastrointestinal tract (Pelaseyed, Bergstrom et al., 2014) 
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1.5.3.1 Mucus types; functions 
There are many different types of mucins expressed in the GI-tract, with their own functions and 
expression patterns (Table 8). As mentioned before, there are membrane-bound and secreted 
mucins, which already strongly determines their function. What follows is a short description of 
mucins expressed in the intestinal tract; 
Table 8 - Mucin gene expression in the GI-tract (adapted from (McGuckin, Lindén et al., 2011)) 
TISSUE EXCRETED MEMBRANE BOUND 
ORAL CAVITY MUC5B, MUC7, MUC19 MUC1, MUC4, MUC16 
STOMACH MUC5AC, MUC6 MUC1, MUC16 
SMALL INTESTINE MUC2 MUC1, MUC3A, MUC3B, MUC4, MUC12, 
MUC13, MUC15, MUC16, MUC17 LARGE INTESTINE MUC2, MUC5AC, MUC6 
 
In the oral cavity, the excreted mucins mostly serve to retain antimicrobial peptides, and interact 
directly with microbes (Frenkel and Ribbeck, 2015), while the membrane bound mucins have 
regular glycocalyx functionality, covering and protecting the mucous tissues, providing 
scaffolding for excreted mucins and signal transduction (Liu, Lague et al., 2002). Additionally, 
saliva acts as a lubricant for food to pass the oesophagus (Wickstrom, Davies et al., 1998). The 
stomach has a dual mucus layer protecting the epithelium from being damaged by the stomach 
acid, while simultaneously allowing for renewal of this stomach acid, but also buffering the pH 
and retaining HCO3- (Taherali, Varum et al., 2017). 
In the small intestine, the excreted mucin (muc2) forms a gel, which manifests as loose and 
patchy, serving mostly to prevent bacterial adherence to the epithelium, retain the plethora of 
antimicrobial products, and prevent microbes from entering crypt (Schneider, Pelaseyed et al., 
2018). In the large intestine, the excreted mucins, the most abundant by far being muc2, form a 
more impenetrable barrier, separating luminal contents from intestinal epithelium (Johansson, 
Larsson et al., 2011). The membrane bound mucins in the small and large intestine are 
numerous, reflecting the increasingly complex interactions with an expanded microbial 
presence. Transmembrane mucins can act as decoys for bacterial adherence (Ashida, Ogawa et 
al., 2011), they can provide steric hindrance to any element set to penetrate (Cone, 2009; Boegh 
and Nielsen, 2015), and they can serve receptor functions (van Putten and Strijbis, 2017). 
Secreted mucins may also function to cover, sequester, and transport particles out of the 
body (Florey, 1962), and as decoys for pathogens (Linden, Mahdavi et al., 2004; Linden, Bierne 
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et al., 2008), in a way that reminds somewhat of airway mucins, which capture and remove 
environmental pollutants and pathogens (Knowles and Boucher, 2002).  
Excreted mucus plays an important role in modulating infectious disease severity. For example, 
Muc2, the main mucin of intestinal excreted mucus, is key in controlling Salmonella infection, as 
evidenced by use of a Muc2-deficient mouse model (Zarepour, Bhullar et al., 2013). The 
researchers showed that O-glycosylation properties of muc2 is essential for this functionality, as 
mutants with aberrant glycosylation show increased susceptibility (Zarepour, Bhullar et al., 
2013). The mechanism behind protection by mucus is more complex than just physical 
obstruction; secreted antibodies like IgM are slightly mucophilic, but diffuse through the mucus, 
accumulating on antigen-covered particles, such as pathogens. Due to this accumulation, even 
normally motile mucus-penetrating bacteria become immobile in the mucus, with antigens 
forming polyvalent low affinity bonds to the gel (Cone, 2009). 
It is often said that contact between bacteria and the epithelium leads to inflammation, and that 
the excreted mucus barrier prevents this contact (Johansson, Gustafsson et al., 2014). While it 
is clear that muc2-/- mice without an excreted mucus barrier develop severe colitis (Van der Sluis, 
De Koning et al., 2006), it has not been clearly shown that this is solely due to epithelium-
bacterial contact. Since it is known that in the small intestine the mucus layer is patchy and easily 
removed (Atuma, Strugala et al., 2001; Ermund, Schutte et al., 2013), the microbial presence 
there should lead to inflammation too if contact alone would be enough, even when taking into 
account that the small intestine has its own array of anti-microbial defences, as discussed in 
1.5.1.1. Still, small intestinal bacterial overgrowth (SIBO), should cause extensive contact 
between epithelium and bacteria, it is however not specifically characterized by ileitis.  
Apart from protecting against microbial threats, the excreted mucus barrier is also involved in 
protecting against chemical agents, such as food-borne environmental pollutants and possibly 
harmful food additives, although this has not been sufficiently studied and documented until 
today (Gillois, Leveque et al., 2018). 
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Besides protective functions, in the intestine, mucus also serves a supportive purpose for the 
resident microbes; mucus produced by the host supports a microbial network of mucolytic 
bacteria, such as Akkermansia muciniphila and associates (Derrien, Vaughan et al., 2004; Belzer, 
Chia et al., 2017). Intestinal mucus thus provides a suitable niche to the commensal microbiota, 
supported by beneficial fucosylation of mucins to support the microbiota (Pickard, Maurice et 
al., 2014), as well as differing glycosylation patterns throughout the intestine, which seem to 
have role in selecting microbial population composition, while at the same time being influenced 
by the microbiota (Sekirov, Russell et al., 2010; Johansson, Jakobsson et al., 2015). For example, 
fucosylation of the glycocalyx is increased by signalling from B. thetaiotamicron, and this fucose 
is then used by this bacterium (Hooper and Gordon, 2001). This example nicely demonstrates 
that host and microbe communicate to shape a suitable niche for the microbiota through mucin 
modifications. 
The goblet cell to total cell ratio in mice progresses upwards throughout the intestine, 
approximately 2:50 in duodenum, 3:50 in jejunum, 6:50 in ileum (Cheng, 1974), and 8:50 in the 
distal colon (Chang and Leblond, 1971), which correlates to the density of microbes in these 
intestinal compartments, which increases from proximal to distal regions. This holds well with 
the general idea that mucus is a main mediator in host-microbe interactions, as part of the 
variety of adaptations of the metaorganism to exist in eubiosis, which are studied in the rapidly 
upcoming field of metaorganism or holobiont research (Esser, Lange et al., 2018). 
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1.5.3.2 A sticky history of organisation 
Much has been written about the organisation, and even the existence, of the gastrointestinal 
mucus barrier. The transparent mucus of the internal, difficult to access, mucosae is prone to 
dry out and notoriously hard to study. It has been debated extensively whether a permanent 
barrier even covers the internal mucosae or not.  
In 1955, in the Croonian Lecture, Sir Howard Florey laid out the current understanding of various 
mucus secretions of mammals at that time. For intestinal mucus, he presented mainly a 
lubricative and protective function. Mucus was thought able to entrap food particles and 
bacteria touching the epithelium “…wrapping them up as it were in an envelope and expediting 
their forward movement…”, but without impeding diffusion of smaller molecules and not 
impeding absorption. Rationale behind this understanding is the higher concentration of goblet 
cells in the large intestine compared to the small intestine, together with the liquid chyme in the 
small intestine and the solid stools in the large intestine, where lubrication is thus of higher 
importance (Florey, 1955). Additionally, questions were raised about whether mucus release in 
response to irritants such as mustard oil is mediated by the central nervous system or 
autonomously by the tissue. Some years later, starting from 1965, a ‘surface coat’ in the 
intestine covering epithelial cells and the microvilli was described, separately from the mucus 
produced by goblet cells, observed using electron microscopy (Ito, 1965; Rifaat, Iseri et al., 1965; 
Mukherjee and Williams, 1967; Monis, Candiotti et al., 1969). This surface coat is produced by 
each cell individually and can vary quite abruptly from cell to the next (see Figure 21). This layer 
is known as the glycocalyx, a term proposed by Stanley Bennett in 1962 (published in 1963) 
meaning ‘sweet husk’, 
from Greek, in 
reference to the 
polysaccharides 
present in this 
layer (Bennett, 1963) in 
many species across 
the biological 
Kingdoms. 
 
 Figure 21 - Surface coat of microvilli can vary strongly from one cell to the next. 
Adapted from (Mukherjee and Williams, 1967) 
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Up until the eighties, the diffusion barrier of the intestinal barrier was thought to be an ‘unstirred 
water layer’ (UWL), water that is not stirred due to proximity to cells, and therefore forces 
absorption to occur only through diffusion, specifically negating the role of the glycocalyx and 
the mucus secretions in absorption (Thomson and Dietschy, 1984). This role was asserted 
earlier, in part because the available space in rat intestine is not sufficient for an UWL of 
adequate thickness to explain the slow diffusion rate observed (Smithson, Millar et al., 1981). 
During this debate, people started to further conceptualize the nature of the mucus gel covering 
gastrointestinal epithelia, and it was proposed that the already familiar UWL covered by a lipid 
membrane is actually hydrated goblet-cell mucin (Nimmerfall and Rosenthaler, 1980). It was 
proposed that the mucus is secreted in a condensed form that subsequently expands in the 
lumen (Allen, 1983). It seems logical that a possible unstirred water layer would be incorporated 
in the mucus layer, based on the strong gel-forming properties and interactions with water of 
this condensed mucin secretion. At the same time, literature started to report on the properties 
of a ‘luminal mucin layer’ (LML), covering epithelia throughout the colon of different species. 
Notably, it was reported that the proximal colon has a thicker but highly variable LML, not 
continuous and mixed with food particles and bacteria, while the distal colon has a thinner layer 
of very compact non-penetrated LML covering the epithelium and separating it from the 
contents, observed in cryo-sections (Sakata and Engelhardt, 1981). 
Later again, in the nineties, the adherent 
mucus layer of human colon biopsies 
was investigated by sectioning fresh 
material after removing the mucosa 
from the muscularis mucosa, and 
observed on filter paper, while keeping 
the tissue moist with saline. In this way, 
a mucus layer of around 150µm is 
observed, see Figure 22 (Pullan, Thomas 
et al., 1994). 
Similarly, Matsuo et al. showed an adherent mucus layer on human colonic biopsies, by rinsing, 
pinning on board, and coloration after fixation with Carnoy’s solution. They reported a 2-layer 
organisation, with an inner layer ranging from approx. 4,5 µm to 12,7µm, and an outer layer 
ranging from approx. 31 to 89µm (Matsuo, Ota et al., 1997). Studies using paraffin-embedded 
Figure 22 - Mucus covering the mucosa of a prepared fresh 
human colonic biopsy. (Pullan, Thomas et al., 1994) 
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rodent intestine fixed in Carnoy’s solution in combination with ex vivo measurements using 
explants mounted in specially designed mucus chambers would then clarify more about the 
function of this mucus covering the epithelial lining on the intestines. In 2008, it was reported 
that ex vivo, the outer layer covering mouse colon is about 100µm, and is easily removed, and 
the inner around 50µm, which is firmly attached to the epithelium. In the same study, in 
histological material, it is shown that the outer layer contains bacteria, while the inner layer does 
not (Johansson, Phillipson et al., 2008). This notion, together with the severe and often lethal 
colitis observed in muc2-/- mice (Van der Sluis, De Koning et al., 2006), which lack a mucus 
barrier, led to the understanding that the mucus barrier is necessary to keep bacteria away from 
the epithelium, and thus essential in preventing inflammation.  
A proper understanding of the nature and functions of the intestinal mucus barrier is important, 
because it impacts the design and veracity of theoretical, practical and mathematical models of 
interactions in the gut. For example, results obtained using promising systems such as gut-on-a-
chip (Kim, Huh et al., 2012) have to be compared to a precise understanding of physiological 
conditions in vivo, to allow realistic interpretation. Additionally, pharmacological approaches 
take interactions of medicinal compounds with the mucosal barrier into account (Netsomboon 
and Bernkop-Schnurch, 2016), and to effectively do this, correct estimations of mucus barrier 
organisation and regulation are essential. 
One thing is sure, mucosae produce mucus… 
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1.5.3.3 Regulation 
Even though the general description of the mucus layer is fairly static, there are several known 
important mechanisms that regulate mucus secretion, and finetune the production in relation 
to different situations and challenges. Since presence of a pathogen is one of the most acute 
naturally occurring challenges to the intestinal epithelium, and protection against pathogens of 
the main functions of the mucus barrier, it stands to reason that it influences mucus barrier 
regulation. NLRP6 inflammasome activity is strongly implied in proper barrier function, as 
NLRP6-deficient mice have a defective mucus barrier, which renders them more susceptible to 
Citrobacter rodentium (Wlodarska, Thaiss et al., 2014). Inflammasomes are multiprotein 
complexes that regulate innate immune responses of cells, integrating information from 
cytokine signalling, microbial products, and damage-associated molecular patterns 
(DAMPs) (Rathinam, Vanaja et al., 2012). Signalling from TLR4 in response to bacterial 
lipopolysaccharides (LPS) causes mucin granule exocytosis of goblet cells, thereby causing an 
increase in its thickness, and flushing away the bacteria from the epithelial surface (Dharmani, 
Srivastava et al., 2009). An insufficient mucus barrier, such as observed in germ-free animals, 
due to lack of signals from microbial products, renders mice exceptionally sensitive to chemically 
induced colitis by treatment with dextran sodium sulphate (DSS) (Kitajima, Morimoto et al., 
2001), indicating both that the microbiota and microbial signalling is necessary for optimal 
mucus barrier regulation, and that the mucus barrier protects against harmful toxic chemicals.  
Colonic crypts are ‘guarded’ by sentinel goblet cells (senGC), which reacts strongly to the 
presence of bacteria by NLRP6 activation by PRR signalling, in response to LPS and flagellin. This 
causes compound exocytosis of muc2 mucus, and triggers mucus release in neighbouring goblet 
cells as well, through an intercellular gap-junction signal (Birchenough, Nyström et al., 2016). In 
the ileum, other PRRs are expressed, and crypts there are not responsive to LPS or 
flagellin (Birchenough, Nyström et al., 2016). This could reflect the different situations in these 
compartments; whereas bacteria reaching the epithelium in the colon is a danger that warrants 
a reaction, in the ileum, where no true separating mucus barrier exists, this is a normal situation. 
Apart from signalling from microbes or luminal chemicals, mucus release is also promoted by 
cholinergic signalling (Specian and Neutra, 1980) and histamine (Castagliuolo, Lamont et al., 
1996). Though both small and large intestine mucus production is activated by acetylcholine, 
the small intestine is by far more sensitive to this (Birchenough, Johansson et al., 2015).  
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Together with the observation that the large intestine is more responsive to TLR activation than 
the small intestine, this reinforces the idea that the mucus release is regulated differently in 
these two different organs; the small intestine mucus barrier more responsive to 
parasympathetic activity, the large intestine more to luminal signalling.  
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1.5.3.4 Dietary effects 
The mucus barrier can be impacted by the diet in several ways. What we eat can have effects on 
the expression of mucins and the regulation of mucus release, but the physical properties of the 
bolus and faeces also have an impact on the properties of the mucus layer, and the rheology of 
mucus excretions. Here, we will look at some examples of known effects of the diet on the mucus 
barrier. 
A major influence on the mucus barrier is dietary fibre; an in vivo rat model testing different 
dietary fibre contents showed that mucus turnover as well as production was reduced by fibre 
deficiency, and different fibres have different effects on these factors (Brownlee, Havler et al., 
2003). In the same vein, fibre deficiency in a mouse model causes the expansion and increased 
activity of mucus-degrading bacterial species, leading to a reduced mucus barrier, and a reduced 
resistance to C. rodentium (Desai, Seekatz et al., 2016). In a way, it speaks for itself that nutrients 
that lead to the production of SCFAs by the microbiota, such as these dietary fibres, have an 
effect on the mucus barrier, because SCFAs have effects on mucus release and 
production (Sakata and von Engelhardt, 1981; Shimotoyodome, Meguro et al., 2000; 
Hedemann, Theil et al., 2009), as well as possible modulation of mucin gene expression (Paturi, 
Butts et al., 2012).  
Dietary lipid intake has an effect on the mucus barrier as well, changing the permeability of this 
barrier, decreasing the mobility of particles (Yildiz, Speciner et al., 2015). Contrary to the effects 
of SCFAs, these effects of lipids play a direct role in interaction with the mucus itself. 
Apart from these effects, because we have already described microbiota interactions with the 
host and its effects on mucus barrier regulation, diets with specific impacts on microbiota 
composition or activity, logically also have an effect on the mucus barrier. 
  
 P a g e  | 83 
  
1.6 Aims and Outline of Thesis 
1.6.1 Hypotheses 
Based on the available literature and the theoretical framework, we propose that FODMAP 
fermentation by the intestinal microbiota can have harmful effects which increase the tendency 
to display gastrointestinal symptoms. This is complementary to the known mechanisms by which 
FODMAP ingestion provokes these symptoms; an increased distension of the intestine by an 
increase of the osmotic load and water volume in the small intestine, and of gas volume in the 
large intestine, generated during fermentation. As functional parameters to these harmful 
effects, we selected to investigate the visceral sensitivity, intestinal barrier function, and 
microbial metabolite profiles of the colonic contents in relation to treatment with selected 
representatives of FODMAPs. We formulate the following hypotheses: 
1. FODMAP ingestion can induce gastrointestinal symptoms of IBS by itself, in an otherwise 
healthy system 
2. This effect relies on the production of harmful bacterial fermentation metabolites, among 
which methylglyoxal 
3. Methylglyoxal and other strong glycation agents lead to an increase in AGEs and a pro-
inflammatory state through activation of RAGE 
A recurring theme and major field of interest in research of gastrointestinal disease and function 
is the relation of the host with their microbiota. In this context, the contact between intestinal 
microbes and host surfaces are considered important, and an understanding of the properties 
of the excreted mucus barrier, which separates microbes from the epithelium in the colon where 
the concentration of microbes is highest, is key to understanding host-microbe relations in the 
intestine. For this reason, to better understand the mucus barrier function, we have identified 
some situations in which information regarding this interesting topic was missing and designed 
experimental approaches to fill in these gaps of knowledge. 
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 (Bierhaus, Schiekofer et al., 2001; Ramasamy, Yan et al., 2006; Bierhaus, Fleming et al., 2012) 
 
To identify approaches of interest to better understand the subject, a mind map of putative 
causal relationships was designed based on literature and logical connections. The fermentation 
of FODMAPs by the gut microbiota leads to the production of methylglyoxal, which in return can 
impact the composition and functionality of the gut microbiota (Russell, 1993; Totemeyer, 
Booth et al., 1998; Tuohy, Hinton et al., 2006; Campbell, Matthews et al., 2010). Because 
methylglyoxal has been named as an important toxic bacterial metabolite (Campbell, Naseem 
et al., 2007; Campbell, Matthews et al., 2010), it has a central place. Its activity as a dicarbonyl 
leads to the production of Advanced Glycation End products (AGEs) which themselves lead to 
immune activation, because they’re recognized as DAMPs by the innate immune system. This in 
turn can lead to symptom generation, and can increase gut permeability, which is also 
implicated in the development of IBS symptoms. In general, it can be inferred that either by 
direct impact or effect on an intermediate actor, most of these factors influence each other in 
various feedback loops.  
Figure 23 - Web of possible causal relations involved in the effects of FODMAPs on IBS symptoms 
+ : positive relation, i.e., increases 
- : negative relation, i.e., decreases 
+ or - : either positive or negative relation 
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1.6.2 Approach 
To investigate the relations between FODMAP intake, IBS symptoms, immune activation, and 
bacterial fermentation products, we have designed and performed animal experiments related 
to each hypothesis; male C57Bl/6 mice have been given FODMAP representatives (lactose and 
fructo-oligosaccharides) for 3 weeks, to induce FODMAP related changes to their physiology. 
Additionally, an anti-glycation agent (pyridoxamine) was administered intended to counteract 
the effects of glycating elements produced during bacterial fermentation of said FODMAPs. 
Next, analyses were performed to answer our questions; 
Hypothesis 1: To test whether FODMAPs can induce IBS symptoms we have measured the 
visceral sensitivity, gut permeability, mast cell counts in the colon, and colonic mucus barrier 
dysregulation in the treated animals. 
Hypothesis 2: To test whether these effects were caused by glycation processes, we have 
analysed whether administration of anti-glycation agent pyridoxamine protects against these 
consequences, additionally, generation of reactive aldehydes and ketones in the colonic 
contents was analysed by HPLC/MS after derivatisation with BBHA (1-((aminooxy)ethyl)-2-
bromobenzene hydrochloride). 
Hypothesis 3: To identify the effect of these glycation processes, we have measured the 
occurrence of advanced glycation end-products (AGEs), and the expression of Receptor for AGEs 
(RAGE) in the colon of treated animals. 
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1.6.3 Experimental procedures 
1.6.3.1 Treatment setup 
C57Bl/6 mice are housed in groups and treated with daily gavages of lactose and/or 
pyridoxamine, or put on a custom FOS diet (AIN-93M +/-10% FOS, starch partly replaced). 
Animals are weighed 2 times per week. Animals for permeability assays and mechanical 
behavioural testing are also used for histological purposes, animals for visceral sensitivity assays 
are not. 
1.6.3.2 Visceral sensitivity: EMG, von Frey 
Since a central IBS symptom relieved with the low-FODMAP diet is abdominal pain/discomfort, 
we set out to measure the possible induction of increased sensitivity by FODMAP ingestion. The 
reference method of recording of electromyographic response to colorectal balloon distension, 
as well as an alternative method of mechanical behavioural testing using von Frey filaments 
were performed. This alternative was necessary as FOS-treatment lead to increased amounts of 
intestinal content that caused the colorectal cavity to remain full even after fasting and 
habituation periods, which would impede reliable data gathering. 
Visceral sensitivity (Electromyography (EMG)) 
Electrodes are implanted into the abdominal muscles and colorectal distensions are used as 
noxious stimuli to evaluate visceral hyperalgesia by electromyographic (EMG) recording. 
Striated muscle’s EMG activity was recorded and analysed according to (Larsson, Arvidsson et 
al., 2003). Basal EMG activity was subtracted from the EMG activity registered during the periods 
of distension.  
This procedure is considered the gold standard in visceral sensitivity analysis, measuring the 
abdominal contractions in response to a painful stimulus in a quantifiable way. Visceral 
hypersensitivity is observable through an increased response to the colorectal distension 
stimulus, both by a response to stimuli that do not provoke a reaction in normosensitive subjects 
(allodynia), as well as an increased response to painful stimuli (hyperalgesia). 
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Mechanical behavioural testing (von Frey) 
Three von Frey filaments with bending force 0.16, 0.6 and 1.4 g are applied to the mid-plantar 
area of each hind paw and nociceptive specific behaviours noted. 
This procedure allows us to compare the central sensitivity of animals, by valuing the 
responsiveness to mechanical stimuli on the hind paws, as well as the abdominal region. Animals 
that have an increased sensitivity exhibit a higher responsiveness. Animals with an increased 
visceral sensitivity will have a higher central sensitivity through sensitization processes mediated 
through the spinal cord (Lamb, Zhong et al., 2006), probably through convergence of primary 
afferents on the same neurons in the spinal cord.  
1.6.3.3 Intestinal permeability 
An important parameter of intestinal health is its permeability, which is known to play a role in 
IBS as well (Dunlop, Hebden et al., 2006; Bischoff, Barbara et al., 2014; Enck, Aziz et al., 2016; 
König, Wells et al., 2016). To investigate the effects of our FODMAP interventions on this 
parameter, we have performed in vivo measurements of intestinal permeability. 
In vivo measurement of permeability using FITC 
Fasted mice are gavaged with 250µl of fluorescein isothiocyanate (FITC) solution (1mg/ml). After 
4 hours, when the entirety of the gastrointestinal has been passed by the solution, 100µl of 
blood is taken and kept in the dark on ice. Serum is recovered and analysed in a 
spectrophotometer. FITC concentration of blood samples is calculated using the standard curve. 
 
This in vivo procedure is designed to measure the passage of a fluorescent marker to the blood, 
reflecting the paracellular or transcellular permeability of the gastrointestinal tract, depending 
on the size and nature of the marker used. We used fluorescein isothiocyanate (FITC), a small 
(~390Da) molecule, meant to measure predominantly the paracellular permeability. 
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1.6.3.4 Immunofluorescence/ histology  
Histological sample preparation 
Collected tissues were fixated for 1 day in Carnoy’s fixative and included in paraffin, and 
subsequently microsectioned and attached to glass microscopical slides. 
Immunofluorescence 
To visualize marker proteins and measure their expression, microscopic immunofluorescence 
assays were used. 
AGE: Slides were deparaffinated and incubated overnight at 4°C with primary antibodies 
(Polyclonal Rabbit-anti-AGE (ab23722), followed by incubation with secondary antibody (Alexa 
Fluor 488 Donkey-anti-Rabbit (A21206). 
Following our hypothesis that FODMAP fermentation leads to the production of reactive 
carbonyl species, we sought to quantify the occurrence of the retained, and cumulative, marker 
of glycation processes, advanced glycation end products (AGEs). 
RAGE: Slides were deparaffinated and incubated overnight at 4°C primary antibodies (Polyclonal 
Goat-anti-RAGE (ab7764), followed by incubation with secondary antibody (Alexa Fluor 488 
Donkey-anti-Goat (A-11055). 
An increased occurrence of AGEs in the tissue can be expected to activate Receptor for AGEs 
(RAGE), which consecutively leads to the increased expression of this receptor (Bierhaus and 
Nawroth, 2009). 
MMCP: Slides were deparaffinated and incubated overnight at 4°C with primary antibodies 
(Sheep anti-mMCP1 (MS-RM8), followed by incubation with secondary antibody (Alexa Fluor 
594 Donkey-anti-Sheep (A-11016). 
Mouse Mast Cell Protease-1 was chosen as a selective marker of (mucosal) mast cells (Dai and 
Korthuis, 2011), to visualize and quantify the mucosal mast cells in histological slides. Because it 
is easy to trigger mast cell degranulation and exocytosis of this marker, particular care was taken 
not to disturb the tissue before fixation, i.e., no touching of the tissue, no flushing of contents, 
no cutting to size, until after fixation. 
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Muc2: Slides were deparaffinated and incubated overnight at 4°C with primary antibodies 
(Rabbit anti-mucin 2 (sc-15334), followed by incubation with secondary antibody (Alexa Fluor 
488 Donkey-anti-Rabbit (A21206). 
Muc2 is the predominant mucin in small intestinal and colonic mucus, and this antibody staining 
is used to very clearly visualize mucus in immunofluorescent slides. This can be combined with 
FISH. 
AB/H&E: Slides were deparaffinated and stained by 5 min in Hematoxylin, 10 min in running 
water, 30 min in Alcian Blue solution (pH 3.0) followed by 5 min in running water, 3 min in Eosin. 
The haematoxylin and eosin stain (H&E) is a standard staining to visualize general morphology 
and recognize immune cell infiltrates in tissues, while also staining bacterial masses, the 
combination with Alcian blue (AB) staining visualizes goblet cells and mucus. The combination 
AB/H&E thus allows to analyse a diverse set of parameters. 
Fluorescent in situ Hybridization (FisH): FISH staining for all bacteria was performed using probes 
EUB338I (5′ CGTGCCTCCCGTAGGAGT 3′), EUB338II (5′ GCAGCCACCCGTAGGTGT 3′), and 
EUB338III (5′ GCTGCCACCCGTAGGTGT 3′) conjugated to DY-590. Slides were deparaffinated and 
incubated with the FISH probes at 48°C overnight.  
These 3 probes (EUB338I, EUB338II, EUB338III) together target virtually all true bacteria (Daims, 
Brühl et al., 1999), so this mix can be used to reliably stain all bacteria found in the intestine, to 
clearly visualize the presence and location of bacteria. 
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1.6.3.5 Markers of immune activation 
Lipocalin-2 
Faecal supernatants were analysed for lipocalin-2 content by ELISA. 
Lipocalin-2 (LCN-2) is a very sensitive marker for intestinal inflammation, even subclinical low-
grade inflammation, where histopathology is not clear (Chassaing, Srinivasan et al., 2012). LCN2 
is produced by neutrophils and macrophages. 
Microscopic score 
Composite micrographs were scored according to protocol on a scale from 0-4 (Neurath, Fuss et 
al., 1995); 0: no signs of inflammation, 1: very low level of leukocytic infiltration, 2: low level of 
leukocytic infiltration, 3: high level of leukocytic infiltration, high vascular density, thickening of 
the colon wall, 4: transmural infiltrations, loss of goblet cells, high vascular density, thickening 
of the colon wall.  
This scoring system for the mouse colon evaluates signs of overt inflammation, and thus grades 
severity of colitis. 
1.6.3.6 Physiological markers of transit 
Transit time 
Mice were temporarily housed in individual cages, carmine red solution was administered by 
intragastric gavage, and starting from 2 hours after administration, every 15 minutes or when 
the researcher noted defecation, the cages were checked for red-coloured droppings, the time 
of first appearance of a red dropping was used to determine the transit time.  
This test tells us how long it takes for material to pass through the gastrointestinal tract, starting 
at the stomach.  
Faecal water content 
Faecal droppings were weighed, dried for 2 days at 80°C, and weighed again. Faecal humidity is 
the percentage of weight lost between wet and dry weights. 
Faecal water content is a reasonable marker of colonic transit time, because a faster transit leads 
to higher percentages of water in faeces (Degen and Phillips, 1996; Lewis and Heaton, 1997b). 
We were interested in transit time and faecal water content because FODMAPs can be expected 
to influence these markers, which is important to consider in relation to further effects of 
treatment. 
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1.6.3.7 Analysis of microbiota composition 
Faecal DNA extraction, 16S rRNA gene sequencing, and bacterial community analysis 
Genomic DNA was obtained from frozen faeces, 16S rRNA was amplified by PCR. Pooled 
amplicon libraries were sequenced employing an Illumina MiSeq. For further data on analysis of 
microbiota, please refer to section 2.2. 
We analysed microbiota profiles to see the effect of lactose treatment on gut microbiota 
composition, as well as the effect of the anti-glycation agent pyridoxamine, because FODMAPs 
have a known prebiotic function, and could therefore be expected to impact microbiota profile 
composition, even at 5 mg daily. 
1.6.3.8 Analysis of carbonyl compounds in colonic content 
Colonic content extracts were incubated with 1-((ammoniooxy)methyl)-2-bromobenzene 
chloride (BBHA) to generate brominated aldehyde derivates which were analysed by high-
performance liquid chromatography coupled to high-resolution mass spectrometry (HPLC-
HRMS). Resulting semi-quantitative mass spectra were analysed statistically to characterize 
differential ions and construct heat-map profiles for the different treatment groups. For a 
complete description, please refer to section 2.2. 
This analysis allows us to follow the effects of our dietary interventions on carbonyl metabolite 
profiles. 
1.6.3.9 Mucus barrier function analysis 
Imaging; Manual-ultra high-resolution Composite Image Overview (MUCIO) 
Manual Ultra-high-resolution Composite Image Overview (MUCIO) approach: datasets of 
overlapping microscope images covering entire slides were generated by manual microscope 
photography and stitched together using dedicated software. The generated composite images 
contain all the information of the data set in a single ultra-high-resolution file. No selection for 
‘representative regions’ is necessary, only obvious artefacts (e.g., possibly folded double/ 
heavily damaged sections) are evaded. Subsequent downscaling is necessary to facilitate 
interaction with images for further applications, but close-up views in full quality can be 
extracted from the original composite. 
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Mucus layer thickness measurements 
The faecal mucus layer thickness was measured every 100 micrometres along the entire imaged 
faecal surface generated with the MUCIO approach. Data interpretation: The hundreds of 
measurements generated were interpreted by calculating several statistics. First of all, of course, 
the average mucus layer thickness is calculated, but this does not tell us anything about the 
variation, and the standard deviation or confidence interval is calculated between individuals, 
not on multiple measurements per individual. To mitigate this, the Coefficient of Variation (CoV) 
is calculated for the dataset of each individual, and these values are compared for treatment 
groups. 
Active goblet cell numbers 
One ratio discharging goblet cell:crypt per mouse based on analysis of 25-90 crypts in transversal 
sections of empty colon, dependent on availability of suitable visual material 
 
By calculating the average mucus layer, the CoV for this mucus layer, as well as the active goblet 
cells in empty colon, we can characterize the mucus barrier function, considering the variable 
situations that naturally occur in the distal colon. 
  
  
   
  
2 Project Results 
Published Work, under Review, 
under Preparation 
 
“To see the world in a grain of sand, and to see heaven in a wild flower,  
hold infinity in the palm of your hands, and eternity in an hour.” 
~William Blake, 1757-1827 
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2 Project Results 
2.1 Mucus organisation is shaped by colonic content; a new view 
While analysing the possible effects of FODMAPs on mucus barrier function, analysing 
histological sections in both regions with and without faeces, some observations were made 
that warranted further investigation. Notably, in sections lacking a faecal pellet, there is a 
marked absence of the classical inner-outer mucus layer organisation. This absence has been 
described before, and explained by the supposed protection from washing off of the mucus layer 
by the faecal pellet (Johansson, Larsson et al., 2011). However, since we routinely acquire and 
fix several centimetres of colon, containing regions with and without faeces, and there is no 
flushing of this intact intestinal tube either before or after fixation, we wanted to test whether 
this absence is due to washing off of mucus, as postulated in literature.  
Therefore, we decided to make longitudinal sections, and image the entire section, to see what 
is going on in the transition from empty to full sections of the colon, and vice versa. Additionally, 
we reasoned that if a possible collapse of the mucus was responsible for the absence of the 
described two-layer system, the bacteria should still be present, but now probably in closer 
contact to the epithelium. To visualize these bacteria, we performed fluorescence in situ 
hybridisation (FisH) of longitudinal and transversal sections of empty and full sections of 
proximal and distal colon.  
The results of this investigation were published in Scientific Reports (Springer Nature).
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colonie content; a new view 
J. B. J. Kamphuis, M. Mercier-Bonin, H. Eutamène & V. Theodorou 
The colonie mucus barrier is commonly described as a continuous double layer covering the epithelium, 
separating the microbiota from the intestinal tissue. This model is currently considered valid throughout 
the colon. The colon is characterised by regional anatomo-functional specificities such as presence and 
consistency of contents and location. ln this study, we characterised the organisation of the colonie 
mucus barrier in proximal and distal colon of rodents by histological and FISH staining, ta king into 
account aforementioned specificities. By using longitudinal sections and imaging extensive areas 
of tissue with and without colonie contents, we have obtained a spatiotemporal overview of mucus 
organisation in the colon. We describe for the first time that the colonie mucus layer covers the faeces 
instead of the epithelium in the distal colon. This faecal mucus layer confines the microbiota to t he 
faeces and prevents it from remaining in empty distal colon. ln the proximal colon, the mucus did not 
forma separating layer between bacteria and epithelium. We conclude that the organisation of colonie 
mucus is reliant on the presence of the colonie content, and the location within the colon. Our findings 
reopen the discussion on the nature of the colonie mucus barrier. 
The intestinal mucus layer has a critical role in gut health. lt facilitates the passage of faeces through the intestine, 
reducing the risk of damage to the gut epithelium 1• The critical importance of intest inal mucus to gut health is 
underlined by the spontaneous development of colitis in Muc2 knockout (Muc2- 1-J mice2, and their increased 
susceptibility to pathogens3• Bacteria of the intestinal microbiota profit the host with their metabolic activities', 
and modulation of the immune system5 . Limiting the contact between intestinal microbes and the colonie epi-
thelium, a thick mucus layer is described that separates the two6• Johansson et a/.7 reported that the distal colonie 
mucus layer is organised in 2 parts, a firm component and a loose one, both built around Muc2 mucin protein. 
This layer has been described to be organised as a loose layer inhabited by bacteria, and a layer firmly attached to 
the epithelium, devoid ofbacteria7• Primarily, this understanding is based on histological observations of trans-
versal sections of colon, imaging the mucus layers separating microbes from the epithelium. lt became evident 
that it was impossible to image the mucus barrier in histological sections lacking a faecal pellet, so the method 
of reference became to section samples containing a faecal pellet to investigate the properties of the mucus layer. 
A given expia nation for this necessity was that the faecal pellet protects and conserves the mucus barrier during 
histological processing7. Additionally, to further investigate mucus barrier properties, ex vivo experiments involv-
ing expiant tissue8, and in vivo experiments have been designed and performed6•9. The general organisation is 
described to be constantly sustained7, though specifics are variable over lime, and influenced by harmful fac tors 
such as in flammation 10 or even the lime frame of microbiota colonisation 11, emphasising the in timate relationship 
between intestinal mucus and gut microbiota. Furthermore, microscopie analysis of the biostructure ofhuman 
faeces shows mucus irregularly intersecting into the faecal mass12, and a mucus layer is observed on expelled 
faeces from rodents as well as humans12• 13• These results obtained from faecal material illustrate the organisation 
of the contents of distal colon, which does not necessarily reflect the situation in the proximal colon. Apart from 
the morphological differences between the proximal and distal colon, the contents too are dissimilar in their 
consistency and humidity; the proximal colon content is liquid whereas the contents of distal colon normally 
form pellets with a firmer consistency. Changes in the physical and biochemical properties of colonie mucus 
have been documented in pathophysiological conditions. For instance, colonie mucus from ulcerative colitis 
(UC) patients in the active phase of the disease is thinner and more penetrable to fluorescent beads compared to 
healthy subjects14 and glycosylation of colonie mucins is found to be correlated with the severity of inflammation 
in UC patients 15. Likewise, O-glycosylation of mucins is strongly affected by chronic psychological stress in rats, 
associated with a flattening and a Joss of cohesive properties of the mucus layer16. Despite data indicating that the 
Neuro-Gastroente rology and Nutrition Team, UMR 1331, INRA Toxalim, INP-EI-Purpan, Université de Toulouse, 
Toulouse, France. Correspondence and requests fo r materials should be addressed to H.E. (email: he lene. 
eutamene@inra.fr) 
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Figure l. A firm mucus layer separates the bacteria from the epithelium. (a) FISH stained transversal section 
(Bacteria: red; nuclear staining DAPI: blue) of rat distal colon. (b) AB/H/E stained transversal section of rat 
distal colon. (c) FISH stained transversal section (Bacteria: red; nuclear staining DAPI: blue) of mouse distal 
colon. (d) AB/H/E stained longitudinal section of mouse distal colon. The FISH staining indicates where the 
bacteria are located, and that this corresponds to the dark blue/purple staining in AB/H/E stained samples. 
properties of intestinal mucus are dynamic and influenced by a disruption of intestinal homeostasis, modification 
of the microbiota, altered food in take, and disturbances in gut motility, little is known about the dynamics of the 
mucus barrier during normal gastrointestinal transit, reflected by the periodic presence and absence of faeces. 
This study is meant to clarify the influence of the colonie Joad on mucus layer structure and organisation in 
physiological conditions in the colon. We performed longitudinal and transversal sections of distal and proximal 
colon of rat and mouse in samples covering regions with and without luminaJ content. We used classical histology 
to characterise tissue and mucus morphology, combined with 'Fluorescent in situ Hybridisation' (FISH) staining 
to localise the gut microbiota. Instead of depicting select microscopie fields, we generated images covering the 
entirety ofboth transversal and longitudinal sections using a Manual Ultra-high resolution Composite Image 
Overview (MUCIO) approach, creating comprehensive overviews of tissue sections, rendering them more under-
standable as well as preventing an image selection bias in our results. 
Results 
Organisation of mucus in distal colon is influenced by the presence of colonie content. In trans-
versal sections of full distal colon, a sterile mucus barrier separated the epithelium from the faeces and the micro-
biota (Fig. ! ). Bacteria were aJmost absent from this layer of about 35µm (Fig. la,b) in rat, and 20 µm (Fig. lc,d) in 
mouse. Changing the direction of sectioning, in longitudinal sections covering both empty and full sections of rat 
distal colon, faecal pellets were completely covered by a sterile mucus layer of variable thickness (36 µm ± 9 µm), 
with a mix ofbacteria and mucus presen t underneath (Fig. 2a-d). The mucus layer only covers the faecal pellet, 
and is not attached to the epithelium (Fig. 2a,c). The dark blue layer (Fig. 2c,d) is rich in bacteria, as corroborated 
by Fig. 1. In t ransversal sections of empty distal colon mucus was not organised in a similar fashion; instead, 
'luminal' mucus without an apparent layer structure was present (Fig. 3). ln these empty sections the tissue was 
folded up neatly, with opposing epithelia very close to each other, sometimes in contact. ln rat tissue, the dis-
tance between opposite epithelia in empty distal colon averages 17 ± 9 µm (Fig. 3a), in mice it averages 16 ± 7 µm 
(Fig. 3c). In contras! to the situation in colon containing faeces, we have not observed bacteria-colonised mucus 
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colonie crypt bulk of faecal pellet 
Figure 2. AB/H/E stained longitudinal section of distal rat colon containing faecal pellets. A sterile mucus 
layer covers the pellet completely. (a) The mucus layers attached to the faeces cover the entire pellet. (b) A 
line ofbacteria-overgrown mucus penetrates the faecal pellet. (c) Sterile (light blue) and bacteria-overgrown 
mucus layers (dark blue) can be recognised, mucus production by goblet cells in the lumen is visible. (d) Sterile 
('inner') and bacteria-overgrown ('outer') mucus layers, are recognised in a manner commonly observed in 
transversal sections. 
in empty distal colon (Fig. 3b,d). A longitudinal section of mouse distal colon containing faeces shows that bac-
teria are confined to the pellet, which consists mostly of alimentary residues embedded in microbiota-colonised 
material (Fig. 4). The sterile mucus layer can be internalised by the colonie contents in mouse distal colon (Fig. 5). 
In this situation, the internalised firm mucus layer remains sterile, seen from the lack of signal in a FISH staining 
(Fig. Sc,d). 
Excreted faeces are covered by a faecal mucus layer. On expelled faecal pellets of mice, a mucus 
layer (24 ± 4.5 µm ) devoid of bacteria covers a mix of bacteria and mucus directly (Fig. 6), as well as the rest of 
the faecal material. This faecal mucus layer has the same appearance and general thickness as the one observed 
previously (Figs I and 2) in distal colon, which covers faecal pellets and separates contents from the epithelium. 
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Figure 3. AB/H/E stained transversal sections of distal rat and mouse colon without faeces. The lumen con tains 
loose mucus, but no bacteria are detected. (a) Close-up of rat empty distal colon (b) FISH staining indicating 
the absence ofbacteria in the lumen of collapsed rat colon. (c) Close-up of mouse empty distal colon. (d) FISH 
staining indicating the absence ofbacteria in the lumen of collapsed mouse colon. (e) FISH staining of rat colon 
containing faeces (Bacteria: red; nuclear stain ing DAPI: blue) serving as a positive control. 
Mucus barrier in proximal colon is affected by consistency of contents. In the proximal colon, 
the microbiota was in contact with the epithelium with a noticeable absence of a significant mucus barrier 
(Fig. 7). The colonie contents were seen to form the first pellet in the distal end of the proximal colon, on the 
transition towards the distal colon. Here, the first establishment of a mucus barrier can be observed, in multiple 
streaks on the most distal part of the newly formed pellet (Fig. 7b). In proximal colon, mucus containing bac-
teria was found in direct contact with the colonie tissue, both in more folded collapsed tissue (Fig. 7c) and in 
tissues where the lumen is distended by colonie contents (Fig. 7d). In mostly or completely collapsed proximal 
colon, bacteria-colonised mucus was found in contact with the intestinal tissue, unseparated by a sterile mucus 
barrier (Figs 7c and 8c,d), in contras! to the situation described earlier for distal colon. In full proximal colon, 
we observed bacteria in contact with the epithelium too, with the microbiota present in an increasing gradient 
towards the tissue (Figs 7d and 8a,b); the highest concentration of bacteria was present around and especially 
below the tissue folds specific to the proximal colon. 
Discussion 
Longitudinal sections of distal colon reveal that the colonie Joad is a determining factor in the organisation of 
the colonie mucus. The mode! of dual mucus layers covering the colonie epithelium is based on observations in 
transversal sections of colon containing a faecal pellet6• We obtained similar observations in transversal sections 
(Fig. 1). To our knowledge, this organisation has never been observed in histological sections ofuntouched tissue 
lacking faecal pellets, reportedly because the faecal pellet is a necessary fac tor fo r mucus conservation during 
the histological procedures7• Our results point out that the faecal pellet is indeed prerequisite for observation 
of the firm mucus layer, but for different reasons. In longitudinal sections, it is noticed that the observed mucus 
layers cover the faecal surface instead of the epithelium, and so are not attached to the epithelial surface (Fig. 2). 
Further supporting this implication, the sterile mucus layer produced by the intestinal mucosa is sometimes 
found inside a faecal pellet, where it can only have ended up after a collision between two faecal pellets (Fig. 5). 
Taken together, these data suggest that the use of transversal sections to observe mucus layer organisation has led 
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Figure 4. ln distal colon, the microbiota is confined to the faecal pellet. (a) AB/H/E stained longitudinal section 
of mou se distal colon. (b) FISH stained (Bacteria in red; nuclei in blue) longitudinal section of mouse distal 
colon. The bacteria are located in the faecal pellet, the lumen of the empty colonie part is almost completely 
devoid ofbacteria, but does contain some loose mucus. A mucus layer devoid ofbacteria, confining the bacteria 
to the faeces, covers the pellet. 
to the misinterpretation that the faecal mucus layer is attached to the epithelium. lnstead, the organisation of the 
mucus layers seems to be determined by faecal pellet transit within the gut. In our experiments, we found that the 
sterile mucus barrier of the distal colon is not continuous, but depends on the presence of a faecal pellet. Still, the 
conditions in empty distal colon are strongly devoid ofbacteria, because a clear majority of microbes are removed 
together with the faecal pellet and ils mucus. A schematic overview of our proposed mucus layer organisation in 
distal colon can be found in Fig. 9. 
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Figure 5. After collisions between faecal pellets in the distal colon, the mucus layers covering their surface 
can be internalised into the resulting composite pellet. (a) AB/HIE stained longitudinal section of distal mouse 
colon. (b) Close-up showing the interna lised firm mucus layer. (c) AB/ H/E stained longitudinal section of distal 
mouse colon. A fi rm mucus layer devoid ofbacteria is found inside the pellet. (d) FISH stained (Bacteria in red; 
nuclei in blue} longitudinal section of mouse distal colon, the internalised firm mucus layer is recognised by the 
absence of bacteria. 
As supported by literature8, mucus is excreted from colonie crypts both in the presence and absence ofluminal 
content, indicating a continuous baseline excretion. In ex vivo experiments, mucus produced by the t issue forms 
a firm inner layer of fresh mucus attached to the epithelium and a loose outer layer of older, more disintegrated 
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Figure 6. AB/H/E stained transversal cross-section of an expelled mouse faecal pellet. (a) A mucus layer devoid 
ofbacteria covers the entire pellet. (b) Apart from alimentary residues and microbiota mixed with mucus, there 
are undigested plant fibres embedded in the faeces, as commonly observed in faecal malter in the gut as well. 
mucus6 •9 • In these conditions, the firm adherent mucus layer of rat colon is reported to be l 16µm9 , or 101 µmin 
in vivo experiments17• In in vivo measurements in mice, the firm mucus layer thickness is stated to be 49 µm•. In 
histological sections of empty distal colon, these loose and firm layers are not observed. In these conditions, the 
lumen is collapsed and the tissue neatly folded, leaving insufficient space to harbour an equally thick mucus layer. 
Indeed, collapsed distal colon of both rat and mouse has epithelia at around 16 µm from each other, leaving just 
8 µmon average per epithelial surface for this supposed mucus layer (Fig. 3). The disparity of these data seems 
linked to the experimental approach; opening the colon and submerging the epithelial surface in buffer solu-
tion, such as usually pract iced in ex vivo and in vivo experiments, might increase the thickness of the observed 
mucus layer. Mucus swells in a wet environment, based on its properties 18• 19, soit is important to notice that the 
humidity levels of the colonie contents in distal colon are normally around 55%, a strong deviation from these 
experimental conditions. Additionally, it is likely that mucus production and release are increased in response 
to mechanical and chemical perturbations of the tissue induced by the experiments. Unfolding of the colonie 
tissue, which is a condition shared between these in vivo and ex vivo experiments and physiological pellet transit, 
might influence mucus secretion. An increased mucus secretion can also be induced by the high concentration 
of microbial products in the faeces, known stimuli of mucus excretion such as short chain fatty acids (SCFAs)20, 
lipopolysaccharides (LPS) and peptidoglycans (PGN)21• Specifically LPS was recently shown to trigger crypts to 
release mucus by activating Nlrp622• These last points are particularly interesting because, as we have shown here, 
the arrivai of the faecal pellet to empty distal colon reintroduces a large microbial presence, and thus increases the 
presence of LPS and other microbial factors; this could represent an important regulatory mechanism by which 
the mucus barrier is formed around the faecal pellet. We posit that colonie crypts release additional mucus onto 
the faecal pellet during ils passage, covering it in a mucus layer. Mucus is notoriously difficult to fix for paraffin 
inclusion. Standard formalin fixation causes the mucus to be completely lost9• However, fixation with Carnoy's 
solution is currently the most sui table option for conservation of the mucus layers for histological purposes23, 
and although shrinkage does still occur24, mucus layers are observed sufficiently well. As discussed earlier, the 
faecal mucus layer is Jess hydrated than mucus in an aqueous environ ment; the resulting increase in density could 
increase the efficiency of fixation and subsequent staining, which means that a possible highly hydrated surface 
mucus layer could remain undetected due to restraints inherent in histological techniques. However, we still 
see that the fo l ding of empty distal colon does not leave enough space for double mucus layers of the thickness 
classically reported. In the proximal colon, in a similar fashion, the complete absence of a separating mucus 
layer can not be explained by this type of artefact, instead of empty space left behind after shrinkage, which is 
normally reported24, we see close contact between bacteria and epithelia. Matsuo et al.23 have shown that it is 
possible to fix mucus layers covering the intestinal epithelium if they are present, even in the absence of intestinal 
contents, in apparent contradiction to our findings. In their experiments, surgically removed human intestinal 
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Figure 7. AB/H/E stained longitudinal section of mouse proximal colon. Proximal sicle of tissue on the left, 
distal on the right. (a) Close-up of proximal part of newformed pellet. (b) Close-up of distal part of newformed 
pellet. (c) AB/H/E stained longitudinal section of mouse proximal colon. No mucus layer separates bacteria 
from epithelium. (d) AB/H/E stained longitudinal section of mouse proximal colon. No mucus layer separates 
bacteria from epithelium. 
tissue is opened longitudinally and the tissue with mucus layers is fixed using Carnoy's solution and subsequently 
histologically visualised. According to our understanding, the patients' preparation for surgery with laxatives 
removing the intestinal contents, the opening of the intestinal tube, and the inevitable passage of time between 
resection and fixation might have led to the formation of attached mucus layers. However, their ability to visualise 
the mucus layers in these conditions using Carnoy's solution seems to indicate that the lack of these attached 
layers in our results is due to actual absence rather than technical artefact. Apparently, surface mucus layers can 
be absent or present, observable or undetectable, depending on the exper imental approach and physiological 
circumstances. These data show the necessity to further characterise both the regulat ion and the presence of 
these secretions in variable conditions, to make sure that a presence is not due to induced formation, and that an 
absence is not due to technical artefact. 
We have no reason to doubt the general fonctions of the formation of a mucus layer in the distal colon in our 
adjusted mode!, which are lubrication 1 and physical separation of bacteria and epithelium6 • Addit ionally, th is 
layer, which covers the entire faecal pellet (see also Fig. 6), in effect isolates the bacteria from the intestinal milieu 
and confines them to the pellet, as we know from previous research that the mucus layer is mostly impenetrable 
to bacteria6. This explains why no typical bacteria-colonised mucus is observed in empty distal colon (Figs 3b,d 
and 4). This heavily diminished presence of microbes in empty distal colon is of relevance to the host, because, 
in the absence of digesta, a large microbial population could be deleterious in the distal colon. Our data suggest 
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Figure 8. Localisation of microbiota in mouse proximal colon. (a) AB/H/E staining of transversal section of 
mouse proximal colon. (b) FISH staining of consecutive transversal section of mouse proximal colon. Bacteria 
are observed in direct contact with the epithelium (a), without a mucus layer to separate them from the tissue 
(a,b). Significantly Jess bacteria are observed in the middle of the contents than near to the mucosa. A high 
concentration ofbacteria is detected particularly under the tissue folds specific to the proximal colon. (c) 
AB/H/E staining of longitudinal section of mouse proximal colon. (d) FISH staining of consecutive longitudinal 
section of mouse proximal colon. In collapsed proximal colon, bacteria mixed with mucus remain present in the 
lumen of folded tissue. 
that the distal colon contains a mostly transient microbiota, confined to the faeces, which means that most of the 
resident gut microbiota is hosted higher in the gut, in the proximal colon and cecum, as we have indeed observed. 
This study, like many other stud ies on mucus organisation, is performed on rodents, which have markedly drier 
faeces than humans do. However, the faecal mucus layer is also observed on human stool 12· 13, so it is likely that 
this organisation of mucus is shared by rodents and humans. The current widely accepted mode! has been based 
on largely the same techn iques and experimental practices that we have used in our study, which supports the 
reliability and relevance of these results. 
In proximal colon, released mucus is directly mixed into the chyme, and virtually no mucus is found without 
bacteria, except at the moment of secretion. This is indicated by the abundance of producing goblet cells in the 
proximal colon, combined with the lack of a significant excreted mucus barrier. Layer formation in the proximal 
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Figure 9. Schematic overview of mucus organisation situations as observed in different sect ions. (al ) ln 
longitudinal sections the mucus layer is found attached to the faecal pellet. (a2) In transversal sections, we 
see the firm mucus layer around the faeces in sections containing faeces. (a3) This cannot be observed in 
transversally sectioned empty colon. (b) Further evidence of adherence of the mucus layer to the faecal pellet 
is provided by the internalisation of the sterile mucus layer inside faecal pellets by collisions between pellets; 
an observation which can not be explained in the classical mode! of mucus organisation in which the observed 
mucus layer is attached to the epithelium. Additionally, the observation of the same mucus layer covering 
expelled faecal pellets (Fig. 6) indicates clearly that this mucus layer covers the faeces. (c) AB/H/E stained 
sections offull and empty mouse distal colon corresponding to the schematic overview of (a) . 
colon is only observed forther towards the transition to distal colon, after the chyme has been shaped into a 
rudimentary pellet under influence of water extraction by normal fonctioning of the colon (Fig. 7b). It is likely 
that the sterile mucus barrier needs a firmer pellet to form, in conditions that prevent it from directly mixing into 
the chyme. lt seems that the classical mucus layer organisation depends on the presence of a firm faecal pellet. 
This indicates that the faecal mucus layer as reported by Shimotoyodome et al. 13, and again shown by us (Fig. 6), 
is already, and continuously, deposited on the faeces relatively soon after it passes the proximal colon, and not, 
as might be expected, starting from the rectum. Simultaneously, we see that mucus mixed with bacteria remains 
in contact with the epithelium in the collapsed lumen of proximal colon (Fig. Sc,d). In contras!, in collapsed 
distal colon, we find mucus devoid ofbacteria instead (Fig. 3). Thal the proximal and distal colon do not have 
an equally thick mucus barrier has also been noted by Ermund et al.24. The use of transversal sections through a 
formed pellet has likely prevented them from observing the lack of a mucus barrier in the proximal colon forther 
towards the cecum. To sum up, in the early proximal colon, production of mucus does not lead to a sterile layer, 
instead mixing into the liquid contents, while in the distal colon, mucus excretion leads to a layer covering the 
drier faecal pellet. 
Because there is a difference in organisation of colonie mucus depending on the location and local stage of 
transit, the fonctions we can attribute to colonie mucus secretions depend on these same factors. The intestinal 
mucus has a modulating effect on the microbiota25, together with specific compounds excreted into it, such as 
defensins, c-type lectins, cathelicidins, and IgA; for reviews on this subject, see for example Duerkop et al.', and 
Liévin-Le Moal and Servin26. In proximal colon, the bacteria are mostly growing near to the mucus-producing 
mucosa, whereas forther inwards the luminal contents are made up of coarser materials with less bacteria (Fig. 8). 
The high density of microbes close to the epithelium indicates that these secretions might support the growth of 
the microbial population. This could increase the efficiency of the microbial digestive fonctions; if the population 
can quick:ly propagate on easily available substrate, the resulting larger population will have a stronger capacity to 
utilise less available compounds in the faeces. Additionally, the excretion of mucus in proximal colon, combined 
with the absorption of water by the mucosa, seems to lead to a change in consistency and shape of the colonie 
contents (Fig. 7). Mucus being released from goblet cells will sequester water from the environment18• 19 • 27 while 
forming a gel, reducing the amount of free water. Mucus released into the chyme can be expected to have a shap-
ing role in the consistency of the colonie contents, where it would serve as a matrix for the microbial commun ity. 
We hypothesize that mucus released into the chyme in the proximal colon serves to support the intestinal micro-
biota, and through the gel-like properties of the mucus helps in giving a firmer consistency to the contents. We do 
indeed see that the bulk of many rnouse faecal pellets is made up of microbe-colonised mucus (Figs lc,d, 4 and 5), 
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indistinguishable from the described6 loose mucus layer containing bacteria. Regarding resource and energy 
efficiency, it seems indeed more expedient to cover the faecal pellet in a thick mucus layer than to cover the entire 
colonie epithelium, to separate these two components. Clearly, a lubricating mucus layer becomes more crucial 
as the pellet gels drier and more compact as il progresses through the colon, to prevent damaging abrasion of 
the tissue. In the proximal colon, when the contents are still liquid, a mucus barrier does not form, even though 
there is significant production. Direct exposure of the colonie epithelium to the microbiota and digesta is gener-
ally expected to cause a strong immune reaction and tissue damage, the prevention of which is often cited as an 
important function of the mucus barrier. The apparent lack of these effects in these physiological conditions in 
the proximal colon warrants further investigation. 
Our MUCIO approach to histology, in combination with multiple orientation sectioning, has allowed for 
a comprehensive overview of the evolution of the mucus barrier throughout the colon. Until now, h istological 
results are commonly depicted in single-image microscopie views, which can complicate a thorough understand-
ing of the full results, might underrepresent possible variations throughout the section, and can give rise to a 
selection bias for 'sui table regions' on a slide. 
In conclusion, we have shown that a mucus layer is attached to and covers faecal pellets in the distal colon, 
isolating the faecal bacteria from the intestinal lumen. Mucus is mixed into the chyme and faeces in the proximal 
colon and in collision events between faeces segments in the distal colon. In the proximal colon, in contras! to the 
distal colon, no firm mucus barrier is formed until the chyme starts to gain a pellet structure. Before the mucus 
layer is established, bacteria are in contact with the epithelial surface, and in these conditions, we should recon-
sider the nature of the barrier function in this region of the colon. 
Materials and Methods 
Animais and sample collection. 8 adult male Wistar rats (Janvier, Le Genest St Isle, France) were 
individually housed in polypropylene cages and offered unlimited access to standard rodent food (Mucedola 
Global Diet 2018, Harlan, Italy) and water. 8 adult male C57BL/6 mice (Janvier, Le Genest St Isle, France) 
were housed in polypropylene cages in groups of 4 and offered unlimited access to standard rodent food 
(Mucedola Global Diet 2018, Harlan, Italy) and water. Rats were euthanized by decapitation, after which 
3 cm of distal colon containing faeces was removed and stored in Carnoy's fixat ive (60% ethanol, 30% chlo-
roform, 10% glacial acetic acid) overnight. Mice were euthanized by cervica l dislocation, after which both 
1.5 to 2 cm of distal colon and of proximal colon covering regions with and without contents were removed 
and stored in Carnoy's fixative overnight. Mouse faecal pellets were collected d irectly from the anus, and 
fixated immediately in Carnoy's fixative overnight. Ali animal experiments were performed in accordance 
with EU directive 20 10/63/EU and approved by the local Animal Care and Use Committee of Toulouse 
Midi-Pyrénées (agreement CEEA-86). 
Tissue processing. The mice and rat tissues were automatically processed by a Shandon™ Excelsior™ 
ES Tissue Processor using the following program: 2 x 60 min anhydrous ethanol, 2 x 60 min butanol, 480 min 
butanol, 3 x 80 min paraffin al 60 °C. Tissue samples were included in paraffin blocks using a Thermo Scientific ™ 
HistoStar™ Embedding Workstation. Tissues were oriented for longitudinal or transversal sectioning. 6µm tissue 
sections, and 4 µm faecal sections were made using a Microm TM HM 340 E microtome and attached to Thermo 
Scientific Menzel-Glaser Superfrost® Plus slides. 
Histological staining (AB/H/E staining) . Paraffin embedded sections were deparaffinised using 
American Master tech Clearify™ and subsequent passage through an increasingly diluted ethanol-water series, 
starting with anhydrous ethanol. Staining was performed by 5 min in Hematoxylin, 10 min in running water, 
30 min in Alcian Blue solution (pH 3.0) followed by 5 min in running water, 3 min in Eosin, 10 min in 95% eth-
anol, followed by dehyd ration in an ethanol series of increasing purity, finishing with dry ethanol, ending with 3 
baths of American Mastertech Clearify™, followed by mounting with Diamount mountant. 
Fluorescent in situ Hybridisation. FISH staining for ail bacteria was performed using probes EUB3381 
(5' CGTGCCTCCCGTAGGAGT 31) , EUB338Il (5' GCAGCCACCCGTAGGTGT 3'), and EUB338III 
(51 GCTGCCACCCGTAGGTGT 3'). After deparaffin ising as described for 'Histological staining' (see above), 
the slides were incubated with FISH hybridisation solution (0.9 M NaCI, 20 mM Tris/HCI, 0.01 % (v/v) SDS, with 
5 ng/µL of EUB338(1/II/III) probes at 48 °C overnight, followed by a washjng step with the hybridisation solution 
without probe at 49 °C for 25 min. Slides were rinsed with demineralised water and briefly air-dried, followed by 
mounting using ProLong Gold® antifade reagent with DAPI (Thermo Fisher Scientific, USA). 
lmaging; Manual Ultra-high resolution Composite Image Overview (MUCIO). Manual Ultra-high 
resolution Composite Image Overview (MUCIO) approach: datasets of 50 to 500 overlapping microscope views 
covering entire slides were generated by manual microscope photography (single photo resolution: 1280 x 1024 
pixels) and stitched together using Microsoft Image Composite Editor (MICE), specifying 'planar motion' in 
the program interface, to best fit the movement of the microscope camera relative to the microscopie slide. The 
generated composite images contain ail the information of the data set in a single ultra-high resolution file. No 
selection for 'representative regions' is necessary, only obvious artefacts (e.g. possibly folded double/heavily dam-
aged sections) are evaded. Sam pies were imaged using a Nikon Eclipse 90i microscope fitted with a DXM 1200 F 
Digital Camera. Image sets were taken with 1 00x or 200x magnification, overlapping and covering complete 
sections. Resulting images were saved uncompressed in TIFF format. To prevent scaling issues, image resolutions 
were only downscaled after the appropriate scale bar was integrated. Subsequent downscaling is necessary to 
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fac ilitate interaction with images for further applications, but close-up views in full quality can be extracted from 
the original composite. 
Data availability. The data generated and analysed during the current study are available from the corre-
sponding author upon reasonable request. 
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2.2 FODMAPs increase visceral sensitivity in mice through glycation processes, 
increasing mast cell counts in colonic mucosae 
This work regroups the main findings of the thesis work, i.e., the effects of FODMAP 
administration on visceral sensitivity, the mucosal mast cell population, the expression of 
Receptor for AGEs (RAGE), and the prevention of these effects by anti-glycation agent 
pyridoxamine, indicating the involvement of glycating processes. Analysis of the gut microbiota 
composition showed no significant effects of our lactose treatment on population composition, 
and no effect for pyridoxamine either. Carbonyl metabolite analysis showed differences 
between control and FODMAP treated groups, but no additional effect by co-treatment with 
pyridoxamine.  
These results and this manuscript are currently under a second round of reviewing in the 
Gastroenterology journal (Elsevier) as an original article. 
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Results 
Supplemental figure 2 - Representative images af sections af colon showing no signs of inf lammation. {A,B}: Contrais of 
lactose, FOS respective/y. {C,D) Lactose-, and FOS-treated, respective/y. 
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Supplemental figure 3 - Microscopie scores of Lactose-pyridoxamine experiments (A) (N=B), and FOS-pyridoxamine 
experiments (B) (N=lO}. Apart /rom a very mild presence of leukocytes in 1 or 2 individua/s in each group, no signs of 
inflammation were observed in any group. 
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2.3 Increased FODMAP intake alters colonic mucus barrier function through 
glycation processes and increased mastocyte counts 
This work reports the results of our investigation of the effects on the colonic mucus barrier of 
FODMAP treatment, as a reflection on intestinal barrier function. We used our MUCIO approach 
and considered our new model of mucus organisation developed in the earlier work presented 
in section 2.1. Apart from finding that FODMAPs can dysregulate the colonic mucus barrier 
function through effects on mucosal mast cells and production of glycating agents described in 
section 2.2 we show that the increased production of mucus in the absence of faecal matter 
goes together with an increased variability and decreased coverage of the faecal mucus layer, 
indicative of a less functional mucus barrier. 
These results and this manuscript are ready to be submitted to the American Journal of 
Physiology – Gastrointestinal and Liver Physiology, as a Rapid Report.
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3 General Discussion 
As mentioned at the start in the introduction, this thesis is part of the NeuroGut project, which 
ran from 2014 to 2018. This Initial Training Network, financed by the European Commission, has 
led to interesting findings, many of which have been published in renowned international 
scientific journals, such as Neurogastroenterology and Motility, Scientific Reports, Alimentary 
Pharmacology and Therapeutics, Neurotherapeutics, and The American Journal of Clinical 
Nutrition. 
More importantly, it has allowed a selection of young researchers to develop their professional 
and personal skills, and international network. For our part in this project, we investigated the 
effects of certain alimentary compounds on intestinal health, in relation to functional 
gastrointestinal disorders, particularly irritable bowel syndrome (IBS), which represents an 
important negative factor on quality of life (QOL) of patients, as well as costing society billions 
of euros in lost work-hours and productivity. IBS patients are increasingly following a low-
FODMAP diet, which is quite effective in improving QOL and appearance of symptoms, but it 
remains somewhat difficult to explain the reason for this efficacity. 
In this thesis dissertation, complementary mechanisms of effect behind the efficacity of the low-
FODMAP diet are explored, by using a mouse model exposed to an increased FODMAP intake. 
We have shown that FODMAP ingestion by itself can induce certain physiological effects 
reminiscent of IBS, such as an increased visceral and central sensitivity (section 2.2), and 
intestinal barrier function dysregulation (section 2.3), and these effects seem related to an 
increase in glycating agents caused by microbial fermentation of these FODMAPs by the gut 
microbiota, indicated by the increased expression of Receptor for AGEs (RAGE), and the 
prevention of observed effects by administration of anti-glycation agent pyridoxamine, a form 
of vitamin B6. The negative effects on visceral sensitivity and barrier function seem to be 
mediated by an increased mucosal mast cell population (sections 2.2, 2.3). 
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3.1 Fermentable carbohydrates and IBS symptoms 
Since FODMAPs are defined by their ‘unabsorbed’ status, individual characteristics, such as 
lactase deficiency or fructose malabsorption, can influence which carbohydrates should be 
considered FODMAPs in different individuals. Some FODMAPs, such as many polyols, fructo-
oligosaccharide (FOS) or fructans, and galacto-oligosaccharide (GOS) are 
undigestible/unabsorbable for all humans, while for others this depends on factors such as dose, 
intestinal health status, transporter complexes, and (brush border) enzyme expression, such as 
for lactose and fructose (Gerbault, Liebert et al., 2011; Brown-Esters, Mc Namara et al., 2012). 
We have used lactose as a representative of FODMAPs, because mice, like all mammals except 
a sub-population of humans, lose lactase activity after weaning, and should be considered 
lactose-malabsorbers. 
The insight that FODMAPs can induce an increased abdominal sensitivity without further 
challenge is interesting, because it indicates that it might render patients even more sensitive 
to the distension that it causes. Because stress is an important factor in IBS symptom 
generation (Qin, 2014; Greenwood-Van Meerveld, Moloney et al., 2016), and mast cells are an 
important mediator in stress-induced visceral hypersensitivity (Gue, Del Rio-Lacheze et al., 
1997) and permeability (Santos, Yang et al., 2001; Barreau, Cartier et al., 2007; Vanuytsel, van 
Wanrooy et al., 2014), it can be expected that the increased mast cell population observed in 
FODMAP-treated animals renders them more susceptible to mast cell mediated effects of 
psychological stress.  
Our finding that the performed FODMAP treatments can increase visceral but also central 
sensitivity fits with the frequent association of FGIDs with non-GI symptoms, such as for 
fibromyalgia and chronic fatigue syndrome (Mathieu, 2009; Wilder-Smith, Olesen et al., 2018), 
all of which are often exacerbated by stress (Mathieu, 2009). The increase in mastocyte counts 
could provide a link between these GI and non-GI symptoms in combination with an increased 
vulnerability to psychological stress, because mast cells can be activated by mental stress 
through nerve system signalling (Castagliuolo, Lamont et al., 1996; Barbara, Stanghellini et al., 
2004; Barbara, Wang et al., 2007; Moon, Befus et al., 2014; Carabotti, Scirocco et al., 2015; 
Zhang, Song et al., 2016). 
Related to the psychological aspects of IBS and fermentable carbohydrates, lactose and fructose 
malabsorption has been linked to a decreased L-tryptophan metabolism, precursor to 
serotonin (Ledochowski, Sperner-Unterweger et al., 1998; Ledochowski, Widner et al., 2000), 
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suggesting a reduced serotonin producing capacity. Indeed, the tryptophan plasma level of 
fructose malabsorbers is reduced (Ledochowski, Widner et al., 2001). Moreover, in depressed 
patients, reduced levels of plasma tryptophan are found (Ogawa, Fujii et al., 2014). In contrast, 
a recent study has found that fructose malabsorption is associated to depression, without a 
significant relation between circulating tryptophan levels and depression (Enko, Wagner et al., 
2018). Conversely, Burokas et al. report that prebiotic unabsorbed carbohydrates FOS and GOS 
exert anti-depressant and anxiolytic effects in mice (Burokas, Arboleya et al., 2017). However, 
in this study plasma tryptophan levels were reduced for the prebiotic groups GOS and FOS+GOS. 
These data indicate a link between disturbed tryptophan-metabolism and non-absorbed 
carbohydrates. While none of these studies deeply explore the mechanism behind these effects, 
Ledochowski et al. propose that non-absorbed carbohydrates react with peptides and amino-
acids, forming complexes that interfere with normal metabolism (Ledochowski, Widner et al., 
2001).  
It is not yet clear whether the effects of FODMAPs on sensitivity and the mucus barrier function 
reported in sections 2.2 and 2.3 are linked, i.e. the mucus barrier dysfunction aggravates the 
increase in sensitivity, or whether both are downstream effects of the increase in mast cells, 
without significantly influencing each other. It is known that barrier defects are correlated to an 
increased sensitivity (Annahazi, Ferrier et al., 2013), in this case increased paracellular 
permeability. A mucus barrier dysregulation could thus also have similar effects on gut 
sensitivity, but the effects observed on this barrier in our model were relatively mild and are not 
likely to have a significant impact on visceral sensitivity without further challenge.  
Reactive microbial fermentation products of unabsorbed carbohydrates could have the same 
effects on tryptophan levels as FOS/GOS, but are generally more prone to strong and fast 
glycation reactions (Campbell, Matthews et al., 2010), and it would be interesting to 
characterize tryptophan levels in FODMAP-treated animals, as well as ethology related to 
depressive and anxious behaviour. We have not observed any obvious differences in mouse 
behaviour between treatment groups, but a dedicated study might be interesting. It would 
therefore also be interesting to see how increased FODMAP intake impacts the chronic stress 
response of mice, for example by using a water avoidance stress (WAS), or maternal separation 
model. It has been shown that the increase in visceral sensitivity and induction of intestinal 
inflammation by WAS is aggravated by FOS in mice (Chen, Du et al., 2017), though in this work, 
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contrary to ours, FOS alone did not have effects, and was administered at lower doses (8g/kg 
b.w., i.e. +/- 0.2g per day, versus our 10% of food intake, i.e. +/- 0.4g per day). 
In IBS patients too, it would be interesting to investigate tryptophan levels on normal and low-
FODMAP diets and relate this to the (improvement in) psychological well-being.  
To definitely prove that glycating carbonyls that cause the physiological effects in our 
experiments are produced in fermentation and not in spontaneous breakdown of 
carbohydrates, a germ-free or microbiota depleted animal model should be used to compare 
metabolite profiles and effects of the treatments an sich. However, the physiology of germ-free 
animals is significantly different from conventional mice. For example, the transit time of germ 
free Swiss-Webster mice is about 60% longer than for conventional Swiss-Webster 
mice (Kashyap, Marcobal et al., 2013). At the same time no beneficial metabolites of microbial 
processing will be produced, which causes an underdeveloped immune system (Parker, Lawson 
et al., 2017). 
An experiment using non-absorbed antibiotics to deplete the microbiota would alter aspects of 
normal digestion and furthermore induce a dysbiosis, which of course has its own effects on gut 
health which could confound the findings. It is important to realize that we have not found 
microbiota profile changes in our experiments involving lactose, and that a reduced or absent 
microbiota by itself could induce visceral hypersensitivity (Verdu, 2006; Luczynski, Tramullas et 
al., 2017), which complicates the reliability of an experiment into these features.  
Confusingly, contrary to what is observed in entirely germ-free animals, some review literature 
report a decrease in intestinal transit time after antibiotic use (Gaskins, Collier et al., 2002). In 
fact, the source reference states “… and the subsequent changes in the intestine, including a 
slower intestinal passage rate,…” (emphasis mine), while the table in the same report does 
indeed imply a reduced transit time (Sweden Ministry of Agriculture, 1997). Other primary 
research do however report an increased whole gut transit (Anitha, Vijay-Kumar et al., 2012; Ge, 
Ding et al., 2017), caused by activation of TLR4 receptors by microbial products (Anitha, Vijay-
Kumar et al., 2012). Apart from supporting the general idea that microbial depletion does indeed 
bring the physiology closer to that of germ-free animals, this illustrates that it can be important 
to check the sources of claims presented in review articles. 
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Concerning visceral sensitivity and the importance of the microbiota, it has proven impossible 
to find information showing the basal sensitivity of germ-free animals, while antibiotic 
treatment (not necessarily microbial depletion) induces an increased visceral sensitivity that can 
be prevented by co-treatment with the probiotic L. paracasei, or its spent medium without live 
bacteria (Verdu, 2006). On the other hand, using intracellular recordings of myenteric plexus 
nerve cells showed that the absence of the microbiome in germ-free mice makes these nerves 
hypo-excitable, and the microbiome is thus necessary for normal excitability (McVey Neufeld, 
Mao et al., 2013), pointing to a less sensitive system in these animals. Until comparable 
techniques are used to compare the visceral sensitivity of germ-free and conventional animals, 
it is not entirely clear whether the microbiome generally increases or decreases this sensitivity.  
In relation to the increased visceral and central sensitivity observed in IBS patients, it would be 
interesting to see if these factors ameliorate after following a low-FODMAP diet for a longer 
period, for example by barostat testing such as used to show visceral hypersensitivity (Bouin, 
Plourde et al., 2002), and a Cold Water Tolerance Test, such as performed in FGID 
patients (Bouin, Meunier et al., 2001) and in fibromyalgia patients (Reyes del Paso, Garrido et 
al., 2011). Interestingly, there is a comorbidity between IBS and fibromyalgia (FM) (Martinez-
Martinez, Mora et al., 2014), where some authors even propose it’s the same disease but 
through the lens of different medical fields (Kindler, Bennett et al., 2011; Clauw, 2015), FM 
patients seem to benefit from a low-FODMAP diet as IBS patients (Marum, Moreira et al., 
2016b), and this affliction too has been linked to mast cell activation (Tsilioni, Russell et al., 
2016).  
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3.2 Immune activation 
We have not observed clear immune activation by our FODMAP treatments, apart from 
mastocyte population increases; faecal lipocalin-2 levels were not significantly different 
between any groups but instead tended to be slightly decreased through FOS-treatment. In IBS 
patients, 3 weeks of low-FODMAP treatment however, lowered pro-inflammatory cytokines IL-
6 and IL-8, but not TNF-α, from levels that never were significantly different from baseline for 
the healthy population, and 10-day FOS supplementation following this low-FODMAP 
intervention did not impact these cytokines in these patients (Hustoft, Hausken et al., 2017). 
This indicates that FODMAPs, but not FOS in particular, can influence cytokine profiles and 
inflammatory processes. Indeed, it is known that FOS as a prebiotic can improve rather than 
worsen inflammation in the intestine (Capitan-Canadas, Ocon et al., 2016), even though it has 
not proven to be effective in improving true inflammatory disorders such as Crohn’s 
disease (Marteau, 2011). Additionally, the low-FODMAP diet has effects on gut microbiota 
profile composition (Staudacher, Lomer et al., 2012; Halmos, Christophersen et al., 2015; 
Hustoft, Hausken et al., 2017; McIntosh, Reed et al., 2017; Staudacher, Lomer et al., 2017), and 
FOS supplementation can help to normalise the microbiota after an increased dysbiosis index 
induced by a low FODMAP intake, although this did worsen the IBS symptom severity (Hustoft, 
Hausken et al., 2017). This indicates that normalising the microbiota profile in this case should 
not be of primary concern, and a ‘dysbiosis’ mainly indicates a change from baseline, without 
necessarily representing a dysfunction. 
To see if the improved inflammatory profile of IBS-patients relies on the same mechanisms as 
described in this thesis, it would be interesting to test whether anti-glycation agents such as 
described in section 1.4.4 can mimic the positive effects observed for the low-FODMAP diet. 
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3.3 Permeability 
We have performed in vivo permeability tests, using oral gavage of the fluorescent marker 
fluorescein thiocyanate (FITC), with non-conclusive results. Differences were striking from time 
to time, but treated groups showed sometimes the highest, and sometimes the lowest 
permeability, and this was not reproducible. This is probably in part due to a mismatch with our 
question; FITC is absorbed throughout the gastrointestinal tract, in which the small intestine 
definitely represents the greatest exchange surface by a large margin, with the colon 
representing 300 cm2, and the small intestine 13400 cm2 of the total of 14100 cm2 surface of 
mouse intestine effective surface (Casteleyn, Rekecki et al., 2010). Of course, we are not sure 
our treatments induced an alteration of permeability, but for previously mentioned reasons, our 
negative results do not necessarily indicate that there is not.  
Increased mast cell counts do imply an increased permeability in basal conditions, as previously 
described (Lee, Park et al., 2013). Further work to test colonic permeability in this model could 
be done using Ussing chambers. However, the observed differences in mast cell populations 
between the tissues will likely produce results that could be considered artefacts. Effectively, 
tissue preparation for mounting in Ussing chambers will degranulate mast cells, increasing gut 
permeability (Moriez, Leveque et al., 2007). Therefore, ex vivo permeability procedures are 
likely to be sub-optimal for our model.  
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3.4 Role of glycation in efficacy of low-FODMAP diet 
To measure the production of 
reactive dicarbonyls that lead to 
AGE production, we set out to 
measure AGE content in 
intestinal tissues. It turned out 
that the antibodies against AGE 
also have high cross-reactivity 
with glycosylated proteins, such 
as those found in mucus (see Figure 24). Apart from complicating immunofluorescent analysis, 
this makes it impossible to use commercial “anti-methylglyoxal” ELISA kits to analyse intestinal 
contents. These kits use anti-AGE antibodies and a standard curve based on BSA-AGE, and 
because we have shown that FODMAP treatments influence the production of mucus, observed 
differences between groups will not necessarily be reflective of different AGE contents.  
In addition, we are not sure which other antigens might be recognized by these antibodies. It 
makes sense that no antibodies against methylglyoxal itself exist, because it is a small non-
antigenic ketone. Because of these complications, we went one step further and quantified 
epithelial RAGE expression, which is upregulated by activation with AGEs (Bierhaus and 
Nawroth, 2009), as presented in section 1.4.3. Even though this is quite an indirect way of 
inferring AGE production, it is of considerable interest because it is the main mediator of its 
effects, and it helps to explain the observed increase in mast cells and mucus production.  
An increase in mastocytes in adipose tissue is seen in a disease heavily linked to AGE production, 
type-2 diabetes (Divoux, Moutel et al., 2012). RAGE activation does indeed lead to mastocyte 
activation (Yang, Yan et al., 2007), and preventing mastocyte activation pharmacologically by 
disodium cromoglycate (DSCG) or by using a mast cell deficient knockout model KitW-sh/W-sh 
attenuates diabetes, improving glucose tolerance (Liu, Divoux et al., 2009). This might indicate 
that disorders involving generation of AGEs can be mediated by mast cell activation, caused by 
increased RAGE activation and expression. In our model, methylglyoxal is not increasingly 
produced systemically, but locally during fermentation in the gut, and its likely for this reason 
that obvious effects were limited to physiological effects in the intestinal tract. 
 
Figure 24 - anti-AGE staining (left), anti-MUC2 staining (right).  
Both strongly stain mucus. 
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It would be interesting to use a RAGE antagonist to directly see specific involvement of RAGE 
activation in the cascade, and to verify that the increase in mastocytes is mediated by RAGE 
activation in our model, like it is in the case of allergic airway sensitization (Ullah, Loh et al., 
2014). Another way to test our proposed model of the mechanistic cascade would be to repeat 
the FODMAP challenges in a mast cell deficient mouse model, these animals should not show 
an increase in visceral sensitivity, although the complete lack of mast cells likely has an effect on 
other components of health, or basal sensitivity, as it is known that mast cells are involved in 
regulation of visceral sensitivity (van Diest, Stanisor et al., 2012; Wouters, Balemans et al., 2016; 
Wouters, Vicario et al., 2016), although in rats, mast cell deficiency apparently does not 
influence the response to anorectal distension (Ohashi, Sato et al., 2008).  
Additionally, it would be of great interest to measure the RAGE expression in intestinal biopsies 
from healthy controls, and IBS patients on normal and low-FODMAP diets, to see whether similar 
mechanisms are at play in humans as we have observed in our work. 
If these mechanisms are shown to play a role in IBS patients, it will be relevant to evaluate the 
efficacy of agents like aminoguanidine to counteract the effects of luminal production of 
glycating agents. Additionally, to support the glyoxalase system, a treatment with tRES and HESP 
such as described in section 1.4.4 would be possibly effective and highly interesting, since this 
ameliorates the health status of obese and diabetic patients on similar principles. 
Explorative results observed in AGE staining of caecal sections show a starkly delineated region 
of high-intensity signal next to the tissue 
(see Figure 25) in control conditions. This 
delineated line is disturbed in lactose-
treated (5mg/day) animals. Besides, in an 
ABHE staining performed on the same 
region no discernible difference can be 
observed. Moreover, a FISH staining does 
not show differences in bacterial population 
density, and neither does a muc2 staining 
indicate a high mucin concentration in this 
region (data not shown). Even though the 
staining for AGEs is not specific, this 
Control Lactose 
Figure 25 - anti-AGE staining in cecum, in control (left), or 
lactose-treated (right) animals. ABHE staining (below) non-
conclusive, but AGE staining shows clear line of highly 
positive material. 
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interesting region highly suggests a bacterial organisation, resembling a biofilm. 
Currently, we propose 3 hypotheses, based on these results; 
1) Effectively, the AGE staining could have stained a glycosylated extracellular protein belonging 
to the biofilm matrix.  
2) Otherwise, maybe the host tissue produces chemicals that support AGE formation, such as 
ROS.  
3) It is also possible that (partial) bacterial breakdown of mucus makes the muc2 staining lose 
specificity, while the less specific AGE staining still stains these glycosylated protein(s) 
(fragments). 
It would be immensely interesting to find/develop a way to determine whether this is a biofilm 
or not, to get more insights in host-microbe interactions in the caecum. Additionally, this might 
help to understand the implications of its possible disruption in response to FODMAP 
treatments.  
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3.5 Mucus barrier 
Concerning the colonic mucus barrier, we have shown that the double layer itself is not a 
continuous barrier covering the entire colonic epithelium (see chapter 2.1). First of all, at least 
in rodents, which are a widely used model for studies on the intestinal mucus barrier (Johansson, 
Phillipson et al., 2008; Johansson, Gustafsson et al., 2010; Johansson, Larsson et al., 2011; 
Petersson, Schreiber et al., 2011; Ermund, Schutte et al., 2013; Holmen Larsson, Thomsson et 
al., 2013; Rodriguez-Pineiro, Bergstrom et al., 2013; Birchenough, Nyström et al., 2016; 
Schneider, Pelaseyed et al., 2018), it is highly variable between the different compartments of 
the colon, with extensive contact between the microbiota and the epithelium in the proximal 
colon, and an effective separation starting from the particular moment a pellet with a higher 
consistency is formed. Secondly, the mucus barrier is dependent on the presence of a faecal 
pellet, and in the absence of contents, no double mucus layer is observed. We can conclude that 
this organisation depends on both space (location), and time (periodic presence of contents), 
and should not be considered stable and uniform. 
These findings have several interesting and possibly important implications. For example, we 
should realize that the microbiota of contents in the distal colon is mostly transient and isolated 
from the host by a covering of sterile mucus that is constantly being deposited on the outside of 
the faecal pellet until defecation, at least in case the stools are solid.  
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This can change the comprehension of how bacteria approach the epithelium, instead of 
penetrating the ‘inner’ mucus layer covering the mucosae, they would have to escape the faecal 
pellet through the faecal mucus layer (see Figure 26). 
Our analyses of FODMAP impact on mucus barrier function are based on this novel model of 
colonic mucus organisation, differentiating the situation between empty and faeces-containing 
distal colon, which is variable. This means that colon epithelium, and the state of its mucus 
barrier, is constantly alternating between situations where a barrier is separating host and 
microbes, and a situation where both barrier and microbiota are apparently mostly absent.  
We have found that our FODMAP treatments induce a dysregulation in this balance, causing 
excessive production of mucus in empty colon, probably due to epithelial irritation as described 
before (Ten Bruggencate, Bovee-Oudenhoven et al., 2006), which then causes an increased 
variability in the faecal mucus barrier, deposited during the passage of faecal pellets. This could 
be interpreted as resembling a system functioning (too) close to capacity. Our approach to 
include the individual CoV calculated from a large dataset of measurements of the mucus layer 
has allowed us to characterize a new factor that can play a role in mucus barrier function 
characterisations. An animal that has a higher CoV but a similar average mucus layer thickness, 
logically has more fragile regions in this barrier, which means it is less well protected. This factor 
(CoV) also seems more sensitive in situations where effects are mild or subtle, as our FODMAP 
treatment has clear effects on the CoV of our treated groups, normalized with pyridoxamine co-
treatment, while average mucus layer thickness was not strongly modified. 
Figure 26 - Two models of microbiota penetrating the mucus barrier.  
A: Classical model of bacteria approaching the epithelium through a mucus barrier.  
B: Bacteria escaping the faeces through the faecal mucus barrier to gain access to the epithelium. 
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It is unlikely that these effects on the intestinal mucus barrier have serious consequences in 
otherwise healthy systems, but it could imply an increased vulnerability to challenges.  
For the proximal colon, where the chyme does not form high-consistency pellets, future 
research to investigate the barrier function and immune tolerance evident from the lack of 
inflammation despite extensive contact between bacteria and host in this compartment of the 
colon will be of great interest.  
In light of a possible increased vulnerability, it would be interesting to challenge FODMAP-
treated mice with pathogens, such as Citrobacter rodentium, a model that shares pathogenic 
mechanisms with putative human pathogens such as E. coli (Collins, Keeney et al., 2014). 
Considering that in the absence of a faecal pellet, the microbiota is strongly diminished, the 
periodic presence of contents and microbial signalling could cause the activity of immune and 
goblet cells, and possibly tissue regeneration, to display waveform functions instead of a 
continuous or stochastic expression, which in itself is an interesting topic for future research. 
We have shown that the mucus layer classically measured in histology is attached to the faecal 
pellets, which means that it should be feasible to measure the mucus layer on Carnoy-fixated 
paraffin-embedded droppings, instead of intestinal sections. The faecal mucus layer on 
droppings is well-conserved and has the same general characteristics as when measured in 
colonic sections (see figure 6 of section 2.1, page 104). This has several important benefits; it is 
non-invasive, non-terminal, and technically easier to perform. Additionally, the same 
individual’s droppings can be analysed throughout an experiment, collected at different 
timepoints, allowing for characterisation of the progressive effects of treatment. In the context 
of the 3 Rs (Replacement, Reduction, Refinement) of animal research, this approach would allow 
us to both Reduce and Refine mucus barrier measurements, obtaining more information from 
each individual, while causing them less harm.  
In patients too, it represents an important improvement, because it can be performed on stools, 
and does not necessitate invasive procedures. It should be verified however that the mucus 
barrier in humans is organised similarly to that of rodents. In any case, a mucus layer covers 
human stools, and it can be analysed, as shown in literature (Shimotoyodome, Meguro et al., 
2005; Swidsinski, Loening-Baucke et al., 2008; Swidsinski, Loening‐Baucke et al., 2008). As it 
becomes more widely accepted that the distal colon mucus layer observed in histology is 
identical to the faecal mucus layer, it will become more attractive to use this approach. 
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3.6 Concluding remarks 
Finally, we come back to our hypotheses: 
1. FODMAP ingestion can induce gastrointestinal symptoms of IBS by itself, in an 
otherwise healthy system 
2. This effect relies on the production of harmful bacterial fermentation metabolites, 
among which methylglyoxal 
3. Methylglyoxal and other strong glycation agents lead to an increase in AGEs and a pro-
inflammatory state through activation of RAGE 
Our current understanding of the FODMAP-induced effects is summarised in Figure 27. 
 
 
Figure 27 - Graphical abstract of hypothetical mechanisms responsible for FODMAP-induced symptom generation 
presented in this thesis.  
FODMAP fermentation in the intestinal lumen leads to the production of harmful bacterial metabolites (i.e., reactive 
carbonyls such as methylglyoxal). These metabolites cause carbonyl stress and the formation of AGEs in the tissue, 
which activates and upregulates RAGE. RAGE activity induces NF-β pathways and increases mast cell activity and 
population size, which leads to increased excitability of nerves, and an increased discharge of mucus by goblet cells, 
which dysregulates the intestinal mucus barrier.  
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We have shown that FODMAPs can indeed induce GI symptoms of IBS by itself, in a healthy 
mouse model. Visceral and central sensitivity were increased, and the colonic mucus barrier 
disrupted. That this effect relies on the generation of reactive dicarbonyls was shown indirectly 
by a preventive effect obtained by co-treatment with pyridoxamine. Due to technical 
constraints, we have not shown directly that AGEs were increased, but the expression of their 
receptor (RAGE) increased in response to treatment and normalized with pyridoxamine co-
treatment. A plausible explanation for both the increased sensitivity and mucus barrier 
dysregulation is the observed increase in mastocyte counts, probably mediated by RAGE, 
interactions that have been reported in literature for other situations.  
Knowing that FODMAPs can influence these factors and a better understanding of the 
mechanisms responsible for the efficacity of the low-FODMAP diet will hopefully lead to 
development of novel approaches to benefit FGID patients, for example by improving dicarbonyl 
stress status in the intestine using pharmacologicals, or by using probiotic bacteria that have an 
increased capacity to detoxify methylglyoxal in situ. 
The work presented in this thesis describes a novel supplementary mechanism by which 
FODMAPs are involved in GI-symptom generation and opens up new approaches to research 
and possibly treat IBS and other FGIDs.
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